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1.  Summary  
  
Historically,   cancers   have   been   histologically   classified   based   on   the   embryonic   origin   of   the  
normal   tissue   they  most  closely   resemble,   thus  providing  diagnostic  and  prognostic   information  
as   well   as   guidance   for   therapy.   Nowadays,   with   the   advent   of   more   sophisticated   next-­
generation  sequencing  (NGS)  technologies  we  are  able  to  catalogue  genetic  aberrations  for  each  
cancer   type,   which   facilitate   the   identification   of   potential   therapeutic   targets   and/or   predictive  
biomarkers.   However,   the   relative   homogenous   genomic   landscape   of   pediatric   cancers  
constitutes   a   major   shortcoming   for   genome-­based   strategies   to   nominate   actionable   targets.  
One  example   is   rhabdomyosarcoma   (RMS),   the  most   common  soft-­tissue  sarcoma   in   children,  
which  presents   two  main  subtypes,  embryonal   (ERMS)  and  alveolar   (ARMS)  RMS.  Despite   the  
great  progress   that  has  been  made   for   treatment  of  RMS  with  conventional   therapies,  up   to  30  
percent   of   patients   still   have  dismal   outcome  and  no   targeted   therapy  has  entered   into   clinical  
practice   so   far.   The   recently   described   genetic   landscape   revealed   the   presence   of   only   rare  
mutations,   apart   from   the   most   recognized   driver   alteration   which   is   the   occurrence   of   either  
PAX3-­FOXO1   or   to   a   lesser   extent   PAX7-­FOXO1   in   ~80%   of   diagnosed   ARMS.   Although  
comprehensive   genomic   profiling   would   readily   capture   such   lesions,   these   do   not   match  
therapeutic   possibilities.   Hence,   procedures   to   functionally   test   the   druggability   of   identified  
aberrations  or   inform  on  alternative   treatment  options   for   individual   patients  would   complement  
the  work   of   pathologists   or   bioinformaticians   and   ultimately   guide   the   treating   physicians.  One  
possibility   takes   advantage   of   direct   drug-­profiling   of   patient   tumor   cells.   Such   high-­throughput  
drug  screens  have  been  widely  performed  in  the  past  for  cancer  cell  lines  but  only  few  identified  
compounds   have  met   clinical   utility.   The   failure   of   existing   pre-­clinical  models   raised   concerns  
about   their   ability   to   recapitulate   characteristics   of   native   tumors   indicating   an   urgent   need   to  
improve  traditional  culture  protocols.  Hence,  to  fill  this  gap  we  aimed  here  to  establish  an  in  vitro  
drug-­profiling  platform   for  RMS.  To   this  end,  we   first  generated  a   large  panel  of  patient-­derived  
xenografts   (PDXs)   and   then   screened   18   different   culture   conditions   to   find   the   suitable  
parameters  for  in  vitro  culture  of  isolated  cancer  cells.  In  this  context,  we  describe  for  the  first  time  
the   detrimental   effect   of   serum   on   primary  RMS   cell   cultures   (RPCs)   and   provide   new   culture  
methods   that   closely   preserve   the   clonal   composition   and   phenotypic   characteristics   of   the  
parental   tumor.   Yet,   we   show   proof-­of-­concept   pharmacological   profiles   of   RPCs   by   using   a  
library  of  FDA-­approved  drugs  or  compounds  in  clinical  development  to  pinpoint  drug  sensitivities  
in   individual  patients.   In   this   regard,  we  describe   the  effect  of  AKT   inhibitors,  which  exhibited  a  
strong   patient-­specific   activity,   further   corroborating   the   utility   of   personalized   pre-­clinical  
systems.   Interestingly,   we   were   able   to   detect   samples   refractory   to   the   standard-­of-­care  
therapies   for   RMS,   reflecting   the   clinical   course   of   the   initial   patients   thus   providing   a  
retrospective  validation  of  our  model.  By  using  a  combinatorial   large  drug-­screen  approach,  we  
Summary  
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identified   ABT-­263   as   top   scoring   drug   capable   of   sensitizing   resistant   RPCs   to   conventional  
chemotherapeutics   (doxorubicin,   etoposide   and   vincristine).   From   a  mechanistic   standpoint   we  
show  that  ABT-­263/standard  chemotherapy  exploit   the  BCL-­XL/MCL-­1  axis  and  partially  rely  on  
the   induction   of   the   pro-­apoptotic   BH3-­only   protein   NOXA.   Finally,   we   also   outline   a   clear  
correlation  between  over-­activation  of  Hh  signaling  and  tumor  recurrence  in  our  set  of  PDX  and  
RPCs   and   demonstrate   the   feasibility   of   pharmacologically   targeting   a   cancer   stem   cell   (CSC)  
signal  to  counteract  chemo-­resistance.  
Taken  together,  the  studies  presented  in  this  thesis  underscore  the  functional  relevance  of  novel  
pre-­clinical  models  to  prioritize  actionable  drug  targets  or  combinatorial  options  for  RMS  patients  
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2.  Zusammenfassung  
  
Lange  Zeit  war  histologische  Analyse  die  Methode  der  Wahl  zur  Tumor  Klassifizierung.  Die  über  
Jahrzehnte   immer   weiter   verfeinerte   Subklassifizierung   in   Kombination   mit   Korrelation   mit  
Therapieerfolg  vereinfacht  auch  heutzutage  die  Wahl  der  Therapie  und  erlaubt  damit  verbundene  
prognostische  Voraussagen.    
Mit   dem   Aufkommen   von   Hochdurchsatz-­Sequenzierverfahren   können   nun   die   ursächlichen  
genetischen  Veränderungen  in  den  verschiedenen  Tumortypen  ermittelt  werden.  Diese  Methode  
ermöglicht   die   direkte   Identifizierung   von   therapeutischen   Zielen   und/oder   prognostischen  
Markern  in  individuellen  Tumoren.  Dies  ist  insbesondere  bei  Tumoren  mit  vielen  Mutationen  von  
grossem  Nutzen.  Bei  kindlichen  Tumoren  ist  die  Zahl  an  genetischen  Veränderungen  pro  Tumor  
allerdings  sehr  klein.  Dies  wiederum  schränkt  die  Menge  an  möglichen   therapeutischen  Zielen,  
welche   mittels   Sequenzierung   identifiziert   werden   können,   stark   ein.   Ein   Beispiel   für   einen  
solchen  Tumor   ist  das  Rhabdomyosarkom   (RMS).  Das  RMS   ist  das  häufigste  Weichteilsarkom  
bei   Kindern,   wobei   man   zwei   Haupt-­Subtypen   unterscheidet,   das   alveoläre   (aRMS)   und   das  
embryonale   (eRMS)  RMS.   Trotz   grossen  Fortschritten   bei   der   Behandlung  mit   konventionellen  
Therapien  sterben  heutzutage  immer  noch  rund  30  Prozent  aller  Patienten  an  diesem  Tumor  und  
neuartige,  gezielte  Medikamente  sind  leider  noch  nicht  erhältlich.  
Das   kürzlich   beschriebene   Mutationsspektrum   im   RMS   zeigt,   dass   rund   80   Prozent   der   Fälle  
hauptsächlich   die   schon   länger   als   ursächliche   Mutationen   bekannten,   spezifischen  
Fusionsproteine   PAX3-­FOXO1   und   PAX7-­FOXO1   aufweisen.   Die   Zahl   weiterer   Mutationen   ist  
hingegen   ist   sehr   klein   und   ausserdem   als   Therapieziel   meist   ungeeignet.   Daher   wäre   ein  
Testsystem,   mit   welchem   man   den   Effekt   von   neuen   Medikamenten   direkt   auf   RMS  
Patientenzellen   messen   kann,   von   grossem   Nutzen   für   die   Klinik.   Zwar   wurden   in   der  
Vergangenheit   einige   Versuche   in   diese   Richtung   unternommen,   dies   hat   aber   leider   nur   in  
seltenen   Fällen   zur   Entdeckung   von   klinisch   wirksamen   Medikamenten   geführt.   Ein   wichtiger  
Grund   dafür   ist,   dass   für   diese   Versuche   meist   eine   geringe   Zahl   an   etablierten   Zelllinien  
verwendet   wurde,   welche   die   Charakteristika   der   Patiententumore   in   ungenügender   Weise  
abbilden.   Eine   Verbesserung   der   Modelsysteme   würde   somit   eine   wichtige   Lücke   schliessen.  
Das  Ziel  der  hier  vorliegenden  Arbeit  war  daher,  eine  optimierte   in  vitro  und   in  vivo  Plattform  für  
Medikamententests   am  RMS  zu  etablieren.  Dazu  haben  wir   erst   eine  grosse  Anzahl   von  RMS  
Tumoren   als   Xenografts   in   Mäusen   etabliert.   Anschliessend   haben   wir   18   verschiedene  
Kulturbedingungen   getestet,   um   die   optimalen   Bedingungen   für   die   in   vitro   Kultur   von   daraus  
isolierten  RMS  Zellen  zu  finden.  Wir  konnten  dabei  zeigen,  dass  insbesondere  Kälberserum,  eine  
wichtige  Komponente   klassischer   Zellkulturmedien,   eine   toxische  Wirkung   auf   die   Primärzellen  
hat.   Unter   bestimmten   Serum-­freien   Bedingungen   hingegen   proliferieren   die   RMS   Zellen   nicht  
nur,  sondern  es  bleiben  auch  wichtige  Eigenschaften  wie  die  klonale  Zusammensetzung  und  der  
Zusammenfassung  
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charakteristische  Phänotyp  des  Ursprungstumors  erhalten.  Wir   haben  derartig   kultivierte  Zellen  
daher   in   einem   zweiten   Schritt   als   Model   für   Screenings   mit   einer   Bibliothek   an   klinisch  
erhältlichen   Medikamenten   verwendet.   Dies   führte   zur   Entdeckung,   dass   RMS   Zellen   von  
gewissen   Patienten   sensitiv   gegenüber   AKT   Inhibitoren   sind.   Mit   Zellen   aus   Tumoren,   welche  
resistent   gegenüber   der   Standardchemotherapie   sind,   wurde   ein   analoges   Screening   in  
Kombination  mit  Chemotherapie  durchgeführt.  Dabei  entdeckten  wir,  dass  die  Substanz  ABT-­263  
RMS  Tumore  für  die  Standardtherapie  (Doxorubicin,  Etoposid  und  Vincristin)  resensitisiert.  Eine  
genauere   mechanistische   Analyse   zeigte,   dass   dieser   Effekt   durch   eine   Kombination   der  
Blockierung   von   BCL-­XL   durch   ABT-­263   und   Runterregulierung   von   Mcl1   durch   die  
Chemotherapie   zustande   kommt.   BCL-­XL   und   MCL-­1   sind   zwei   anti-­apoptotische   Proteine,  
welche  in  resistenten  Tumoren  häufig  hochreguliert  sind.  
Zum  Schluss  konnten  wir  mittels  unserer  Xenograft  Sammlung  auch  eine  klare  Korrelation  von  
aktiviertem   Hedgehog-­Signaling   und   Tumor-­Rückfall   zeigen.   Pharmakologische   Blockierung  
dieses  mit  Stammzellen  assoziierten  Signalwegs  hatte  ebenfalls  eine  resensitisierende  Wirkung  
gegenüber  der  Standardtherapie.    
Zusammengefasst   bestätigt   unsere   Studie,   dass   optimierte   Tumormodelle   einen   wichtigen  
Beitrag   zu   einer   effizienteren   und   zielführenderen   Identifikation   von   Therapieansätzen   für   das  
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3.  List  of  Abbreviations  
  
     
ABC   ATP-­binding  cassette    
aCGH   array  comparative  genomic  hybridization  
ADAM   A  disintegrin  and  metalloproteinase  
AKT  (PKB)     Protein  kinase  B  
ALDH1   Aldehyde  Dehydrogenase  1    
ALL   acute  lymphoblastic  leukemia    
AML   acute  myelogenous  leukemia    
APAF   apoptosis  protease-­activating  factor  1    
APC   Adenomatous  polyposis  coli    
ARMS   Alveolar  RMS  
ATM   Ataxia-­telangiectasia  mutated  
ATR   Ataxia-­telangiectasia  and  RAD3-­related  protein  
AXIN2   Axis  inhibition  protein  2  
BAD   BCL-­2-­associated  death  promoter  
BAK   BCL-­2  antagonist/killer  
BAX   BCL-­2  associated  X  protein  
BCC   basal  cell  carcinomas    
BCL-­2     B-­cell  lymphoma  2  
BCL-­B     BCL-­2-­like  protein  B  
BCL-­XL     B-­cell  lymphoma-­extra  large  
BCNS   Basal  Cell  Nevus  Syndrome  
BCOR   Back  central  optic  radius  
BFL/A1     BCL-­2-­related  protein  A1  
BID   BH3-­interacting  domain  death  agonist  
BIM   (BCL2L11)  BCL-­2-­like  protein  11  
BMF   BCL-­2-­modifying  factor  
BOC   brother  of  CDO    
CAM   chorioallantoic  membrane    
CDK4   Cyclin-­dependent  kinase  4  
CDKN   Cyclin-­dependent  kinase  inhibitor  
CDO   cell  adhesion  molecule  down-­regulated  by  oncogenes    
CDX   cell-­derived  xenografts    
CKI   casein  kinase  family    
CLL   chronic  lymphocytic  leukemia    
CML   Chronic  myeloid  leukemia  
CMT1000   Center  for  Molecular  Therapeutic  1000    
CNS   central  nervous  system    
CNV   copy  number  variants    
COG   children’s  oncology  group    
  CRC   colorectal  cancer    
CRISPR/cas9   Clustered  Regularly  Interspaced  Short  Palindromic  Repeats/  
associated  protein-­9  nuclease  
CSC   cancer-­stem  cell    
CSL   CBF1/Suppressor  of  Hairless/LAG1  
DAPI   4’,6-­Diamidino-­2-­Phanylindole  
DHH   Desert  Hedgehog    
DISP   Dispatched    
DLL   Delta-­like  ligand  
DMEM   Dulbecco’s  Minimum  Essential  Medium  
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DMSO   Dimethylsulphoxide  
DPD   dihydropyrimidine  dehydrogenase    
DTP   Developmental  Therapeutic  Program    
ECM   extracellular  matrix    
EpSSG   European  paediatric  Soft  tissue  sarcoma  study  group    
ER   estrogen  receptor    
ERK   Extracellular  signal  Regulated  Kinase  
ERMS   Embryonal  RMS  
ESC   Embryonic  stem  cells    
FBS   Fetal  Bovine  Serum  
FBXW7   F-­box/WD  repeat-­containing  protein  7  
FDA   Food  and  Drug  Administration    
FGFR   Fibroblast  growth  factor  receptor  
FISH   fluorescence  in  situ  hybridization    
FOXO   Forkhead  box  O  
Fz   Frizzled    
GAS1   Growth  arrest-­specific  gene  1  
GEM   genetic-­engineered  mice    
GEMM   Genetically  engineered  mouse  models    
GF   growth  factor  
GLI   Glioma-­associated  oncogene    
GPCR   G-­protein-­coupled  receptor    
GSK3-­b     glycogen  synthase  kinase  3  b    
HBC   human  breast  cancer    
HDAC1   histone  deacetylase  1    
HES   Hairy  and  enhancer  of  split-­1  
HEY   Hairy/enhancer-­of-­split  related  with  YRPW  motif  protein1  
Hh   Hedgehog  
HHIP   Hedgehog-­interacting  protein    
IGF   Insulin  growth  factor  
IHC   immunoistochemistry  
IHH   Indian  Hedgehog    
IRSG   Intergroup  Rhabdomyosarcoma  Study  Group    
JAG   Jagged    
JFCR39   Japanese  Foundation  for  Cancer  Research  
LEF1   Lymphoid  enhancer-­binding  factor  1  
LRP   lipoprotein  receptor-­related  protein  
MCL-­1     Induced  myeloid  leukemia  cell  differentiation  
MDM   Mouse  double  minute  
MDR1   multidrug  resistance  protein  1  
MEK   Mitogen-­activated  protein  kinase  
mESC   mouse  embryonic  stem  cell  
MM   multiple  myeloma  
MOMP   mitochondrial  outer  membrane  permeabilization  
MRF   myogenic-­regulatory  factors  
MTOR   mammalian  target  of  rapamycin  
MYC   Myelocytomatosis  oncogene  
MYF   Myogenic  factor  
NCI   National  Cancer  Institute  
NF1   Neurofibromin  1  
NICD   Notch  intracellular  domain  
NOS   not  otherwise  specified  
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NSCLC   non-­small  cell  lung  cancer    
PCP   planar  cell  polarity  
PDGFRA   Platelet-­derived  growth  factor  receptor  A  
PDX   patient-­derived  xenografts  
PFN   PAX-­fusion  negative  
PFP   PAX-­fusion  positive  
PI3K   Phosphoinositide-­3-­kinase  
PKA   Protein  kinase  A  
PLK1   Polo-­like  Kinase  1  
PPTP   Pediatric  Preclinical  Testing  Program    
PUMA   P-­53  upregulated  modulator  of  apoptosis  
qRT-­PCR     quantitative  Real-­Time  Polymerase  Chain  Reaction  
RAS   Renin-­Angiotensin  System  
RBPJ   Recombination  signal  binding  protein  for  immunoglobulin  Kappa  J  
region  
RMS   Rhabdomyosarcoma  
RPCs   RMS  primary  cultures    
RT   radiotherapy    
SC   stem  cell    
SFRP3   secreted  frizzled-­related  protein  3    
sgRNA   small  guide  RNA  
SHH   Sonic  hedgehog    
SMN   second  malignant  neoplasm  
SMO   Smoothened  
SSR   site-­specific-­recombinase  
SUFU   suppressed  of  fused    
Tam   4-­hydroxytamoxifen    
TCF/LEF   T-­cell  factor/lymphois-­enhancer  factor    
TIC   tumor-­initiating  cell    
TMZ   temozolomide  
TRE   tet-­regulatory  elements    
tTA   tetracycline  transactivator  protein    








1  The  paragraphs  4.6.2.3,  4.6.2.3.1,  chapter  4.7  and  paragraph  7.4  have  been  adapted  from  the  published  review:    
Manzella,   G.   and   Schäfer,   B.W.,   Interfering   with   Hedgehog   Pathway:   New   Avenues   for   Targeted   Therapy   in  
Rhabdomyosarcoma.  Current  drug  targets,  2016.  17(11):  p.1228-­1234.  	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4.  Introduction1  
4.1.  Cancer:  a  general  overview  
Cancer  is  a  group  of  diseases  characterized  by  an  abnormal  growth  of  “malignant”  cells,  able  to  
invade   their   surrounding   stroma   and   eventually   spread   throughout   the   body.   It   represents   the  
second  leading  cause  of  death  with  about  22,000  deceases  a  day  worldwide  and  is  predicted  to  
rise  by  40%  in  2030  [1,  2].  
There  are  more  than  100  types  of  cancers,  which  can  be  classified  into  four  main  groups  based  
on  their  histological  origin:  carcinoma  (from  epithelial  cells),  sarcoma  (from  mesenchymal  cells),  
hematological   tumors   (from   blood   cells)   and   neuroectodermal   malignancies   (from   cells   of   the  
nervous  system).  A  report   from  2012  estimated  that   in  adults,  cancers  of   the   lung,  the  prostate,  
the   breast   and   the   colon   are   the  most   common  and   account   for   the  majority   of   cancer-­related  
deaths  worldwide  (Figure  1A,  right)  [1].  A  different  scenario  is  observed  for  childhood  cancers  (0-­
14  years),  which  have  a  different  incidence  and  tumor  spectrum.  For  instance,  they  represent  less  
than   2%   of   the   global   cancer   burden   albeit   remain   a   leading   cause   of   death   in   children   in  
developed  countries.  Children  develop  mostly  hematologic  tumors  followed  by  brain  tumors  and  
sarcoma  (Figure  1A,  left)  [3,  4].  The  causative  mechanisms  of  cancer  can  be  intrinsic  or  extrinsic.  
Among   intrinsic   mechanisms   we   find   genetic   alterations   that   can   be   hereditary   or   caused   by  
random   accidents   of   nature   [5,   6].   Extrinsic   factors   include  mainly   exposure   to   chemicals   (i.e.  
asbestos,   benzene   etc.),   physical   agents   (ionizing   and   non-­ionizing   radiation)   or   biological  
components   (virus   or   bacteria)   as   well   as   age   and   life   style   (exercise,   tobacco   or   alcohol  
consumption   etc.).   Each   of   these   factors,   directly   or   indirectly,   can   promote   the   transition   of   a  
single   cell   (monoclonal   model)   or   multiple   cells   (polyclonal   model)   from   a   “normal”   to   a  
“malignant”   state.   At   the   molecular   level,   this   is   a   multistep   process   in   which   cells   gradually  
acquire   the  ability   to   switch  on  pro-­proliferative,  anti-­apoptotic  and  self-­sufficient  growth  signals  
through   both   genetic   and   epigenetic   changes   that   ultimately   lead   to   the   formation   of   a   tumor  
mass  with   the   potential   to  metastasize   (Figure   1B)   [7,   8].   It   is   now   clear   that   such   structure   is  
composed   of   genotypically   and   phenotypically   distinct   tumor   cells,   which   also   collaborate   with  
stromal   counterparts   to   build   up   a   well-­defined   cancer   ecosystem   protected   from   immuno  
detection  and  provided  of  oxygen  and  nutrient  supply  (Figure  1B)  [9,  10].  The  evidence  of  these  
malignant   traits   can   explain   why   treatment   remains   still   a   challenging   task   for   the   majority   of  
cancer   types.   In   principle,   the   ideal   therapy   aims   at   the   cessation   of   the   tumorigenic   state   by  
inducing   cell   death,   senescence   or   differentiation   while   sparing   normal   cells.   To   do   so,   an  
important  prerequisite  is  the  availability  of  pre-­clinical  models  being  discussed  in  the  next  chapter.  
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Figure   1.   Frequency   of   cancer   in   children   and   adults   and   Hallmarks   of   cancer.   (A)  
Frequency  of  cancer  diagnosed  in  children  (left)  and  adults  (right)  according  to  2012  Surveillance,  
Epidemiology   and   End   Results   (SEER)   data.   Adapted   from   [3].   (B)   The   10   malignant   traits  
characterizing  cancer.  Adapted  from  [10].    
  
4.2.  Pre-­clinical  models  of  cancer  
The   final   goal   of   cancer   research   is   to   find   medical   agents   of   clinical   benefit.   They   include  
nonspecific  cytotoxic  chemotherapeutics,  which  interfere  with  rapidly  dividing  cells  irrespective  of  
normal  or  cancerous  phenotype  and  targeted  therapy,  which  is  oriented  towards  a  cancer  specific  
vulnerability.  If  chemotherapy  remains  the  standard  of  care  for  the  majority  of  cancers,  molecular-­
oriented  compounds  are  also  on  their  way  to  the  clinic.  Successful  examples  of  these  are  retinoic  
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acid   for   treatment   of   leukemia   bearing   PML-­RARa   translocation,   herceptin   for   HER2+   breast  
cancers   and  gleevec   for  BCR-­ABL+   chronic  myeloid   leukemia   (CML)   patients   [11].   To   achieve  
this,  both  basic  and  translational  research  rely  on  the  use  of  pre-­clinical  models  that  can  serve  as  
tools  to  study  the  biology  of  cancer  and  design  new  treatment  strategies  [12].  Both  in  vitro  and  in  
vivo   models   are   widely   used   in   pre-­clinical   settings   and   each   of   them   has   strengths   and  
weaknesses.  
  
4.2.1.  In  vitro  models  
  
4.2.1.1.  Cancer  cell  lines:  historical  perspective    
In  1952  Gey  and  colleagues  established  the  first  human  cancer  cell  line,  which  was  derived  from  
an   adenocarcinama   of   the   cervix   and   named   Hela   (Figure   2)   [13,   14].   They   reported   a  
“continuous  culture  for  almost  1  year  in  a  mixture  of  chicken  plasma,  bovine  embryo  extract  and  
human  placenta   cord   serum”   [15].   This  was  also   the   period  when  Dulbecco  described   the   first  
procedures   of   propagation   of  monolayer   cultures   through   the   use   of   trypsin,   which   is   routinely  
used   in   standard   culture   protocols   nowadays   [16].   Only   few   years   later,   traditional   cell   culture  
media   were   defined   in   order   to   limit   the   variability   of   biological   fluids   or   tissue   extracts,   and  
together  with  the  development  of  methods  of  cryopreservation,  boosted  the  generation  of  cancer  
cell   lines   from  a  wide   range  of   tumor   types   [16-­18].  However,   in   the   late   1970s,   the   validity   of  
cancer  cell  lines  as  pre-­clinical  model  was  questioned  by  the  study  of  Nelson  and  Flandermeyer  
who  documented  an  inter-­  and  intraspecies  contamination  of  most  of  the  cell  cultures  available  at  
that   time   (279   cell   lines)   [19].   Thus,   most   of   the   pre-­clinical   platforms   were   based   on   mouse  
allograft   models   of   which   the   Developmental   Therapeutic   Program   (DTP)   from   the   National  
Cancer  Institute  (NCI)  is  a  well-­known  example  since  1955.  Over  almost  30  years  of  drug  testing,  
only   few   compounds   entered   the   clinic   comprising   mostly   cytotoxic   drugs   (i.e.   vincristine   and  
procarbazine),  and   later  on  was  clearly  demonstrated   the  poor  predictive  value  of  such  models  
[20-­22].  Based  on  these  disappointing  data,  cancer  cell   lines  caught  again  the  attention  as  new  
tools  to  anticipate  drug  response  in  cancer  patients.  The  pioneering  initiative  in  this  direction  was  
the  National  Cancer  Institute  60  (NCI60)  program  launched  in  the  late  1980s,  intended  to  offer  a  
new  anticancer  screen  platform  able  to  interrogate  a  panel  of  60  cancer  cell  lines  (representative  
of   9   tumor   types)   for   the   response   to   10.000   compounds   a   year   [23].   This   big   scientific   effort,  
represented  not  only  the  base  for  future  high-­throughput  technologies,  but  led  to  the  discovery  of  
new  candidate  anticancer   agents.  One  example,   is   the  proteasome   inhibitor   bortezomib,  which  
was  approved  by  US  Food  and  Drug  Administration  (FDA)   for   the   treatment  of  myeloma  only  8  
years   since   its   discovery   [23].   Additionally,   the   Japanese   Foundation   for   Cancer   Research  
(JFCR39)  platform  in  1999  and  the  Molecular  Therapeutic  1000  (CMT1000)  screen  in  2006  were  
established  with  the  goal   in  mind  of   increasing  the  repertoire  of  cancer  cell   lines  for  drug  profile  
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and   facilitate   data   extrapolation   based   on   new   data   mining   techniques   able   to   predict  
mechanisms  of  action  of  new  compounds  (Figure  2)  [18,  23].  Importantly,  with  the  advent  of  new  
genomic-­   and   transcriptomic-­based   technologies,   it   was   possible   to   integrate   mutational  
information  or  gene  expression  signatures  with  drug  sensitivities,  which  opened  the  possibility  of  
stratifying   patients   according   to   molecular   attributes   rather   than   to   histiopathologic   proprieties  
[18].   This   underscores  also   the  enormous  heterogeneity   across   cancer   patients   and   raises   the  




Figure   2.   Timeline   of   the   key   discoveries   for   the   establishment   of   in   vitro   pre-­clinical  
models.  Adapted  from  [18].  
  
  
4.2.1.2.  Cancer  cell  lines  and  patient-­derived  cells:  the  pros  and  cons  
As  mentioned  above,  2D  culture  of  cancer  cells  is  a  gold  standard  model  for  cancer  research  that  
helped   to   increase  our   current   understanding  of   the  molecular   circuitry   of   cancer   as  well   as   to  
identify   molecular   targets   for   translation   research   purposes.   An   easy   explanation   for   their  
widespread   use   can   be   ascribed   to   three   main   characteristics:   1)   easy   to   manipulate   and  
propagate,  2)  suitable  for  large  high-­throughput  approaches  and  3)  circumvent  ethical  issues  and  
challenges   associated   with   labor-­intensive   and   time   consuming   animal   models   [24].   However,  
monolayer   cell   cultures   cannot   suit   the   perfect   cancer   model   and   inherent   caveats   should   be  
taken   into   considerations   according   to   the   research   question   to   address.   For   instance,   an  
important  criticism  accompanying  this  model  is  that  it  lacks  of  heterotypic  interactions  with  stromal  
cells,   a   functional   relevant   feature   of   the   primary   tumor   (Figure   3).   As   consequence,   only   cell-­
autonomous   effects   can   be   assessed,   thus   precluding   the   possibility   of   identifying   cancer  
vulnerabilities   dependent   on   the   microenvironment   (i.e.   vasculature,   immune   system   etc.)   or  
leading   to   misinterpretation   regarding   the   importance   of   relevant   signaling   pathways   [25,   26].  
Also,   repeatedly   in   vitro   passaged   cancer   cell   lines   are   often   associated  with   “plastic”   artifacts  
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due  to  genomic   instability  and  are  selected  for  high  proliferative  cells   leading  to  a   loss  of   tumor  
heterogeneity  (Figure  3)  [12,  27,  28].    However,  these  limitations  might  be  mitigated  with  the  use  
of  short-­term  culture  of  patient-­derived  cells,  which  can  also  accomplish  the  important  function  of  
maintaining   the   representation   of   rare   cancers   for   in   vitro   biological   studies   [25].   Furthermore,  
patient-­derived  cells  might  replace  the  multitude  of  misidentified  cancer  cell  lines  still  in  circulation  
among  the  scientific  community  and  also  extend  the  knowledge  of  patient-­to-­patient  variability  for  
personalized  medicine  interventions  [19,  25].  Nevertheless,  their  derivation  is  often  limited  by  the  
size   of   the   tumor   biopsies   or   technical   difficulties.   Hence,   new   culture   methods   have   been  
recently   described   for   certain   cancers   together   with   new   biologically   relevant   in   vitro   model  




Figure  3.  Derivation  of  cell  lines  from  the  primary  tumor.  Schematic  representation  of  the  two  
main  drawbacks  associated  with  traditional  approach  of  culturing  cancer  cell  lines  namely  loss  of  
tumor  microenviroment  and  clonal  selection.  Modified  from  [31].  
  
4.2.1.3.  3D  models:  a  lesson  from  developmental  biology  for  the  formation  
of  tumor  organoids    
Tumor  organoids  can  be  simply  described  as  cancer  cells  embedded  in  a  three-­dimensional  (3D)  
matrix,   which   can   self-­organize   in   an   organ-­like   structure   reminiscent   of   the   original   tumor  
architecture.  The   idea  of  expanding  normal   tissues  ex  vivo   is  an  old  concept   that  started   in   the  
early   1900’s   with   the   hanging   drop   method   for   culturing   tissue   fragments,   which   was   further  
refined  in  the  1950’s  with  the  studies  of  chicken  embryogenesis  [32,  33].  Twenty  years  later,  the  
extracellular  matrix  (ECM)  was  recognized  as  a  critical  component  of  tissues  that  can  affect  cell  
morphogenesis  and  differentiation  (i.e.  hepatocytes  and  mammary  epithelial  cells),  a  feature  that  
could   not   be   mimicked   on   simple   plastic   [34].   Notably,   with   the   discovery   of   matrigel   in   1977  
(matrix   extracted   from   chondrosarcomas)   and   the   establishment   of   the   first   mouse   embryonic  
stem   cell   (mESC)   line   in   1981,   researchers   had   all   the   tools   to   recapitulate   mechanisms   of  
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organogenesis  in  complex  3D  in  vitro  systems  [34,  35].  However,  only  with  the  seminal  studies  of  
Hans  Clevers   and  Yoshiki   Sasai   in   the   late   2000’s   that   organoids   became   popular   among   the  
scientific   community   [24].   Indeed,   mini   organ-­like   structures   could   be   finally   established   by  
combining  defined  culture  conditions  mimicking  the  specific  tissue  microenviroment  together  with  
the  use  of  stem  cells  or  progenitor  cells  and  matrix  support  (Figure  4).  These  structures  fulfill  two  
important   characteristics   of   morphogenesis   namely   cell   segregation   and   fate   specification   of  
progenitor  cells   [35].     Consequently,   they  have   important   implications   in  disease  modeling  such  
as  infectious  and  degenerative  diseases  as  well  as  cancer.    
  
                                               
Figure  4.  Schematic  overview  of  the  current  organoids  generated  from  PSCs.  Adapted  from  
[36].  
  
4.2.1.4.  Tumor  organoids  as  preclinical  model  
Tumor  organoids  represent  the  evolution  of  2D  cancer  cell  lines  and  cover  the  “dimensionality”  of  
in  vivo   tumor  models  (Figure  5).  Currently,   they  have  been  established  from  a  variety  of  cancer  
entities   including   colorectal,   prostate,   pancreas   and   glioblastoma   tumors   [37-­40].   Due   to   their  
spatial  organization,  tumor  organoids  are  suitable  to  capture  the  heterogenic  cellular  distribution  
and  to  study  how  this  is  influenced  by  the  tumor  microenviroment  including  exposure  to  nutrients,  
oxygen  and  growth  factors  although  this  occurs  by  simple  diffusion.  For  instance,  in  glioblastoma-­
derived   organoids   it   was   possible   to   recapitulate   the   perivascular   and   hypoxic   niche  
characterizing   the  primary   tumor  specimens.   In  particular,  a  defined  hierarchical  organization  of  
the  tumor  cells  was  observed,  with  proliferative  SOX2+  cancer-­stem  cells  (CSCs)  populating  the  
periphery   of   the   organoids   close   to   the   differentiated   and   radiosensitive   SOX2-­   cells   whereas  
quiescent  and  radioresistant  CSCs  were  confined  to  the  hypoxic  regions.  Therefore,  this  enables  
the   investigation   of   dynamic   changes  within   phenotypically   and   functionally   diverse   cancer   cell  
subpopulations,  which  might  affect  therapy  response  [40].  Similarly,  organoids  derived  from  early  
and   late   stage  colorectal   cancer  patients  offered  an   in   vitro   platform   to   investigate  niche   factor  
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requirements   during   cancer   evolution   along   with   occurring   genetic   alterations   [41].   This   latter  
could   be   modeled   in   engineered   organoids   via   Cripr/CAS9   and   helped   to   clarify   that   driver  
mutations   followed   by   genomic   instability   are   needed   for   the   invasive   behavior   of   colorectal  
cancers  [42].  Such  study  also  highlights  the  feasibility  of  genetic  manipulation  in  tumor  organoids.    
Despite   recent   findings   pointing   towards   implementation   of   tumor   organoids   for   precision  
medicine   strategies,   still   it   may   take   some   time   before   this   methodology   enters   co-­clinical  
programs.   In   fact,   high-­throughput   drug   screens   in   tumor   organoids   require   considerable  
expertise   and   the   heterogeneity   in   size,   shape   and   drug   penetration   can   complicate   the  
reproducibility  of  drug-­response  analysis   [43].  Similar   to  cancer  cell   lines,   tumor  organoids   lack  
the  cellular  microenviroment  albeit   “heterotypic  organoids”  might  be  explored   in   the  near   future.  
Yet,   the  3D  architecture   is   not   amenable   to  blood   tumors,   accounting   for   a   large   fraction  of   all  
human  cancers  and  for  which  in  vitro  studies  are  still  hampered  by  the  absence  of  efficient  culture  
methods.   Overall,   tumor   organoids   can   be   viewed   as   a   “young”   but   attractive   and   promising  
predictive  technology  that  falls  in  between  traditional  cancer  cell  lines  and  in  vivo  mouse  models  
of  cancer.    
  
  
Figure   5.   Generation   of   tumor   organoids.   Organoids   can   be   generated   upon   embedding  
tumor-­derived   cell   suspensions   in   matrigel   and   under   defined   culture   conditions.   Clonal  
heterogeneity   and   tissue   architecture   can   be   preserved   but   similar   to   cancer   cell   lines,   only  
homotypic  interactions  are  present.  Modified  from  [31].    
  
4.2.2.  In  vivo  models:  Mouse  models  
Mice   constitute   a   versatile   tool   for   modeling   human   diseases   due   to   their   close   genomic  
(including   disease-­related   genes)   and   anatomic   similarity   to   humans,   relatively   easy   to   handle,  
little  in  size  and  the  fact  that  they  multiply  quickly.  However,  important  differences  exist  including  
transcription   regulation,   chromatin   organization,   immune   system,   drug  metabolism   and   lifetime  
[44,  45].  Hence,  which  would  be  the  most  appropriate  predictive  model  of  human  cancer?  Ideally,  
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tumors  resembling  the  human  counterpart  should  arise  from  genetic  lesions  and/or  environmental  
factors   responsible   for   human   cancers   through   a   multistep   process   occurring   in   a   native  
microenvironment   [46].   Although   many   of   these   features   could   be   recapitulated   in   genetic-­
engineered  mice   (GEM)  and  carcinogen-­induced  cancer  models,  still   the  molecular  and  cellular  
diversity  encountered   in  cancer  patients  might  be  better  preserved   in  patient-­derived  xenografts  
(PDXs).  Some  of  these  models  will  be  discussed  in  the  next  paragraph.  
  
  4.2.2.1.  PDX  models  
PDX  models  are  generated  by  implantation  of  freshly  resected  tumor  biopsies  as  tumor  pieces  or  
cell   suspensions   in   immunodeficient   mice   (often   NOD/SCID   and   NOD/SCID/IL2l-­receptor   null  
(NSG))  either  subcutaneously  or  orthotopically  (Figure  6).  Since  tumor  tissues  are  expanded  and  
maintained  in  a  more  physiological  environment  in  vivo,  PDXs  are  considered  to  provide  a  better  
approximation  of  human  tumor  biology  than  cell-­derived  xenografts  (CDXs),  which  are  generated  
from  transplantation  of  cancer  cell  lines  adapted  to  thrive  on  plastic.  Accordingly,  several  studies  
demonstrated  a  general  preservation  of  tumor  patient  characteristics  in  these  non-­autochthonous  
models   in   terms   of   genetic   and   transcriptomic   landscape   as   well   as   histopathologic   features  
although  continuous  mouse-­to-­mouse  passages  are  associated  with  a  progressive   replacement  
of  human  with  murine  stroma  [47].  Such  validations  can  be  performed  by  copy  number  variants  
(CNVs)   analysis   and   DNA   sequencing   to   study   the   clonal   composition,   immunoistochemistry  
(IHC)   to   detect   lineage-­specific   markers   and   RNA   sequencing   approaches   to   confirm  
concordance  of   gene  expression   profiles   between   tumor   donor   and  PDX   [47].  Despite   the   fact  
that  expanding  patient-­derived  tumor  tissues  directly  into  mice  is  not  a  new  concept,  only  recently  
there  has  been  a  renewed  interest  in  PDX  models  from  both  the  industry  and  academia.  Probably  
this   is   due   to   an   increasing   availability   of   systematic   clinical   data   annotation   and   sample  
collections,  accessibility  to  novel  and  more  affordable  genome  sequencing  technologies  for  tumor  
characterization  along  with  the  recognized  failure  of  traditional  pre-­clinical  platforms.  In  fact,  PDX  
models  have  major  advantages  for  drug  development  studies.  They  offer  the  unique  opportunity  
of   simulating   clinical   trials   in   a   population   of  PDX   carrying  mice   reflecting   the   inter-­patient   and  
intra-­tumor  heterogeneity  encountered  in  the  clinic.  This   is  demonstrated  by  the  close  treatment  
response   concordance   (~   90%)   between   PDX   and   original   tumors   achieved   in   human   breast  
cancer   (HBC)  or  non-­small   cell   lung  cancer   (NSCLC)   [48-­50].  Such  phenotype   is  not   limited   to  
conventional   therapies   but   can   be   also   extended   to   targeted   agents   as   observed   for   the  
anticipated  resistance  to  MEK,  PI3K/mTOR  and  EGFR  inhibitors  in  KRAS-­mutant  colorectal  PDX  
models  [47].  Hence,  PDX-­based  pre-­clinical  trials  might  inform  on  patient  stratifications  and  guide  
decision-­making  process  for  treatment.  In  line  with  this,  a  parallel  drug  testing  in  PDX  models  and  
humans  has  been  proposed  for  a  real-­time  assessment  of  treatment  response,  which  can  provide  
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alternative  treatment  modalities  for  the  patient  and  integrate  functional  information  about  potential  
resistance  mechanisms  (reviewed   in   [51]).  Although  ongoing   trials  demonstrate   the   feasibility  of  
these   approaches,   the   establishment   of   PDXs   is   often   hampered   by   the   low   take-­rate   and   the  
long   time  of  engraftment   [51].   In   fact   this  can  be  affected  by  different  variables  such  as  mouse  
strain,   site   of   inoculation,   tumor   type   (i.e.   NSCLCs   have   a   high   take   rate)   or   subtype   (i.e.  
metastatic   or   recurrent   tumors   are   often   over-­represented)   [47].   To   limit   the   cost,   enlarge   the  
spectrum  of  compounds  to  test  and  obtain  predictive  information  in  a  beneficial  time  frame  for  the  
patient,   the   “one  mouse,   one  patient   paradigm”  has  been  proposed   [52,   53].  The  experimental  
model   posits   that   treatment   in   individual  mice   carrying   independent   patient-­derived   tumors   can  
reflect  the  response  of  a  larger  population,  thus  encompasses  the  need  of  using  large  cohorts  of  
mice.  However,  the  lack  of  human  stroma  and  intact  immune  system  are  the  major  drawbacks  of  
these   models,   which   can   be   partially   overcome   with   the   new   “humanized”   mouse   models  
although  they  are  still  in  their  infancy  and  currently  remain  challenging  and  expensive  [54].  
  
                                            
                                                                   
Figure   6.   Establishment   of   PDX   models.   Tumor   biopsies   from   cancer   patients   are   directly  
implanted  into  the  mouse  host.  After  a  variable  latency  phase,  tumors  eventually  grow  and  can  be  
further   expanded   in   a   new   cohort   to   perform   biological   studies.   This   system   prevents   plastic  
adaptation,  preserves  molecular  and  cellular  characteristics  of   the  original  specimen  but   in  vivo  
passages  are  associated  with  a  gradually  loss  of  the  human  stroma.  Modified  from  [55].  
  
4.2.2.2.  GEMM  
Genetically  engineered  mouse  models   (GEMM)  provide  an  autochthonous  system   to  model  de  
novo  cancer  formation  and  progression  upon  genetic  manipulation  of  the  host  genome.  They  can  
be  simply  classified   in   transgenic  and  endogenous  GEMM  (Figure  7).   In   transgenic  GEMM,   the  
transgene   (i.e.   exogenous   cDNA   encoding   for   an   oncogene   or   a   dominant   negative   tumor  
suppressor   gene)   is   expressed   at   non-­physiological   levels   under   either   constitutive   or   lineage  
specific   promoters   into   the   germline   (Embryonic   stem   cells   (ESCs))   or   somatic   cells   (tissue-­
directed  expression  via  adenoviral  constructs)  (Figure  7A)  [56].  Also,  spatiotemporal  regulation  of  
the  transgene  can  be  achieved  via  two  common  methods,  the  tetracycline  (tet)-­inducible  system  
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or   tamoxifen-­regulatable  proteins   (Figure  7A)   [57,  58].  Briefly,   in   the   former  case,   tet-­regulatory  
elements  (TRE)  are  placed  upstream  of  a  minimal  promoter  driving  the  expression  of  the  cDNA  of  
interest   whereas   the   tetracycline   transactivator   protein   (tTA)   or   its   mutated   form   (rtTA)   is  
controlled  by  tissue-­specific  promoters.  In  presence  of  doxocycline,  a  tetracycline  derivative,  tTA  
binding   is   displaced   from   TRE   and   the   expression   of   the   target   gene   is   inhibited   (TET-­OFF)  
whereas   rtTA   binding   is   induced   thus   promoting   transcription   of   the   gene   product      (TET-­ON)  
(Figure  7A,  upper  and  middle  panel).    
The  tamoxifen  system  is  mostly  used  to  generate  inducible  transcription  factors  or  recombinases.  
Here,  a  tissue-­specific  promoter  drives  the  expression  of  the  target  fused  to  the  estrogen  receptor  
(ER),   which   hijacks   the   regulated   protein   into   the   cytosol   in   its   inactivated   form.   Hence,   the  
presence  of   the  ER  ligand,  4-­hydroxytamoxifen  (Tam)  promotes  the  nuclear   translocation  of   the  
active  chimeric  product  (Figure  7A,  lower  panel).    
In  endogenous  GEMM,  traditional  or  novel  genomic  targeting  tools  (i.e.  spontaneous  homologous  
recombination,   engineered   nucleases   and   CRISPR/CAS9   system)   enable   genome-­editing  
modifications  (i.e.  knock-­out  or  knock-­in)  at  the  endogenous  loci  of  ESCs  [56].  Thus,  deletion  of  
tumor   suppressor   genes   or   insertion   of   cancer-­specific   mutations   can   be   applied   under   their  
native  regulatory  machineries.  Also   in   this  case,  conditional  models  are  available,  which  rely  on  
site-­specific-­recombinase  (SSR)  systems  such  as  the  CRE-­loxP  technology  (Figure  7B)  [59].  This  
method   is   based   on   the   tissue-­specific   or   inducible   expression   of   the   recombinase   CRE   and  
insertion   of   pair   of   inverted  DNA  elements,   or   loxP   sites   (elements   recognized   by  CRE)   in   the  
gene  of  interest.  LoxP  sites  can  flank  a  particular  exon  of  the  target  sequence  and  depending  on  
their   orientation,   CRE   can   induce   deletion   or   inversion   thus   disrupting   the   gene   function.  
Otherwise,  a  stop  codon  flanked  by  loxP  can  be  placed  to  suppress  gene  function,  which  can  be  
reversed   by   the   CRE-­mediated   excision   of   the   STOP   codon.   Conditional   knock-­out   not   only  
allows   a   spatio-­temporal   control   but   can   bypass   embryonic   lethality   following   genetic  
manipulations   in   the   germline.   Generally,   GEMM   are   particularly   suitable   models   to   study  
homeotypic   tumor-­stroma   interactions   and   dissect   the   role   of   the   tumor   microenviroment   or  
immune  system  in  cancer  [54].  For  example,  by  using  GEMM  was  possible  to  functionally  explore  
the   contribution   of   mutations   found   in   human   stromal   compartments   and   their   implication   in  
tumorigenesis   as   revealed   for   Tp53   deficiency   or   loss   of   TGF-­b   responsiveness   in   mouse  
fibroblasts   that   accelerates   prostate   cancer   [60,   61].   Also,   it   was   documented   an   augmented  
aggressiveness  of  skin  cancer  following  metalloproteinase  supply  of  bone  marrow-­derived  cells  or  
that  mice  depleted  of  Tp53  and  Perforin  expression  are  predisposed  to  lymphoma,  a  phenotype  
that   is   partially   dependent   on   cytotoxic   CD8(+)   T   lymphocytes   [62,   63].   Importantly,   GEMM  
helped  not  only  in  understanding  the  tumor  promoting  features  of  several  oncogenes  but  also  to  
distinguish  their  role  a  different  phases  of  cancer  progression.  The  most  notable  example  is  the  
TGF-­b   paradox   in   cancer,   a   cytokine   that   can   elicit   tumor-­promoting   or   suppressive   functions  
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depending   on   the   stage   of   the   tumor   [64].   Probably,   one   of   the   most   exciting   applications   of  
GEMM   remains   the   possibility   of   investigating   the   cell-­of-­origin   in   cancer,   which   may   have  
relevant   implications   for   the   design   of   therapies   or   detection   of   early-­disease   biomarkers   [65].  
More  importantly,  key  studies  demonstrate  the  rationale  of  using  GEMM  as  pre-­clinical  platform  to  
validate  the  response  of  targeted  therapies  or  combination  strategies  in  murine  tumors  harboring  
mutations  similar  to  those  found  in  human  cancers  [66-­68].  Accordingly,  it  has  been  proposed  the  
use   of   GEMM   for   testing   therapies   in   defined   genetic   contexts   that   guides   clinicians   in   the  
identification  of  the  best  treatment  for  a  particular  group  of  patients  [69].  However,  similar  to  PDX  
models,  also  GEMM  are  expensive  and  laborious  as  well  as  require  specialized  expertise  to  deal  
with  extensive  complex  breeding.  Additional  shortcomings   include   the  poor  genetic  variability  of  
the   tumors   and   the   non-­synchronous   tumorigenesis   [11].   Taken   together,   GEMM   share   to   a  
certain  extent,  common  characteristics  with  other  in  vivo  models  but  they  faithfully  recapitulate  not  
only  cell-­intrinsic  but  also  cell-­extrinsic  proprieties  of  cancer.  
  
  
     
                                                                                                                          
                                  
                                                                                                              
  
     
                            
  
Figure   7.   Transgenic   and   endogenous   GEMM.   (A)   Transgenic   GEMM.   (A,   upper   panel)  
Constitutive  and  inducible  expression  of  an  oncogene  or  a  dominant  negative  tumor-­suppressor  
gene   (DN   TSG)   under   an   exogenous   tissue-­specific   promoter   (TSP).   (A,   middle   panel)  
Tetracycline-­Inducible   expression   of   the   transgene   (Tg)   via   TET-­ON   (doxocycline   triggers   the  
expression  of  Tg)  or  TET-­OFF  system  (doxocycline  blocks  transcription  of  Tg).  (A,  lower  panel)  
Inducible  expression  of  the  oncogene  via  the  tamoxifen  system.  The  protein  of  interest  is  fused  to  
the  estrogen  receptor  (ERT)  and  is  sequestered  into  the  cytosol  by  the  heat  shock  protein  (HSP)  
whereas   the   presence   of   tamoxifen   (TAM)   activates   the   chimeric   product.   (B)   Conditional  
endogenous  GEMM.  (B,  upper  panel)  The  recombinase  CRE  can  be  expressed  to  induce  gene  
knock-­out  via  recognition  of  the  LoxP  sites  (blue  arrowheads)  flanking  an  exon  of  interest  placed  
in  the  same  orientation.  Also,  a  stop  codon  flanked  by  LoxP  sites  can  be  inserted  into  a  gene  of  
interest  previously  mutated  (asterix  denotes  mutations)  to  inhibit  its  expression.  Only  in  presence  
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of  CRE,  the  mutated  allele  can  be  re-­expressed  via  excision  of  the  stop  codon  (B,  lower  panel).  
Modifed  from  [11,  56].  
  
4.3.  Chemoresistance  in  cancer:  intrinsic  and  acquired  resistance  
In   the   early   1900s,   Paul   Ehrlich   coined   the   word   “Chemotherapy”   to   describe   the   use   of  
chemicals   as   therapy   for   disease.   Thereafter,   most   of   the   drugs   originally   used   for   cancer  
treatment   included   nitrogen   mustard,   folate   antagonists   (i.e.   methotrexate),   antibiotics   (i.e.  
actinomycin   D),   thiopurines   (i.e.   5-­fluorouracil   (5-­FU)),   plant   alkaloids   (i.e.   procarbazine),   and  
corticoids  [22].  They  were  developed  with  the  idea  of  killing  cancer  cells  without  a  real  rationale  
for   their   tumor   specificity   and   represent   what   we   commonly   call   “standard   chemotherapy”.  
Despite  the  general  skepticism  on  their  application  in  patients  in  1960s  due  to  their  side  effects,  
the   subsequent   adjustment   of   treatment   protocols,   the   availability   of   alternative   pre-­clinical  
models,   the   implementation   of   new   drug   combinations   and   multimodal   schedules   led   to   a  
remarkable   improvement   in   progression-­free   survival   of   cancer   patients.   The   best   examples  
remain  leukemia,  Hodgkin’s  disease  and  metastatic  testicular  cancers  [70-­72].  Interestingly,  also  
in   the   era   of   the   “targeted   therapy”,   cytotoxic   drugs   are   still   considered   the   standard   of   care  
treatment   for   a  wide   range  of   cancer   entities.  Nonetheless,   nowadays,   complete   eradication   of  
cancer   is  at   least  partially  hindered  by  the  onset  of  relapse  disease  following  resistance  to  both  
conventional  and  molecularly  targeted  therapy.  
Drug   resistance   can   emerge   as   de   novo   self-­defense   mechanism   to   counteract   anti-­cancer  
therapy   (acquired   resistance)   or   be   a   native   characteristic   of   the   tumor   that   preexists   prior   to  
treatment   (intrinsic   resistance).   Although   in   the   first   scenario,   genetic   determinants   cannot   be  
excluded,  it  is  more  likely  that  the  exposure  to  the  drug  can  induce  an  adaptation  process  from  a  
drug  sensitive  to  a  drug-­tolerant  phenotype  trough  epigenetic  changes  and/or  fluctuations  in  gene  
expression.  Hence,  cells  surviving  to  the  selective  pressure  of   the  drug,  can  be  further  selected  
and  promote  the  emergence  of  a  resistant  population  [73-­75].  This  dynamically  survival  strategy  
might   explain   why   some   relapsed   cancers   can   be   re-­sensitized   to   the   initial   treatment   upon   a  
period   of   “drug   holyday”   [76,   77].   In   the   second   case,   intrinsically   resistant   subpopulations   are  
present  in  the  bulk  of  the  tumor  before  treatment  start  and  eventually  outgrow  under  drug  therapy.  
Re-­population  of   the   lesion  can  be  driven  by  few  hundreds  to  thousands  cells  and  occur  over  a  
long   time   frame   as   demonstrated   for   chemorefractory   metastatic   colorectal   cancer   (CRC)  
receiving  an  EGFR  inhibitor  (ponatinib)  [78].  Therefore,  assuming  a  tumor  mass  composed  of  109  
cells,  one  would  expect  to  find  one  resistant  cell  (neutral  prior  to  treatment)  in  a  million  cells  [79].  
The  proportion  of   resistant   cells  harboring  a  mutation   that  also   increases   the   fitness  of   the  cell  
independently   on   the   treatment   is   anticipated   to   be   intuitively   higher.   Paradoxically,   even  
deleterious   resistant  mutations   (conferring   low   fitness)   are   predicted   to   still   populate   late-­stage  
cancers   [80].   Beside   the   genetic   heterogeneity,   also   non-­genetic   alterations   can   play   a   pivotal  
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role   in   intrinsic   cancer   resistance   including   aberrant   activity   of   signaling   pathways,   drug   target  
modulation   (changes   in   expression   levels),   cell   cycle   arrest,   metabolic   reprogramming   and  
epigenetic   changes   [81-­83].   Each   of   these   functional   proprieties   can   be   incorporated   by   the  
CSCs,  which  are  recognized  as  relevant  mediators  of  drug  resistance  since  are  often  spared  by  
chemotherapy   [84].  CSCs  and   the  underlying  molecular  mechanisms  of  drug   resistance  will   be  
described  in  the  next  paragraph.  
  
4.3.1.  Cancer  stem  cells  and  chemoresistance  
CSCs   are   defined   as   tumor-­initiating   cells   (TICs)   characterized   by   self-­renewal   ability,   multi-­
lineage   differentiation   potential,   long-­term   tumorigenicity   and   are   especially   refractory   to  
conventional   anti-­mitotic   agents   (Figure  8A)   [85-­87].  Due   to   their   similarity   to   stem  cells   (SCc),  
CSCs  are  believed  to  arise  from  genetic  or  epigenetic  alterations  of  their  normal  counterpart.  This  
is  also  in  line  with  the  view  that  they  can  give  rise  to  a  tumor  progeny  composed  of  cells  at  distinct  
stages  of  differentiation  reflecting  the  lineage  hierarchy  of  the  tissue  of  origin  [87].  For  example,  
CSCs   in   pediatric   brain   tumors   resemble   neural   stem   cells   sharing   the   propensity   to   generate  
neural-­lineage  cells  (i.e.  neurons  and  glia)  when  transplanted   in  vivo   [88].  However,   it  has  been  
postulated   that  CSCs  might  also  originate   from  a  more  mature  cell   type  via  a  de-­differentiation  
process  that  promotes  stemness  [89-­91].  The  CSC  model  is  particularly  fascinating  as  it  looks  at  
cancer  as  an  abnormal  organ  that  conserves  mechanisms  operating  during  normal  development  
and  organ  function.  Indeed,  SCs  are  essential  for  morphogenesis  at  the  embryonic  stage  and  for  
tissue   homeostasis   later   on,   thereby   contributing   to   a   tight   balance   of   tissue-­specific  SC  pools  
and   differentiated   cells   during   tissue   turnover   and   repair   [92].   Similarly,  CSCs   are   expected   to  
restore  the  tumor  hierarchy  upon  exogenous  insults  such  as  chemotherapy  or  radiotherapy  thus  
promoting   cancer   relapse.   In   support   of   this   hypothesis,   an   elegant   lineage   tracing   study   in  
GEMM   of   glioblastoma   demonstrated   that   nestin+   CSCs   (GFP   labeled)   were   left   behind   by  
temozolomide   (TMZ)   treatment,   an   alkylating   agent   used   for   the  management   of   brain   cancer  
patients   [93].   Interestingly,   tumor  could  be   re-­established  by   the   residual  GFP+  cells  upon  drug  
withdraw   and   ablation   of   this   subset   of   cells   impaired   tumor   development.   Accordingly,   two  
independent   studies   showed   that   leukemia   initiating   cells   present   in   untreated   tumors   were  
enriched  upon  chemotherapy  and  could  drive  relapse  disease  [94,  95].    
Several  molecular  mechanisms  of  drug  resistance  have  been  attributed  to  CSCs  including  over-­
expression   of   drug   efflux   pumps   or   detoxifying   enzymes,   quiescence,   capacity   to   survive  DNA  
damage  mediated   by   overexpression   of  DNA   repair   systems   and   evasion   of   apoptosis   (Figure  
8A)  [81,  84,  92].    
Cells   can   take   up   drug   molecules   via   either   active   transport   or   passive   diffusion   but   the  
mechanism   whereby   chemotherapy   gets   into   cells   is   poorly   understood.   Nevertheless,   de-­
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regulation   of   drug   uptake   constitutes   an   obvious   “escape”   system   for   cancer   cells   to   get   rid   of  
cytotoxic   drugs.   The  most   studied   transporters   in   the   context   of   drug   resistance   are   the   ATP-­
binding   cassette   (ABC)  efflux   pumps,  which  actively   transport   drugs  out   of   cells.  Among   them,  
ABCB1  (or  multidrug  resistance  protein  1,  MDR1),  ABCG2  (or  breast  cancer  resistance  protein)  
and  ABCC1  (or  multidrug  resistance  associated  protein  1)  have  been  shown  to  be  up-­regulated  in  
many  cancers  and  to  correlate  with  poor  overall  survival  [82,  96-­98].  A  second  barrier  mounted  by  
cancer   cells   to   counteract   the   effect   of   chemotherapeutics   is   drug   inactivation.   In   this   regard,  
dihydropyrimidine   dehydrogenase   (DPD)   and   Aldehyde   Dehydrogenase   1   (ALDH1),   are   well  
known  detoxifying  enzymes  conferring  resistance  to  5-­FU  and  alkylating  agents,  respectively  [82,  
99].   As   consequence,   the   activity   of   both   ABC   transporters   and   ALDH1   are   also   used   as  
surrogate  markers   to   identify   and   purify  CSCs   in   cancer.   A   further   peculiarity   of  CSCs   is   their  
ability  to  hide  from  anti-­mitotic  drugs  by  slowing  down  the  cell  cycle  reaching  a  quiescent  state,  a  
way   to   repair   DNA,   avoid   additional   deleterious   mutations   and   escape   apoptosis   [92].  
Furthermore,   cell   cycle   restriction   can   be   induced   by   environmental   clues,   including   physical  
interaction  with  the  niche  (i.e.  bone  morrow  for   leukemic  blasts)  or  by  niche-­derived  factors  (i.e.  
endothelial  derived   thrombospondin  1   for  dormant  breast  cancer  cells)   [100-­103].  Probably,   this  
plasticity  might  explain  the  long  time  needed  before  tumor  recurrence  occurs  and  represents  the  
main  hurdle  to  conventional  anti-­cancer  agents  targeting  active  cycling  cells  either  in  the  S  (DNA  
damaging  agents)  or  M  phase  (anti-­mitotic  compounds).  Hence,  the  killing  rate  of  a  drug  does  not  
necessary   correlate  with   a   therapeutic   benefit   since   resistant   clones  might   be   refractory   to   the  
treatment.  On  the  other  hand,  compounds  with  a  low  killing  rate  but  targeting  resistant  clones,  are  
anticipated  to  be  paradoxically  more  efficient  in  tumor  control  or  eradication  (Figure  8B)  [79].        
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Figure   8.   Intrinsic   model   of   chemoresistance   following   the   CSC   model   and   therapeutic  
challenges.   (A)  CSCs  (red)  are   intrinsically   resistant   to  conventional   treatment   through  several  
molecular   mechanisms   including   altered   drug   efflux,   drug   target,   DNA   repair,   apoptosis   and  
increased   detoxification   ability.   Therefore   CSCs   are   selected   following   treatment   and   can   re-­
populate   the   tumor   lesion.   Modified   from   [104,   105]   (B)   Mathematical   model   depicting   three  
scenarios:  Therapy  1  and  2  with  the  highest  killing  rate  are  initially  more  effective  (first  year)  but  
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eventually   fail   longer   control   of   cancer.   However,   therapy   3   with   the   lowest   killing   activity   but  
specific  for  resistant  clones  leads  to  tumor  eradication.  Adapted  from  [79].  
  
4.3.2.  Evading  apoptosis  and  chemoresistance  
Although   conventional   chemotherapy   remains   the   mainstay   of   cancer   treatment,   its   mode   of  
action   has   been   poorly   understood   so   far.   The   original   rationale   relied   on   the   assumption   that  
anticancer  agents  should  interfere  with  the  high  division  rate  of  cancer  cells,  which  would  be  more  
vulnerable   than   normal   cells.   This   basic   idea   is   probably   the   key   of   success   for   traditional  
cytotoxic  agents  and  would  justify  their  therapeutic  window  observed  in  cancer  patients.  However,  
it  does  not  explain  why  some  high  proliferative  tumors  are  resistant  and  some  low  cycling  cancers  
are  more  sensitive  to  chemotherapy  [106].  Albeit  many  of  the  factors  mentioned  earlier  can  play  a  
role,  one  possibility   is   that  cancers  might  be  differentially  susceptible   “   to  die”.  One  of   the  most  
studied  form  of  cell  death  is  apoptosis  or  programmed  cell  death  characterized  by  cell  shrinkage,  
chromatin  condensation  and  DNA   fragmentation,  membrane  blebbing   followed  by   the   formation  
of  apoptotic  bodies  ready  to  be  phagocytosed  by  macrophages  [107].  Disabling  apoptosis  is  one  
of  the  pre-­requisites  needed  for  a  cell  to  become  cancerous  but  does  not  mean  that  tumor  cells  
are   insensitive   to   apoptotic   stimuli   [9,   10,   108].   Paradoxically,   the   oncogenic   stress   present   in  
malignant  cells  can  lower  their  apoptotic  threshold,  a  phenomenon  known  as  “priming”  for  death  
(Figure  9)  [106,  109].  Indeed,  two  landmark  studies  demonstrated  that  cancers  not  only  are  more  
primed  to  die  than  normal  tissues  but  that  priming  is  also  an  indicator  of  chemosensitivity  or  risk  
of  recurrence  (Figure  9)   [106,  110].  A  corollary   is   that  when  tumors  encounter  apoptotic  signals  
such  as  those  provoked  by  chemotherapeutics,  is  likely  that  a  selection  process  of  cells  evading  
apoptosis  takes  place  and  contributes  to  chemoresistance  [108].  
Death  signaling  from  chemotherapy,  ultimately  lead  to  either  activation  of  pro-­apoptotic  signaling  
or  inhibition  of  pro-­survival  factors.  One  example  is  the  BCL-­2  family,  which  mainly  mediates  the  
intrinsic   apoptosis   or   mitochondrial   pathway.   This   family   includes   “effectors”   (BAX   and   BAK),  
activators  (BIM,  BID  and  PUMA),  sensitizers  (NOXA,  BAD  and  BMF)  and  inhibitors  (BCL-­2,  BCL-­
XL,  MCL-­1,  BFL/A1  and  BCL-­B)  of   apoptosis   [111].  Hence,   in   presence  of   a   stress   signal   (i.e.  
chemotherapy),   pro-­apoptotic   “effectors”   can   be   activated   and   their   oligomerization   promotes  
mitochondrial   outer  membrane   permeabilization   (MOMP)   followed   by   cytocrome  C   release   into  
the   cytosol.   Here,   it   promotes   the   formation   of   the   apoptosome,   a   complex   composed   of   the  
initiator  caspase  9  and   the  apoptosis  protease-­activating   factor  1   (APAF),   leading   to  proteolytic  
activation  of  the  executioner  caspases  (caspase  3  and  7)  and  cell  death  [82].    
Both  BCl-­2  and  BCL-­XL  over-­expression  and  combined  BAX/BAK   loss  can  confer   resistance   to  
chemotherapy,  although  genetic  inactivation  of  BAX/BAK  is  rarely  found  in  cancer  [108,  112-­115].  
Furthermore,  BAX,  PUMA  and  NOXA  are  also  transcriptional  targets  of  TP-­53,  which  is  mutated  
in  ~50%  of  cancer  entities  and  often  activated  upon  DNA  damage  to   induce  either  apoptosis  or  
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cell   cycle   arrest   [116-­119].   Therefore,   it   is   not   surprising   that   a   non-­functional   TP-­53   is  
accompanied   with   resistance   to   standard   genotoxic   chemotherapy   regimens   and   worse  
prognosis.    
The   beauty   of   anti-­apoptotic   compounds   targeting   directly   the   mitochondrial   machinery   is   that  
they  can  bypass   the  need  of  an   intact  TP-­53.  For   instance,  a  small  molecule   inhibitor  of  BCL-­2  
(ABT-­199)   was   recently   approved   by   FDA   for   the   treatment   of   chronic   lymphocytic   leukemia  
(CLL)   patients   harboring   17p   chromosomal   deletion   (containing   TP-­53)   [120].   Yet,   promising  
results  from  phase  II  clinical  trials  in  refractory  acute  myelogenous  leukemia  (AML)  patients  have  
been   recently   shown   for  ABT-­199  as   single  agent   [121].  The  specificity   of  ABT-­199   for  BCL-­2,  
overcomes  the  on-­target  thrombocytopenia  associated  with  the  inhibition  of  BCL-­XL  by  ABT-­263,  
a  pan  BH3  mimetic   targeting  BCL-­2,  BCL-­XL  and  BLC-­W   [122].  However,   pre-­clinical   data   still  
support   the   use   of   low   doses   ABT-­263   in   combinatorial   treatments   (mainly   with   standard  
chemotherapy),   which  might   be   exploited   also   for   non   BCL-­2   driven-­malignancies   (Figure   9C)  
[123-­126].  The  feasibility  of  targeting  the  apoptotic  machinery  by  using  for  example  BH3  mimetics  
that   simulate   the   function   of   pro-­apoptotic   BCL-­2   members,   opened   new   avenues   for   cancer  
treatment  and   is  demonstrated  by   the   impressive   responses  observed   in   some  cancer  entities,  
mostly   lymphomas.   This   renewed   interest   of   pharmaceutical   companies   led   also   to   the  
development  of  specific   inhibitors  of  other  BCL-­2  members,  such  as  BCL-­XL  and  MCL-­1,  which  
already   entered   clinical   trials   for   hematological   malignancies.   Since   MCL-­1   is   well   known   to  
compensate  for  BCL-­2  or  BCL-­XL  inhibition,  the  combination  of  a  specific  inhibitor  of  MCL-­1  and  
BCL-­2  (or  BCL-­XL)  might  offer  a  valid  approach  to  limit  the  onset  of  resistance  to  BH3  mimetics  
[127].  
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Figure   9.   Priming   for   apoptosis   and   response   to   chemotherapy.   (A)  Cancer   cells   that   are  
more  close  to  the  edge  of  apoptosis  (“primed”)  are  also  more  sensitive  to  further  apoptotic  stimuli  
(i.e   the   ones   induced   by   chemotherapy)   that   induce   irreversible   commitment   to   cell   death.   (B)  
“Unprimed”  cells  are  more   resistant   to   the  anti-­cancer  activity  of  cytotoxic  drugs  since   they  are  
more  distant  from  the  cliff’s  edge  (C)  “Unprimed”  cells  can  be  pushed  closer  to  the  cliff’s  edge  by  
a  sensitizer  agent  that  “prime”  cancer  cells  for  apoptosis  (i.e.  BH3-­mimetics)  and  only  following  a  





4.4.  Pediatric  cancers:  epidemiology,  etiology  and  treatment  
Although  childhood  cancers  are  relatively  uncommon,   they  represent   the  first  cause  of  disease-­
related  death   in  children  (0   to  14  years  of  age)  with  an   incidence  of  ~0.015%  every  year   [128].  
The   most   common   cancers   in   children   younger   than   15   years   old   are   acute   lymphoblastic  
leukemia   (ALL)   (25.4%),   central  nervous  system   (CNS)   tumors   (20.6%)  and  sarcomas   (10.9%)  
[129].  However,   the  distribution  of  cancers   for  15-­19-­year  olds   is  drastically  different  accounting  
mainly   Hodgkin   disease   (16.2%),   germ-­cell/gonadal   tumors   (12.5%)   and   a   lower   incidence   of  
CNS   cancers   (9.8%)   (Figure   10A)   [129].   This   discrepancy   might   reflect   the   need   for   the  
oncogenic  event  to  occur  at  defined  developmental  stages  when  a  specific  cell  population  might  
be  present  or  be  more  abundant.  For  example,  the  peak  of  incidence  for  bone  tumors  correlates  
with   the   phase   of   skeletal   growth   spurt   in   adolescence   when   de-­regulation   of   bone-­lineage  
transcription  factors  might  take  place  [130].  Therefore,  given  the  short  latency  of  tumors  occurring  
early   in   life,   is   likely   that   intrinsic  “errors”   in  development  rather   then  environmental   risk   factors,  
might  cause  tumorigenesis.  This  might  also  explain  the  rare  occurrence  of  pediatric  carcinomas  
and   the   low   mutational   burden   of   childhood   cancers,   which   mostly   harbor   chromosomal  
rearrangements   (Figure   10B)   [7,   131].   Also,   the   distinct   biology   of   childhood   tumors   might  
underlie  the  different  therapeutic  response  and  outcome  between  children  and  adults  presenting  
the  same  disease.    
Pediatric   cancer   patients   are   generally   treated   with   a   multimodal   protocol   including   surgery,  
radiotherapy   and   chemotherapy.   Such   approach   led   to   a   dramatic   improvement   of   the   overall  
survival  from  28%  in  1960  to  a  near  80%  to  date  (Figure  10C)  [132].  Despite  this  great  success,  
survival   rates   for   high-­risk   group   pediatric   sarcomas,   retinoblastoma   and   ALL   remains   dismal  
under  current  treatment  strategies  [133].  Importantly,  long-­term  side  effects  following  aggressive  
chemotherapy  and   radiotherapy   regimens   remain  a  critical  clinical  concern.   In   fact,  one   third  of  
the   survivors   experience   a   severe   or   life   threatening   effect   such   as   organ   dysfunctions   or  
development  of  second  malignant  neoplasms  (SMNs)  [134].  Hence,  less  toxic  and  more  effective  
therapies  are  urgently  needed.  One  valid  option   is  offered  by   the   targeted   therapy  but  only   few  
FDA  approved  agents  entered  the  clinic  and  are  mostly  limited  to  hematological  pediatric  tumors  
[133].  Additionally,  drug  development   for  childhood  cancers   is  hampered  by   the  poor   interest  of  
pharma   companies   and   the   small   population   of   children  who   can   participate   into   clinical   trials.  
Therefore,  to  prioritize  therapies  approved  for  adult  cancers  that  might  be  tested  in  children,  the  
NCI  founded  the  Pediatric  Preclinical  Testing  Program  (PPTP),  a  consortium  for  screening  agents  
in   clinical   development   in  PDX  models   of   childhood   cancer   [132].  However   only   few  drugs  are  
tested  annually  and  the  tolerated  drug  doses  in  children  might  be  completely  different  from  adults  
due  to  dissimilarities  in  drug  absorption  kinetics,  expression  of  metabolic  enzymes  and  the  limited  
functionality  of  immature  excretory  organs  [132].    
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Figure   10.   Tumor   incidence   by   age   in   children,   number   of   somatic  mutations   in   a   wide  
range   of   cancer   entities   and   survival   rate   for   pediatric   cancers.   (A)   Tumor   incidence   in  
children  younger  than  15  years  old  (blue  bar)  or  between  15  and  19  years  old  (red  bar).  Adapted  
from  [129].   (B)  Horizontal  bars   indicate   the  25  and  75%  quartiles.  MSI,  microsatellite   instability;;  
SCLC,   small   cell   lung   cancers;;   NSCLC,   non–small   cell   lung   cancers;;   ESCC,   esophageal  
squamous   cell   carcinomas;;   MSS,   microsatellite   stable;;   EAC,   esophageal   adenocarcinomas.  
Adapted  from  [7].  (C)  5-­year  survival  rate  for  childhood  cancer  patients  between  1960  and  2004.  




4.5.1.  Epidemyology  and  histological  classification  
Rhabdomyosarcoma  (RMS)  is  a  striate-­muscle  lineage  malignancy  that  accounts  for  about  48%  
of  all  soft  tissue  sarcomas  diagnosed  in  children  or  adolescents  younger  then  14  years  old  [128].  
This  corresponds  to  ~4.3  cases  per  million  children  (0-­19  years  old)  with  the  peak  of  incidence  at  
5   years   of   age   or   younger   and   is   slightly  more   common   in  males   than   females   (>1.15)   [128].  
According   to   the   histological   classification,   the   two   most   common   subtypes   of   RMS   are   the  
embryonal   (ERMS)   (~75%   of   RMS)   and   the   alveolar   (~16%   of   RMS)   RMS   followed   by  
pleomorphic   RMS,   undifferentiated   RMS   and   “not   otherwise   specified”   RMS   (NOS).   However,  
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NOS   and   pleomorphic   RMS   are   relatively   more   common   in   adults   and   are   associated   with   a  
poorer   outcome   than  RMS   in   children   [135]   ERMS   and   ARMS   are   distinguishable   both   at   the  
histological   and   localization   level   (Figure   11).   For   example,   ERMS   shows   a   clear   pattern   of  
skeletal   muscle   differentiation,   from   a   more   immature   mesenchymal   to   more   differentiated,  
elongated  muscle  tumor  cells  and  with  a  stromal-­rich  appearance  whereas  ARMS  is  composed  of  
small,  round,  poor  differentiated  and  densely  packed  cells  organized  around  spaces  reminiscent  
of   pulmonary   alveoli   (Figure   11B)   [136].   ERMS   can   arise   anywhere   in   the   body,   but   it   occurs  
mainly  in  the  head&neck  (29%  of  the  cases)  and  genitals  (18%)  whereas  ARMS  is  more  frequent  
in  the  extremities  (39%)  followed  by  head&neck  (22%)  [128].  
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Figure  11.  RMS  localization  and  histology.  (A)  Primary  sites  of  RMS.  Adapted  from  [137].  (B)  
Hematoxylin  &  Eosin  staining  of  ARMS  (left)  and  ERMS  (right).  
  
4.5.2.  Diagnosis  and  prognosis  
The  diagnosis  of  RMS  is  based  on  the  identification  of  skeletal-­muscle  differentiation  features  or  
rhabdomyoblast-­like  cells  (from  greek:  rhabdo  =  cross  striated  +  myo=  muscle)  which  is  routinely  
performed  via  immunoistochemical  staining  for  muscle  specific  proteins.  These  include,  DESMIN,  
MYOGLOBULIN,   Z-­BAND   PROTEIN,   MYO   D,   MYOSIN,   MUSCLE-­SPECIFIC   ACTIN   and  
MYOGENIN  [138,  139].  DESMIN  positivity   is  widely   found   in  RMS  whereas  MYOGENIN  seems  
to  be  more  expressed  in  ARMS  compared  to  ERMS  [140,  141].  Further  confirmation  of  RMS  can  
be  achieved  via  electron  microscopy  to  visualize  Z  band-­material  and  ACTIN-­MYOSIN  bundles.  
The   histological   appearance   of   the   tumor   provides   both   classification   criteria   and   prognostic  
information   with   ERMS   having   an   intermediate   prognosis   whereas   ARMS   and   undifferentiated  
RMS  have   the  worse  outcome   [142,  143].  However,   further  variables  of  prognostic  significance  
include   age   (children   younger   than   1   or   older   than   9   years   have   unfavorable   prognosis),  
localization   of   the   primary   tumor   site   (i.e.   limbs   are   considered   unfavorable   sites),   number   of  
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metastatic  sites  at  diagnosis  and  bone  morrow  involvement.  If  all  of  these  factors  are  combined,  a  
better  patient  stratification  of  responders  or  non-­responders  to  standard  therapy  can  be  achieved  
[144].   Additionally,   molecular   tools   are   also   implemented   in   the   clinic   when   the   diagnosis   is  
uncertain.   For   instance,   RT-­PCR   or   fluorescence   in   situ   hybridization   (FISH)   are   supportive  
technologies   to   identify  ARMS  harboring  chromosomal   translocations   resulting   in  PAX3-­FOXO1  
or   PAX7-­FOXO1   fusion   proteins   [145,   146].   The   potency   of   molecular-­based   stratification   is  
highlighted   by   the   fact   that   20%   of   histologically   classified   ARMS   lack   expression   of   these  
chimeric  factors  and  are  molecularly  and  clinically  indistinguishable  from  ERMS  [147,  148].    
After  diagnosis  of  the  histological  type  of  RMS,  doctors  evaluate  the  extent  of  the  tumor  mass  and  
if   it  has  spread,  by  assigning  a  cancer  stage,  which  help   for   the  stratification  of  patients   in   risk  
groups   (low-­,   intermediate-­   and   high-­risk   groups)   and   guides   for   treatment   options.   Two  major  
staging  system  are  applied  for  the  management  of  RMS  patients  namely  TNM  staging  and  clinical  
grouping   staging   (CG)   system,   developed   by   the   Intergroup  Rhabdomyosarcoma  Study  Group  
(IRSG)  [149,  150].  The  TNM  system  is  applied  before  treatment  start  and  classifies  RMS  in  four  
stages   based   on   tumor   site   and   size,   involvement   of   lymph   nodes   and   presence   of   distant  
metastasis.   The   CG   system   defines   four   clinical   groups   according   to   the   extent   of   their   initial  
surgery   and   cancer   spread.  This   is   particularly   important   since   it  was   shown   that   patients  with  
completely  excised  tumors  have  a  better  prognosis  than  patients  with  residual  tumor  [151].  
  
4.5.3.  Treatment  
Nowadays,   RMS   patients   are   treated   with   a   multimodal   approach,   which   includes   surgery  
radiotherapy   (RT)   and   combination   of   chemotherapy   regimens.   This   is   the   result   of   numerous  
clinical  trials  performed  mainly  by  the  soft  tissue  sarcoma  committee  of  children’s  oncology  group  
(COG)   in   the   United   States   and   the   European   paediatric   Soft   tissue   sarcoma   study   group  
(EpSSG)  over  the  last  40  years  [152].    
Surgery   is   performed   if   the   functionality   of   the   organs   can   be   preserved   and   if   there   are   not  
severe   cosmetic   consequences.   For   instance,   wide   local   excision   is   highly   recommended   for  
RMS  occurring   in   the  prostate,   the  bladder   and  extremities  whereas   is   often  not   necessary   for  
vulvar,  vaginal  and  orbital  tumors  which  are  highly  sensitive  to  chemotherapy  and  is  often  limited  
to  incisional  biopsies  for  not  superficial  head  and  neck  RMS.    
RT  is  applied  to  remove  residual  tumor  mass  where  surgery  is  not  complete  or  not  feasible  such  
as  head,  neck  and  pelvis.  Additionally,  RT  seems  to  provide  a  better  outcome  also  for  completely  
resected  ARMS  tumors  [153].  However,  70%  of  patients  with  orbital  tumors  have  impaired  vision,  
many  have  developmental  abnormalities,   fibrosis  and  SMNs  [154,  155].  For   this  reason  EpSSG  
limits   the   use   of   RT   in   young   children   (i.e.   RT   is   not   recommended   for   tumors   that   regress  
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completely  after  chemotherapy)  whereas  COG  investigators  suggest  a  local  aggressive  treatment  
already  at  the  diagnosis  [152].  
Systemic  chemotherapy   is  an   indispensible   tool   to  reduce  tumor  burden  or  attempt   to  eradicate  
metastatic  lesions.  Over  decades,  several  combinations  of  de-­bulking  chemotherapeutics  with  or  
without   RT,   modifications   of   dose   schedules   and   implementations   of   risk-­based   patient  
stratifications  contributed  to  nearly  triple  the  survival  rate  of  pediatric  RMS  since  the  early  1960s  
[156].  The  mainstay  standard  chemotherapy  regimen  is  the  VAC  protocol  pioneered  by  Wilbur  et  
al.   in   1974,   which   combines   vincristine,   actinomycin   D   and   cyclophosphamide   [157].   In   some  
cases   of   low-­risk   groups,   cyclophosphamide   is   omitted   whereas   for   intermediate   and   high-­risk  
groups   topoisomerase   inhibitors   are   often   included   (i.e.   doxorubicin,   etoposide,   irinotecan,  
topotecan  etc.)  [152].    
Despite   advances   in   therapy,   there   has   been   only   a   modest   improvement   over   the   last   three  
decades  and  still  metastatic  spread,  resistance  to  cytotoxic  chemotherapeutic  agents  followed  by  
long-­term  sequelae  represent  the  main  challenge  for  the  achievement  of  a  complete  cure.  Indeed,  
30%  of  RMS  patients  continue  to  experience  relapse  disease  and  only  17%  of  these  survive  after  
5   years   with   a   median   surivival   time   from   the   first   recurrence   of   only   0.8   years   [158].   The  
treatment   plan   for   this   group   of   patients   is   not  well   defined   and   in  most   of   the   cases   the   only  
option  is  an  intensification  of  chemotherapy  (often  the  same  as  previously  administered)  but  the  
success   rate   remains   very   dismal   [159,   160].   Once   relapse   occurs,   several   factors   can   guide  
treatment  strategies  including  time  to  relapse  since  treatment  was  completed,  if  local,  regional  or  
distant  recurrence  and  the  regimen  of  chemotherapy  and/or  radiotherapy  administered  previously  
in  the  patient.  Usually  recurrence  is  common  after  maximum  3  years  but  if  tumors  progress  under  
therapy,   the   prognosis   is   very   poor   (~12%   probability   to   survive   4-­years   post-­relapse)   and  
becomes  incurable  if   it   is  disseminated  [161].  In  these  cases,  palliative  radiotherapy  can  help  to  
reduce   pain   or   prevent   spinal   cord   compression.   Hence,   there   is   an   increasing   need   to   find  
alternative   and  more   innovative   therapeutic   modalities,   which  might   help   high-­risk   group   RMS  
patients   and   limit   the   incidence   of   metastasis   and   relapse.   Although   targeted   therapy   has   not  
entered  clinical  practice  for  the  management  of  RMS  so  far,  the  increasing  knowledge  about  the  
molecular   mechanisms   underlying   the   disease   will   certainly   provide   the   basis   for   new   RMS-­
directed  therapies  in  the  near  future.    
  
4.6.  Biology  of  Rhabdomyosarcoma  
4.6.1.  Genetic  landscape  and  etiology  
ARMS  and  ERMS  have  been  classically  identified  as  the  two  main  RMS  subtypes  based  on  their  
distinct   histology.   However,   it   is   now   clear   that   such   classification,   although   holds   prognostic  
significance,  is  too  simplistic.  In  fact,  when  we  have  a  deep  look  into  the  genetic  features  of  RMS  
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we  can  distinguish  two  clear  clusters,  PAX-­fusion  positive  (PFP)  and  PAX-­fusion  negative  (PFN)  
tumors,   which   have   distinct   gene   expression   signatures,   methylation   patterns   and   genetic  
landscape   [162-­165].   Briefly,   about   80%   of   ARMS   are   PFP,   of   which   the   majority   are  
characterized  by   the   t(2;;13)(q35;;q14)  and  a  small   fraction  by   the   t(1;;13)(p36;;q14)  chromosomal  
rearrangements   resulting   in   the   PAX3-­FOXO1   and   PAX7-­FOXO1   fusion   proteins,   respectively  
[166].   Alternate   PAX-­fusion   products   have   also   been   identified   such   as   PAX3-­FOXO4   (single  
case),  PAX3-­NCOA1,  PAX3-­NCOA2  and  PAX3-­INO80D  (single  case)  [167].  In  this  subgroup,  the  
DNA  binding  domain  of  the  PAX  product  is  fused  to  the  transcriptional  trans-­activation  domain  of  
the   fusion   partner,   generating   aberrant   transcription   factors   that   at   least   in   the   case   of   PAX3-­
FOXO1  (the  most  characterized)  is  essential  for  the  etiology  and  maintenance  of  this  subtype  of  
RMS  [167-­170].  Generally,  PFP  have  a  very  low  mutation  burden  compared  to  PFN  tumors,  with  
an  average  of  0.1  protein-­coding  mutation/Mb  and  no  recurrent  point  mutations.   In  some  cases  
the   chimeric   protein   is   the   only   somatic   aberration   present,   highlighting   once   again   its   pivotal  
tumorigenic  function  (Figure  12)  [164].  Additionally,  loci  containing  CDK4  (12q13-­q14,  12%  of  the  
cases)   and  MYCN   (2p24,   20%   of   the   cases)   genes   are   the  most   frequently   amplified   in   PFP  
samples   and   the   former   is   associated   with   worse-­failure   free   and   overall   survival   [171].   In  
contrast,   PFN   tumors   have   a  more   complex   genetic   landscape  with   recurrent  mutations   in   the  
RAS  pathway   including  NRAS,  HRAS  and  KRAS  themselves  where   the  mutations  are  mutually  
exclusive   across   PFN   patients   but   are   never   found   in   PFP   samples.   Further   alterations   in   the  
RAS  family  members  include  the  catalytic  subunit  of  PI3K  (PIK3CA)  up-­stream  of  RAS  and  one  of  
the   direct   effectors  NF1   (Figure   12)   [164,   172].   The   iper-­activation   of   the  RAS   signaling  might  
represent   one   of   the   earliest   causative   de-­regulation   occurring   during   PFN   tumorigenesis   as  
demonstrated  by  zebrafish  models  of  RAS-­induced  RMS  [173].  Interestingly,  RAS  status  might  be  
used  as  new  bio-­marker  to  better  stratify  PFN  patients,  since  it  was  shown  that  75%  of  the  high-­
risk  and  45%  of  the  intermediate  risk  group  patients  contained  mutations  in  the  RAS  pathway  but  
none  of   them   is   found   in   low-­risk  groups   [172].  Although   this   indicates  a  certain  dependency  of  
PFN  tumors  on  the  RAS  machinery,  most  of  the  inhibitors  tested  against  the  RAS/PI3K  pathway  
had  no  significant  activity  in  short  term  cultures  derived  from  PFN  xenografts.  In  contrast,  agents  
targeting  oxidative  stress  were   the  most  effective  suggesting  a  new  vulnerability   for  PFN  cases  
[172].  Another  striking  genetic  signature  specific  for  PFN  tumors  is  the  recurrent  alteration  of  the  
P53   axis   (~26%   of   PFN)   including   mutations   in   TP-­53   itself,   amplifications   of   its   negative  
regulators  MDM4   or  MDM2   and   loss   of   CDKN2A   (p16/p14   ARF),   a   physiological   inhibitor   of  
MDM2   [164,   172].   Additional   alterations   include   the   cell   cycle   regulator   FBXW7   (missense  
mutations),  receptor  tyrosin  kinases  (FGFR4,  PDGFRA  and  ERBB2),  the  transcriptional  repressor  
BCOR  and   loss  of  heterozygosity   (LOH)  at  11p15.5   locus  containing  H19,   IGF2  and  CDKN1C,  
which  probably  contributes  to  IGF2  over-­expression  and  dependency  on  IGF  axis.    
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Despite   the  genetic  diversity,  PFP  and  PFN  have  a  common  myogenic  make-­up,   composed  of  
myoblast-­like   cells   that   seem   to   be   trapped   in   a   proliferative   state.   However,   the   degree   of  
skeletal  muscle  differentiation  differs  between  the  two  subtypes  and  might  reflect  the  distinct  cell  
of  origin.  According  to  this,  different  mouse  models  demonstrated  that  PFN  tumors  develop  from  
a   wide   range   of   muscle   cells   including   undifferentiated   satellite   cells,   progenitor   cells   and  
maturing  myoblasts   [174,   175].   Notably,   they   can   also   arise   from   pre-­adypocite   precursors   as  
well,  probably  explaining   the  existence  of  RMS   in  anatomic  sites   lacking  skeletal  muscle   [176].  
On   the   other   hand,   the   only   mouse   model   of   PFP   that   mimics   the   human   counterpart   was  
generated  by  a  conditional  knock-­in  of  Pax3-­Foxo1   in  the  terminal  skeletal  muscle  differentiated  
Myf-­6-­expressing   cells  with   or  without   InK4a/ARF   or  Tp53   deletion   [177].   This  might   support   a  
reprogramming   activity   of   PAX3-­FOXO1   toward   a   more   immature   phenotype   during   skeletal  
muscle   development   and   is   consistent   with   the   fact   that   forced   expression   of   PAX3   or   PAX7  
impair   differentiation   of   myoblasts   and   satellite   cells,   respectively   [167,   178].   Yet,   intricate  
epigenetic   networks   have   also   been   proposed   as   potential   mechanisms   of   the   deregulated  
myogenic   program   driven   by   PAX   fusions   [179].   Since   RMS  might   be   the   result   of   defects   in  
embryonic   processes   regulating   skeletal   muscle   lineage,   is   not   surprising   to   find   recurrent  
aberrations  of  developmental  signaling  pathways  being  discussed  in  the  next  chapter.    
  
  
Figure  12.  The  genomic  landscape  of  RMS.  Adapted  from  [164].  
  
4.6.2.  Aberrant  developmental  signaling  pathways  in  RMS  
The  Notch,  Wnt   and  Hedgehog   (Hh)   signaling   pathways   have   critical   functions   during   skeletal  
muscle  development  or   regeneration  by   regulating  self-­renewal,  differentiation,  proliferation  and  
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survival  of  muscle  stem  cell  pools  or  their  progeny  [180].  In  RMS,  both  Notch  and  Hh  have  been  
shown   to   have   tumor-­promoting   effects   whereas   canonical   Wnt   signaling   has   been   recently  
recognized  as  a  bona  fide  tumor-­suppressor  pathway.  
  
4.6.2.1.  Notch  pathway  
The  Notch  signaling  activation  requires  the  communication  between  neighboring  cells  since  both  
Notch   receptors  and   ligands  are   transmembrane  proteins.   In  mammals,   there  are  six  canonical  
Notch  ligands  (Delta-­like  1,  2,  3  and  4  (DLL1-­4),  JAGGED  1  and  JAGGED  2)  and  four  receptors  
(NOTCH1,   2,   3   and   4).   Once   the   ligand   binds   the   cognate   receptor,   a   two-­step   preoteolytic  
cleavage   mediated   by   metallo-­proteinases   (ADAM)   first   and   then   by   the   g-­secretase   enzyme,  
allows  the  release  of  the  intracellular  fragment  (intracellular  Notch,  NICD)  into  the  cytosol  before  
its   nuclear   translocation   where   it   forms   a   complex   with   CSL   (CBF1/Suppressor   of  
Hairless/LAG1)/RBPJ  to  regulate  transcription.  Among  Notch  target  genes,  the  most  common  are  
HES,  HEY,  MYC,  CyclinD3  (CCND3)  and  CDKN1A  (Figure  13)  [181].  
Different   types   of   anti-­Notch   signaling   agents   are   in   clinical   development   including  monoclonal  
antibodies   (i.e.   mAB   targeting   DLL4),   decoy   Notch   receptors,   inhibitors   of   Notch   transcription  
complex   and   g-­secretase   (Figure   13).   These   latter   have   shown   some   promising   results   in   pre-­
clinical  and  clinical  trials  but  are  often  associated  with  toxicities  in  the  gastrointestinal  tract  due  to  
alterations  of  crypt  progenitors  [181].  
  
                                                     
Figure   13.   Notch   signaling   pathway.  Canonical   Notch   signaling   and   relavant   antagonists   in  




Notch   target   genes   such   as  HEY1  and  HES1  as  well   as  Notch   receptors   (NOTCH  2   and   to   a  
lesser  extent  NOTCH  3)  have  been  found  to  be  highly  up-­regulated  in  RMS  primary  tumors  or  cell  
lines,  indicating  iper-­activation  of  the  pathway  [182,  183].  Accordingly,  silencing  of  HEY1  or  HES1  
decreases   cell   proliferation   whereas   inhibition   of   NOTCH   3   also   increases   terminal   skeletal  
muscle  differentiation.  Although  NOTCH  1  seems  not  over-­expressed  in  RMS,  its  interference  by  
both   genetic   and   pharmacological   means   reduces   tumor   growth   in   vivo   [182,   183].   This   is  
corroborated   by   a   recent   study   showing   that   constitutive   activation   of   NOTCH1   promotes   self-­
renewal   and   tumorigenicity   in   a   zebrafish  model   of   PFN  RMS   by   partially   blocking   the  ME2C-­
mediated   skeletal   muscle   differentiation   [184].   Finally,   single   cases   of   NOTCH   1,   2   and   3  
mutations   have   been   documented   for   RMS   and   are   associated   specifically   with   PFN   tumors  
[172].  
  
4.6.2.2.  Wnt  pathway  
Currently,  three  different  Wnt  pathways  have  been  recognized:  the  canonical,  the  non-­canonical  
planar   cell   polarity   (PCP)   and   the   non-­canonical   Wnt/Ca2+   signaling.   Among   these,   the   most  
studied  is  the  canonical  Wnt  signaling  pathway,  which  is  involved  in  many  aspects  of  embryonic  
development   including   cell   fate   specification   during   myogenesis   by   controlling   myogenic-­
regulatory  factors  (MRFs)  [185].    
WNT  ligands  comprise  a  large  family  of  secreted  proteins,  which  upon  binding  to  the  FRIZZLED  
(Fz)/   lipoprotein   receptor-­related  protein   (LRP)   complex,   favor   the   stabilization   and   subsequent  
nuclear   translocation   of   b-­CATENIN,   the   main   effector   of   Wnt   signaling.   In   the   nucleus,   b-­
CATENIN  forms  a  complex  with  the  T-­cell  factor/lymphois-­enhancer  factor  (TCF/LEF)  to  activate  
the  transcription  of  the  down-­stream  target  genes  (i.e.  AXIN2,  MYC  and  cyclinD1).  In  absence  of  
the   ligands,   the   pathway   is   in   an   off   state   leading   to   a   rapid   destruction   of   b-­CATENIN   upon  
phosphorilation   by   the   serine/threonine   kinases   CK1   and   GSK3a/b.   Hence,   b-­CATENIN   is  
trapped   in   the  destruction  complex   formed  by  AXIN,  Adenomatous  polyposis  coli   (APC)  and  b-­




                                                                                 
Figure  14.  Canonical  Wnt  signaling.  Adapted  from  [186].  
  
Although   canonical  Wnt   signaling   activation   has   oncogenic   activities   in  many   types   of   cancers  
(mostly  colon  cancer),  this  seems  not  the  case  for  RMS  [187].  Indeed,  different  lines  of  evidence  
suggest  that  either  inhibition  of  upstream  antagonists  such  as  secreted  frizzled-­related  protein  3  
(SFRP3)  or  interference  with  activators  of  the  destruction  complex  (i.e.  GSK3b)  induce  myogenic  
differentiation   and   impair   proliferation   in   RMS   [188,   189].   Similarly,   investigations   of   the  
downstream   transcription   factor   LEF1   (activator   of  Wnt   signaling)   led   to   the   conclusion   that   it  
constrains   the   aggressiveness   of   RMS   [190].   Therefore,   these   studies   suggest   that   the   pro-­
differentiation  ability  of  canonical  Wnt  pathway  during  muscle   regeneration   is  also  conserved   in  
RMS   [191].   However,   if   this   is   a   general   mechanism   or   applies   only   to   a   subgroup   of   RMS  
tumors,   remains   to  be  addressed  since  activating  mutations  of  b-­CATENIN  have  been  reported  
for  a  subset  of  RMS  patients  [172].  
  
4.6.2.3.  Hedgehog  pathway  
As  most  of   the  molecular   circuits,   the  mammalian  Hh  signaling  can  be   ‘dissected’   into   its  main  
components   including   ligands   (Desert   Hedgehog   (DHH),   Indian   Hedgehog   (IHH)   and   Sonic  
hedgehog   (SHH)),   an   inhibitory   transmembrane   receptor   (Patched   (PTCH)),   a   ligand-­activated  
co-­receptor   (Smoothened   (SMO))  and   the  down-­stream  effectors   (Glioma-­associated  oncogene  
(GLI)   transcription   factors   GLI1,   GLI2   and   GLI3))   mediating   the   cellular   response   (Figure   15).  
Even  though  the  exact  role  of  the  three  Hh  ligands  in  vertebrate  is  not  fully  understood,  they  have  
overlapping   roles   or   elicit   different   responses   mainly   depending   on   their   spatial   and   temporal  
localization.  For  example,  SHH  is  essential  for  limb  development  as  well  as  neural  tube  formation  
[192,  193],  IHH  promotes  chondrocytes  proliferation  and  bone  specification  [194,  195],  while  DHH  
is   mainly   expressed   in   testis,   where   it   is   involved   in   male   sexual   differentiation   [196].   The  
common   feature   of   Hh   ligands   is   their   lipophilicity   due   to   a   dual   lipidation   by   the   binding   of   a  
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cholesterol  molecule  to  the  C-­terminus  and  a  palmitoyl  group  to  the  N-­terminus.  In  particular,  the  
cholesterol   moiety   is   required   for   the   autocleavage   of   the   inactive   precursor   in   an   active   N-­
terminal   form  before  being  released  by  Dispatched  (DISP),  a   transmembrane  transporter  acting  
on   the  signal-­sending  cell   [197,  198].  The  binding  of  Hh   ligands   to   the  12-­transmembrane-­span  
protein   PTCH   promotes   ligand-­receptor   internalization   and   subsequent   lysosomal   degradation  
[199].  Hence,  SMO,  a  member  of   the  G-­protein-­coupled  receptor  (GPCR)  family   translocates   to  
the  mammalian  primary  cilium  and  releases  the  downstream  GLI  zing-­finger  transcription  factors  
from  suppressed  of   fused   (SUFU)   inhibition.   In   vertebrates,  GLI1,  GLI2  and  GLI3,  mediate   the  
expression  of  Hh  target  genes,  most  of  which  are  still  unknown  [200,  201].  GLI2  and  GLI3  are  the  
main   Hh-­regulated   activator   and   repressor,   respectively.   They   both   contain   an   N-­terminal  
repressive  and  C-­terminal  activating  domain.  The  Hh  Off-­state  allows  the  C-­terminally   truncated  
GLI3   to   block   the   transcription   of   the   Hh   responsive   genes.      In   contrast,   Hh   ligand-­mediated  
activation   of   the   pathway   leads   to   the   processing   of   GLI   full-­length   proteins   in   C-­terminal  
transcriptional   activators   and   degradation   of   the   N-­terminal   repressor   forms.   Moreover,   the  
balance  of  active/repressive  proteins   is   tightly  controlled  by  post-­translational  modifications  and  
may  be  altered  in  cancer  [202].  On  the  other  hand,  GLI1  is  a  constitutive  activator  lacking  the  N-­
terminal   repressor   domain   and   its   expression   is   directly   regulated   by   GLI2   in   response   to   Hh  
ligands  as  well  as  by  non-­canonical  Hh  signaling  [200,  203].  
  
                                                     
Figure  15.  Hedgehog  pathway.  (left)  Hh  off  state  and  (right)  Hh  activation.  Adapted  from  [204]  
  
4.6.2.3.1.  The  ‘self  control’  of  Hedgehog  pathway  
Several  mechanisms  modulate   the   response   to  Hh  signals  at  different   cellular   levels.  First,   cell  
adhesion  molecule   down-­regulated   by   oncogenes   (CDO)   and   brother   of   CDO   (BOC),   are   two  
transmembrane   proteins,   which   act   as   ‘helpers’   of   PTCH   to   bind   the   ligands   and   trigger   Hh  
pathway  activation   [205].  A   recent   report  has   identified  BOC  as  a  mediator  of  Hh-­induced  DNA  
damage   leading   to  medulloblastoma   progression,   indicating   the   relevance   of   these   proteins   in  
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controlling  Hh   signaling   [206].  Growth  arrest-­specific   gene  1   (GAS1)   and  Hedgehog-­interacting  
protein   (HHIP)  are   two  vertebrate-­specific   cell   surface  proteins,  which  positively  and  negatively  
regulate  Hh   distribution,   respectively   [202,   207,   208].   Second,   different   kinases,   phosphatases  
and   ubiquitin   ligases   can   post-­translationally  modify   Hh   pathway  members   to   control   signaling  
activity.   For   instance,   in   absence   of   Hh   ligands,   GLI   transcription   factors   are   sequentially  
phosphorylated  by  protein  kinase  A  (PKA),  glycogen  synthase  kinase  3  b  (GSK3-­b)  and  different  
members   of   casein   kinase   family   (CKI).   This   allows   the   ubiquitination   and   subsequent  
proteasome-­mediated   degradation   of   the   C-­terminal   transactivation   domains.   This   process   is  
reverted  by  SMO  activation,  which  limits  GLI  phosphorylation  and  leads  to  stabilization  of  the  full-­
length  or  C-­terminal  activator  forms  [209].  Moreover,  GLI1  and  GLI2  can  undergo  acetylation  as  a  
repressive   signal   for   their   transcriptional   output   whereas   the   histone   deacetylase   1   (HDAC1)-­
dependent   deacetylation   does   the   opposite   [210].   Finally,   a   further   control   of   the   pathway   is  
offered  by  GLI-­mediated  transcription  of  three  Hh  components  PTCH1,  HHIP  and  GLI1,  activating  
both  positive  and  negative  feedback  loops.  In  this  respect,  their  expression  is  considered  as  the  
most  reliable  readout  of  Hh  pathway  activation.  
  
4.7.  Role  of  Hedgehog  pathway  in  RMS  
The  first  link  between  Hh  and  cancer  comes  from  studies  of  Gorlin  Syndrome  (also  called  Basal  
Cell   Nevus   Syndrome,   BCNS),   a   heritable   condition   characterized   by   several   developmental  
abnormalities   and   association   with   higher   risk   to   develop   tumors   than   the   normal   population,  
mostly  multiple  basal  cell   carcinomas   (BCC),  medulloblastoma,  and  RMS  (although  at  very   low  
incidence)   [211,  212].  Since   its  discovery   in  1960,  different  researches  attempted  to   identify   the  
locus   associated   with   this   autosomal   dominant   disease.   Finally,   more   than   thirty   years   later,  
PTCH  has  been  reported  as  the  candidate  gene  responsible  for  BCNS  and  therefore  as  a  tumor  
suppressor   gene   [213-­216].   Subsequently,   the   generation   of   mice   heterozygous   for   Ptch  
confirmed  the  involvement  of  Hh  pathway  over-­activation  in  RMS  tumorigenesis  [217].  According  
with  this,  up-­regulation  of  Hh  target  genes  such  as  GLI1  and  PTCH1  has  been  demonstrated  by  
retrospective  analysis  of  RMS  patient  samples  or  in  human  RMS  cell  lines  [218-­222].  Additionally,  
activation  of  Hh  pathway  seems  to  be  specific  for  PFN  tumors  and  significantly  identifies  patients  
with   poor   prognosis   [219,   220,   223,   224].   Despite   this   recognized   role   of   Hh   in   RMS,   the  
contribution   of   the   ligand-­based   signaling   versus   non-­canonical   pathway   activation   in   sporadic  
RMS   is   still   unclear.  Discordant   studies   searching   for   inactivating  mutations   in  PTCH   or  SUFU  
genes  and  amplifications   in  SMO   or  GLI   loci   have  been  published.  For   instance,  a   cytogenetic  
approach  of  12  separate  RMS  patients  identified  4  cases  with  losses  in  the  chromosomal  region  
containing  the  PTCH1  gene  [225].  Similarly,  a  linkage  analysis  led  to  comparable  conclusions  in  
one  third  of  PFN  samples  analyzed  [218].  Controversially,  Calzada  et  al.,  did  not  detect  mutations  
in  the  coding  sequence  of  PTCH1   in  14  RMS  sequenced  [226].  This   is  corroborated  by  another  
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study   showing   absence   of  PTCH1   loss-­of-­function  mutations   or  SMO   amplifications   in   26  PFN  
tumors   examined   [220].  Also,   a   recent  whole-­genome  sequencing   (WGS)  analysis   on   16  RMS  
tumors   ruled   out   the   presence   of   mutations   in   members   of   Hh   pathway   [172].   Also,   SHH  
immunoreactivity   is   not   common   in   RMS   and   the   higher   Hh   activity   in   PFN   compared   to   PFP  
does  not  correlate  with  SHH  mRNA  levels,  which  are  unchanged  between  the  two  subtypes  [218-­
220].  However,  we  have  previously   found  a   positive   correlation   of   IHH  and  DHH  mRNA   levels  
with   the  expression  of  Hh   target  genes   in  RMS  supporting   the  hypothesis  of  a   ligand-­mediated  
activation  of  Hh  pathway  [224].Therefore,  underestimation  of  the  role  of  the  other  two  Hh  ligands  
might   have   led   to  misleading   conclusions   and   further   studies   need   to  more   carefully   elucidate  
their  role  in  RMS.  In  summary,  hyperactivity  of  Hh  pathway  is  a  common  feature  in  the  PFN  RMS  
and   only   a   subset   of   RMS   exhibits  mutations   in   components   of   the  Hh   pathway,   which  would  
potentially   argue   for   non-­canonical   pathway   activation.   However,   the   role   of   other   tumor-­
associated  pathways,  which  can   interplay  with  diverse  components  of  Hh  signaling  and  thereby  
contribute  to  its  activation,  is  still  poorly  investigated.  
  
4.7.1.  Mouse  models  of  Hedgehog-­driven  RMS  
Investigation  of   the   ‘cell   of  origin’   is  one  of   the  most   intriguing   research   topics   in  RMS.  To   this  
end,   gene-­targeting   tools   developed   over   the   last   years   have   been   used   to   generate   animal  
models  of  RMS,  highlighting  the  central  role  of  Hh  in  the  tumorigenesis  of  this  pediatric  soft  tissue  
sarcoma.   In   1998  Hahn   et   al.,   established   the   first  mouse  model   of  RMS  directly   involving  Hh  
pathway.   The   authors   showed   that   Ptch1   haplodeficient   mice   develop   RMS   tumors   with  
molecular   features  of   the  PFN  subtype  although  with   low   frequency   [217,  227].  Accordingly,  all  
RMS  from  Ptch+/-­  mice  over-­expressed  Gli1  and   Insulin-­like  growth   factor  2   (Igf2).  Furthermore,  
the  epistatic  function  of   Igf2   to  Ptch1  was  later  confirmed  in  mice  double  mutants  for  Ptch1  and  
Igf2   (Ptch+/-­   and   Igf2+/-­)   [228].   In   contrast   to  Ptch1+/-­   mouse  models,   ubiquitous   activation   of   a  
mutated   form   of   a   Smo   allele   (Rosa26-­SmoM2)   leads   to   the   generation   of   RMS   with   higher  
penetrance  [229].  In  addition,  mice  heterozygous  for  Sufu  (Sufu+/-­)  in  P53-­/-­  or  Ptch1+/-­  background  
harbor  RMS   tumors   to   the   same   extend   as  Ptch1+/-­  mice   [230,   231].   By   contrast,  mice  Sufu+/-­  
develop  only  microscopic  skin  lesions.  This  suggests  that  P53  knockout  affects  the  tumorigenesis  
of  Sufu   +/-­   mice   and   that   there   is   no   genetic   interaction   between  Ptch1   and  Sufu   loci   in   RMS  
tumorigenesis.   Recently,   Rajurkar   et   al.,   provided   additional   insights   into   the   link   between  
aberrant  Hh  pathway  activation  and  the  cellular  context  responsible  for  RMS  tumorigenesis  [232].  
They  reported  that  specific  expression  of  SmoM2  in  postnatal  (P10)  Shh-­producing  cells  as  well  
as  in  Gli1-­expressing  cells  did  not  lead  to  RMS  formation  within  4  months.  This  was  also  true  for  
forced  expression  of  SmoM2,  Gli2  (Gli2DN)  alone  or  in  combination  with  Gli1  in  postnatal  satellite  
cells  (Pax7  positive).  Therefore,  the  authors  ruled  out  the  possibility  of  Hh-­induced  postnatal  RMS  
formation   in  Hh-­expressing  compartments  and  myogenic  cells,  which   is  consistent  with  another  
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study   suggesting   the   adipocyte   lineage   as   the   PFN-­initiating   population   [233].   Surprisingly,  
restriction  of  Smo-­M2  expression  to  adipocytes  resulted  in  80%  incidence  of  PFN  RMS  which  is  
far  higher  than  Ptch1+/-­  and  Sufu+/-­;;P53-­/-­  mice.  More  important,  RMS  was  the  only  type  of  tumor  
detected,  providing  a  tool   to   investigate  therapeutic  strategies  specifically   for   this  tumor.  Such  a  
model  might  explain  why  RMS  originates   from   regions  of   the  body   lacking  skeletal  muscle   (i.e.  
genitourinary  and  biliary  tract)  [233].  Controversially,  Rubin  at  al.  demonstrated  that  concomitant  
inactivation  of  Ptch1   and  P53   (Ptch1+/-­,P53-­/-­)   in   a  wide   range  of   cells   of   the  myogenic   lineage  
(satellite  cells,  early  and  more  differentiated  myoblasts)  contribute  to  RMS,  which  is  not  the  case  
of  P53  loss  alone  [234].  In  general,  discrepancies  in  the  tumor  incidence  for  Ptch1+/-­  and  Smo-­M2  
mice  might  reflect  differences  in  signaling  activity  or  suggest  that  they  do  not  completely  lie  on  the  
same   axis   to   promote   RMS   tumorigenesis.   Alternatively,   the   stage   at   which   the   pathway   is  
switched   on   in   these  mouse  models  might   account   for   distinct   susceptibility   to   this   tumor.   For  
example,   the   large  population  of  uncommitted  precursors  present  at   the  early  embryonic  phase  
might   be   an   important   source   of   RMS   onset   in   Ptch1+/-­   mice   during   development   [227].   All  
together,   these   findings   underscore   the   crucial   function   of   Hh   pathway   in   RMS   tumorigenesis  
even  though  the  cellular  context  and  the  time  at  which  the  uncontrolled  activation  of  the  pathway  
becomes   oncogenic   is   still   not   clear.   Finally,   different   mouse   models   have   been   proposed   as  
preclinical   platforms   for   RMS-­specific   therapies   (Figure   16).   However,   if   these   models  
recapitulate  the  human  situation  need  further  clarification.  
    
                                                                                 
Figure  16.  Mouse  models  of  Hh-­driven  RMS.  Genetic  manipulation  of  different  components  of  
Hh  pathway  such  as  Ptch1,  Sufu  and  Smo  leads  to  RMS  tumorigenesis.  Sufu  inactivation  favors  
RMS   formation   only   in   combination   with   P53   knock-­out   whereas   Ptch1+/-­   can   do   the   same  
without   P53   ablation.   Also   combination   of   Ptch1+/-­   and   P53-­/-­   specifically   in   the   myogenic  
compartment   gener-­   ates  RMS.  Similarly,   constitutive   and   ubiquitous   activation   of   Smo-­  M2   or  
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specific   expression   in   preadipocytes   causes   RMS   but   not   if   expressed   in   Hh   expressing   or  
responsive  cells  as  well  as  in  satellite  cells.  Finally,  Gli1/2  activity  in  Pax7+  cells  is  not  sufficient  
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5.  Subject  of  Investigation  
  
RMS  accounts  for  the  majority  of  pediatric  soft-­tissue  sarcomas  and  current  treatment  regimens  
are  based  on  traditional  multimodal  protocols  including  surgery,  radiotherapy  and  chemotherapy.  
Despite   the   recognized  clinical  benefit  of   these  conventional   therapies,  no   further  progress  has  
been  made  in  the  past  decades  and  the  response  of  high-­risk  groups  remains  dismal.  Moreover,  
the  lack  of  a  molecularly  oriented  therapy  for  the  management  of  RMS  patients  outlines  the  need  
to   revisit  pre-­clinical  models   for   translating  research   findings   into  clinical  practice.  Hence,   in   the  
present  thesis,  we  set  out  to  develop  a  reliable  pre-­clinical  system  to  anticipate  drug  responses  in  
RMS  patients   and   study   chemo-­sensitizing  mechanisms   to   conventional   treatments.   To   pursuit  
this   latter,  we  either  employed  unbiased  high-­throughput  drug  screens  or   tested  the  potential  of  
anti-­CSC  approaches.    
Overall,  we  defined  the  following  aims:    
  
1.   To  establish  a  novel  pre-­clinical  platform  to  model  inter-­patient  heterogeneity  and  test  
personalized  treatment  strategies  for  RMS  patients  (Manuscript  1).  
  
2.   To  identify  combinatorial  therapeutic  options  for  RMS  patients  refractory  to  standard-­
of-­care  therapies  (Manuscript  2).  
  
3.   To   study   the   role   of   Hh   signaling,   a   CSC-­associated   pathway,   in   the   context   of  
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Personal  contribution:  Wachtel  M.  and  I  performed  all  experiments,  except:  
-­in  vivo  experiments:  performed  by  Römmele  M.  (Supp.  Figure  1B)  
-­aCGH  analysis:  performed  by  Zhang  L.  (Figure  3B  and  suppl.  Figure  2)  
-­immunoistochemistry  (IHC):  performed  by  Bode  P.K.  (Figure  3A)    
  
























Cancer   is   a   complex   and   heterogeneous   disease,   which   represents   a   leading   cause   of   death  
worldwide   and   the   subject   of   global   attention   over   the   past   century.   In   this   regard,   innovative  
genomic   and   proteomic   technologies   developed   during   the   last   decades   contributed   to   major  
advances  in  the  understanding  of  the  underlying  biology  and  treatment  of  this  malignancy  leading  
to   a   significant   decrease   of   cancer-­related   deaths   to   date   [1,   2].      Especially   genetic   analysis  
nowadays  is  a  clinical  routine  for  many  cancers  and  allows  identification  of  patient  specific  driver  
oncogenes   that   serve   as   relevant   therapeutic   targets.   Unfortunately,   genome-­based   drug  
selection   is   not   feasible   for   tumors  which  are  driven  by  mutated  but   “undruggable”   targets   and  
have   an   otherwise   low   mutational   burden,   a   characteristic   of   many   pediatric   sarcoma   and  
leukemia.    
One  tumor  type  belonging  to  this  class  is  Rhabdomyosarcoma  (RMS),  which  is  the  most  common  
soft-­tissue  sarcoma  in  children  and  subsumes  different  histological  subtypes  all  having  cells  with  
characteristics   of   skeletal-­muscle   differentiation.   The   two  main   subtypes,   alveolar   (ARMS)   and  
embryonal   (ERMS)   RMS,   are   characterized   by   distinct   genetic   alterations.   Most   ARMS   are  
associated   with   specific   chromosomal   translocations   leading   to   the   formation   of   either   PAX3-­
FOXO1  or  PAX7-­FOXO1  fusion  protein,  which  are  critical  oncogenic   factors  driving   the  disease  
as   well   as   providing   a   diagnostic   and/or   prognostic   value,   but   as   transcription   factors   are  
challenging  drug  targets  [3-­5].  A  part  of  the  ERMS  is  characterized  by  mutational  activation  of  the  
Ras   pathway.   Consistent   with   the   low  mutation   rate   of   cancers   in   children,   only   17.8   and   6.4  
somatic  mutations  per  tumor  were  found  in  ARMS  and  ERMS,  respectively.  On  average,  only  5  of  
these  are  expressed,  and  a  small  fraction  holds  the  potential  for  druggability  [4].  Despite  the  great  
progress  that  has  been  made  for  treatment  of  RMS,  up  to  30  percent  of  patients  still  have  dismal  
outcome  under   current   therapeutic   strategies   and   no   targeted   therapy   has   entered   into   clinical  
practice   so   far   [6].   The   lack   of   a   molecular-­oriented   therapy   for   the   management   of   RMS  
highlights  the  need  for  improvement  of  cancer  research  to  find  relevant  new  therapeutics.    
Hence,   to   address   these   limitations   alternative   drug   selection   processes   might   be   used.   One  
possibility  is  represented  by  the  unbiased  use  of  drug  libraries  for  screening  for  cancer  –specific  
vulnerabilities,  an  approach  which  necessitates  an  appropriate  cancer  model  system.  Along  this  
view,  cancer  cell  lines  have  been  used  as  gold  standard  model  for  cancer  research  since  the  first  
derivation   of   a   human   cell   line   from   a   cancer   patient   in   the   early   ’50s,   which   also   served   as  
important   tool   to   define   culture  media   and   procedures   of   cell   propagation   in   vitro   [7].   The   low  
success  rate  of   translation  of  preclinical  data  acquired  with  cell   lines   to   the  clinics  however  has  
called  the  suitability  of  cell  lines  as  preclinical  models  into  question.  Indeed,  long-­term  passaged  
cell   lines   are   often   associated   with   down-­regulation   of   important   signaling   pathways,   gain   of  
additional  genomic  aberrations  and   loss  of   intra-­tumor  heterogeneity   that   fail   to   recapitulate   the  
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initial   tumor  where   they  were  derived   from   [8-­11].  Hence,   to  overcome  some  of   these  caveats,  
patient-­derived   xenografts   (PDXs)   have   been   routinely   used   to   assess   therapy   efficacy,  
pharmacodynamic/pharmacokinetic   parameters   and   study   tumor-­stroma   interactions   [12,   13].  
Although  PDX  models  offer  an   important  platform   for  expansion  of  patient-­derived  biopsies  and  
closely   resemble   the   original   tumor   specimen   at   the   morphological   and   molecular   level,   they  
might  be  not  affordable   in  terms  of  cost  and  space  for  many  laboratories  and  are  unsuitable  for  
large   high   throughput   drug   testing   [14,   15].   For   instance,   in   the   Pediatric   Preclinical   Testing  
Program  (PPTP),  a  multi-­institutional  consortium  for  evaluating  drug  candidates  in  a  large  cohort  
of  PDXs  representative  of  childhood  cancers,  only  12  drugs  annually  are  tested  [16].  This  makes  
PDX  as  a  good  model  for  drug  validation  rather  than  for  drug  discovery  [17].  For  the  latter  primary  
cultures  of  cancer  cells  represent  more  suitable  model.  Importantly  however,  protocols  for  primary  
cancer  cell  cultures  have  been  established  in  only  a  small  number  of  entities  yet  [10,  11,  18].  
Here,  we  set  out  to  develop  a  functional  predictive  preclinical  “toolkit”  which  combines  the  use  of  
PDX   models   and   primary   cultures   for   RMS.   In   this   respect,   we   present   a   systematic  
characterization  of  optimized  culture  conditions  for  PDX-­derived  RMS  cells  and  provide  a  side-­by-­
side  comparison  with  standard  culture  protocols.  Importantly,  we  detected  that  traditional  culture  
conditions   with   presence   of   serum   has   a   toxic   effect   on   primary   RMS   cells   and   leads   to   the  
outgrowth   of   resistant   clones.   Additionally,   we   show   the   feasibility   of   using   our   in   vitro   drug  
platform-­based   screen   to   pinpoint   patient-­specific   pharmacological   vulnerabilities   with   a   high-­





In  vitro  culture  condition  screen  with  PDX-­derived  rhabdomyosarcoma  cells    
In   order   to   set   up   a   culture   system   that   closely   preserves   the   phenotypic   and   molecular  
characteristics  of   the  parental   tumor,  we  followed  the  scheme  depicted   in  (Figure  1A).  First,  we  
aimed  to  determine  the  optimal  culture  conditions  supporting  the  growth  of  the  RMS  tumor  cells  
(RTCs)   in  vitro.  For   that,  at   least   two   independent   tumors   from  8  different  RMS  PDX  models  (3  
ARMS   and   5   ERMS   established   previously   [15,   19]   and   in   this   study   (Suppl.   Table   1))   were  
allowed  to  grow  s.c.  in  mice  up  to  1  cm3,  followed  by  tumor  isolation,  dissociation  into  single  cell  
suspension  and  culture  in  a  96-­well  plate  format.  We  compared  18  different  culture  conditions  by  
combining   each   of   three   different   media   (DMEM   and   F10   both   supplemented   with   10%   heat  
inactivated   fetal   bovine   serum   (FBS)   and   Neurobasal   (NB)   supplemented   with   serum  
replacement   B-­27)   with   three   different   vessel   substrates   (no   coating,   Matrigel   and   gelatin  
coatings),  each  in  presence  or  absence  of  EGF  plus  bFGF  (GF).  When  cells  reached  confluency  
in   one   of   the   conditions   (normally   within   1-­3   weeks),   cell   viability   was   determined   by   WST-­1  
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assay.   In   parallel,   cell   morphology   was   analyzed  microscopically.   This   first   approach   revealed  
that  F-­10  based  media  was  generally  not  effective   in  supporting  RTC  growth  and  therefore  was  
not   further   studied   (Figure   1B).   In   contrast,   NB   based  medium   supported   growth   of   cells   from  
most   PDX,   especially   in   combination  with  Matrigel.   In   some   cases,  NB  medium   supplemented  
with   GF   and   combined   with   Matrigel   coating   even   scored   as   the   top   condition,   such   as   for  
SJRHB013759_X1C   (ARMS)   and   RMS_ZH04_XC   (ERMS)   with   cell   viability   values   ranging  
between  ~126%  to  307%  of  the  DMEM-­GF  condition,  which  was  used  as  reference  (Figure  1  B  
and   Suppl.   Table   2).   DMEM   based   conditions,   independent   from   coating   or   presence   and  
absence  of  growth  factors,  supported  survival  of  cells  across  all  samples  but  SJRHB013759_X1C  
(Figure  1B  and  Suppl.  Table  2).   In   several   cases,   the  DMEM  conditions   led   to   the  highest   cell  
viability   values   measured.   Importantly   however,   morphological   analysis   revealed   that   cells   in  
DMEM  medium  often  had  an  increased  size  and  were  rich  in  stress-­fibers,  suggesting  that  these  
cells,  despite  being  viable  during  this  short-­term  culture,  might  have  stopped  proliferation  at  some  
point   (Suppl.   Figure   1A).   In   case   of   two   aRMS   samples   (SJRHB013757_G1C   and  
SJRHB010463_X16C)  elongated  and  multinucleated  cells  with  a  myotube-­like  morphology  were  
detected   in   DMEM   cultures   (Figure   1C   and   Suppl.   Figure   1A),   suggesting   that   these   cells  
differentiated   along   the  myogenic   pathway.   Comparative   immunofluorescence   (IF)   analysis   for  
myosin   heavy   chain   (MHC)   expression,   a  marker   of   terminal   skeletal  muscle   differentiation,   in  
SJRHB013757_G1C   cells   grown   in   parallel   in   DMEM   and   NB   medium   confirmed   this   pro-­
differentiation  effect  of  the  DMEM  condition  (Figure  1D).  In  contrast,  cells  in  NB  medium  generally  
remained   small   and   stress-­fiber   free   and   did   not   upregulate   muscle   differentiation   markers  
(Figure  1C-­E).    
The  growth  factors  especially  enhanced  growth  of  aRMS  cells,  while  in  eRMS  they  had  less  effect  
or   affected   cell   viability   even   negatively,   such   as   in   case   of   SJRHB012_RC   cells   on   uncoated  
plates  or   in  combination  with  gelatin-­coating  (Figure  1C,  right  panel).  Interestingly,  correlation  of  
effects   of   growth   factors   on   cell   viability   with   genomic   data   revealed   that   among   the   eRMS  
especially  the  Ras-­pathway  mutant  ones  were  not  affected  (Table  1).  Finally,  in  three  cases,  the  
procedure  failed  to  generate  cancer  cell  cultures  where  outgrowth  of  mouse  cells  was  observed  
(data  not  shown).  
Taken  together,  these  initial  analyses  revealed  dramatic  differences  in  behavior  of  cultures  from  
individual   RMS   tumors   in   different   culture   conditions   as   well   as   some   heterogeneity   in  
requirements   among   the   different   tumors.   However,   taking   into   account   both   cell   viability   and  
morphology,  NB  based  conditions  in  combination  with  Matrigel-­coating  represent   in  many  cases  





Evaluation  of  the  long-­term  proliferation  capacity  of  rhabdomyosarcoma  cells  cultured  in  
NB  and  DMEM-­based  conditions  
In  order  to  validate  the  superior  performance  of  NB  medium,  we  next  compared  DMEM  and  NB  
based  conditions  on  the  long-­term  proliferation  rate  of  RTCs.  We  monitored  the  cell  numbers  of  2  
ARMS   (SJRHB010463_X16C,   SJRHB013759_X1C)   and   4   ERMS   (SJRHB012_RC,  
SJRHB13758_X1C,   SJRHB13758_X2C   and   RMS_ZH04_XC)   cultures   over   a   period   of   1-­2  
months  by  counting  cell  numbers  at  every  passage  (Figure  2A).  Interestingly,  we  found  that  in  5  
out  of  6  cases  (~83%),  NB-­derived  cells  continuously  proliferated  with  an  exponential  growth  rate  
regardless   of   the   passage   number,   whereas   cell   counts   in   DMEM  were   decreasing   over   time  
starting  already  from  an  early  time  point  on  passage  1  or  2  (Figure  2A).  Only  SJRHB13758_X2C  
cells,   harboring   a   TP53   mutation   (table   1)   could   be   easily   propagated   also   in   DMEM   with   a  
growth   kinetic   indistinguishable   from   the   one   in   NB  medium,   reflecting   the   high   take-­rate   and  
aggressiveness   of   this   particular   tumor   observed   in   vivo   (Figure   2A   and   data   not   shown).  
Interestingly  we  observed,  in  DMEM  cultures  of  two  tumors  (SJRHB012_RC  and  SJRHB012_SC)  
that   a   small   number   of   cells   resisted   these   suboptimal   growth   conditions   and   continued   to  
proliferate,   first   forming  outgrowing  clones   (DMEM_clones),  which   then  could  be  propagated   to  
confluent  monolayers  within  1-­2  months   (Suppl.  Figure  1A).  When   transplanted   into  mice,  both  
NB-­derived  cells  and  DMEM_clones   from  SJRHB012_RC  were   tumorigenic   (engraftment   in  5/5  
mice)  and   displayed   similar   growth   kinetics   (Suppl.   Figure   1B,   left   panel).   In   contrast,   only   2/4  
(50%)   of   DMEM_clones   and   all   NB-­derived   cells   (4/4)   from   SJRHB012_SC   engrafted   in   mice  
(Suppl.  Figure  1B,  right  panel).  Thus,  an   in  vitro  selection  and/or  adaptation  process  is  required  
for  DMEM_clones  to  re-­gain  a  proliferative  status  that  is  not  always  maintained  in  vivo.    
To   determine   the   components   in   the   DMEM  mixture,   which   are   detrimental   to   cell   fitness,   we  
repeated  the  proliferation  assay  by  seeding  cells  from  four  tumors  in  DMEM  or  NB  based  medium  
supplemented  one-­by-­one  with  B27,  FBS  or  the  combination  of  both  (Figure  2B).    This  approach  
revealed  that  FBS  is  the  component  that  negatively  affects  the  growth  of  all  RTC  cultures,  both  in  
DMEM  and  NB  medium.  Interestingly  however,  in  one  of  the  tested  cases  (SJRHB013759_X1C)  
this   toxic  effect  was  completely   reverted  by  co-­addition  of  B-­27  and   the  combination  generated  
even  a  synergistic  pro-­proliferative  effect,  which  was  more  prominent   in  NB   than  DMEM  based  
medium   (Figure   2B).   Hence,   albeit   our   empiric   attempts   underscore   the   difficulty   to   generalize  
culture  conditions,  they  clearly  identify  serum  as  the  main  undesirable  component  for  RTCs.    
In  parallel,  we  also  validated  the  effects  of  the  growth  factors  in  order  to  identify  which  of  them  is  
responsible   for   the   detected   biological   effects.   For   that,  we  determined   the   proliferation   rate   of  
selected   growth   factor-­activated   (SJRHB013759_X1C)   and   -­inhibited   (SJRHB012_RC)   RTC  
cultures   under   all   possible   growth   factor   permutations   in   NB   medium   (Figure   2C).   In   case   of  
SJRHB012_RC  bFGF  inhibited  cell  proliferation  and  induced  a  drastic  change  in  cell  morphology  
(Figure  2C  and  Suppl.  Figure  1D).  Despite   resembling  myogenic  differentiation,   this  phenotype  
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was   not   associated   with   MHC   upregulation   (Suppl.   Figure   1D).   In   contrast,   proliferation   of  
SJRHB013759_X1C  cells  was  strongly   induced  by  bFGF,  while  EGF  had  only  a  small   inductive  
effect,  which  was  additive  with  the  one  from  bFGF  in  combination  tests  (Figure  2C,  lower  panel).  
In  summary,  these  results  indicate  that  selected  culture  conditions  identified  through  our  platform  
outperform  conventional  cell  line  protocols,  which  are  highly  detrimental  to  most  RTCs  due  to  the  
presence  of  FBS.  Furthermore,  we  confirmed  the  growth  factor  susceptibility  in  a  subset  of  RTC  
cultures  and  uncovered  a  tumor-­suppressive  role  of  bFGF  in  a  single  case.  
  
Genomic  and  histological  characterization  of  matched  PDX  and  RTCs.    
In  order   to  confirm   the   tumor  nature  of   the  cultured  cells  and   to  elucidate   if   the  applied  culture  
conditions  exert  a  selection  pressure,  we  performed  comparative  DNA  copy  number  analysis  of  
matched   PDX   tumors   and   RTCs   using   array-­CGH.   Overall,   we   detected   a   high   level   of  
concordance  between  PDXs  and  RTCs   (Figure  3A  and  Suppl.  Figure  2A).  Furthermore,  DAPI-­
staining   of   cell   nuclei,   allowing   discrimination   of   mouse   from   human   cells   based   on   different  
staining  patterns  revealed  maximally  14.5%  mouse  cells  in  the  cultures  (Suppl.  Figure  2B).  Taken  
together,  these  data  confirm  that  all  RTC  cultures  indeed  represent  cancer  cells  and  that  they  are  
genomically  stable  in  NB-­based  medium.  Nevertheless,  in  accordance  with  previous  studies,  we  
also   noticed   some   small   differences   in   DNA   copy   numbers   between   PDX   and   corresponding  
RTCs   (Figure   3A).   This   was   even   more   pronounced   for   DMEM_clones.   For   instance,  
SJRHB012_SC  DMEM_clone  was  characterized  by  a  unique  loss  in  chromosome  4  and  gain  in  
chromosome  2,  consistent  with  a  selection  process  or  acquisition  of  additional  genetic  alterations  
upon  DMEM  culture  (Figure  3A,  lower  panel).    
Although   several   studies   demonstrated   that   PDX   models   retain   most   of   the   molecular   and  
histopathologic   characteristics   of   the   primary   tumors,   little   is   known   about   the   phenotype   of  
tumors  generated  with  matched  cells  propagated  in  vitro,  particularly  in  case  of  RMS.  To  address  
this   issue,   we   generated   s.c.   xenograft   tumors   using   cells   from   RTC   cultures   (cell-­derived  
xenografts;;   CDX)   and   compared   their   histological   characteristics   with   the   one   from   PDX   and  
original  patient  tumors,  if  available.  For  that,  tumor  sections  were  assessed  for  cell  morphology  by  
haematoxylin  and  eosin  (H&E)  staining  or  for  presence  of  cells  with  skeletal  muscle  differentiation  
by   immunohistochemical   detection   of   Desmin   and  Myogenin.   This   analysis   revealed   that   both  
PDX   and   CDX   retain   RMS   features   phenocopying   the   tumor   architecture   and   the   degree   of  
myogenic  differentiation  of  the  primary  tumor  (Figure  3B).  Altogether,  these  findings  showed  that  
NB-­derived  cells  maintain  most  of  the  copy  number  changes  of  their  parental  PDX  and  faithfully  





In   vitro   compound   screen   with   RTCs   informs   on   pharmacological   vulnerabilities   of  
individual  tumors  
Based  on  the  low  mutational  burden  of  RMS  tumors,  we  next  asked  whether  our  established  RTC  
cultures   represent   a   suitable   pre-­clinical   model   to   unveil   actionable   drug   targets   in   individual  
tumors.  Therefore,  we  developed  an  in  vitro  proof-­of-­concept  high-­throughput  screen  employing  a  
compound  library  containing  204  drugs.  This  contains  both  Food  and  Drug  administration  (FDA)-­
approved   drugs   and   small   molecules   in   clinical   development,   together   covering   a   range   of  
functional   classes   of   targets,   as   well   as   standard   chemotherapeutics   used   for   RMS   therapy  
(Suppl.  Table  3).  A  panel  of  15  RMS  cell  cultures   including  8  RTCs   (5  ERMS  and  3  ARMS),  3  
DMEM_clones  and  4  commonly  used  cell  lines  (2  ERMS  and  2  ARMS)  were  treated  for  72h  with  
a   final   drug   concentration   of   500   nM.  We   used  WST-­1   assay   as   read-­out   for   cell   viability   and  
generated  a  hit  map  depicting  drug  responses  based  on  the  percentage  of  living  cells  relative  to  
DMSO  control  (Figure  4A).  Overall,  70/204  (~34%)  of  the  drugs  decreased  cell  viability  more  than  
20%   in   at   least   one   sample.   Unsupervised   hierarchical   clustering   analysis   using   the   response  
data  revealed  that  all  PAX3-­FOXO1  positive  samples  clustered  together,  while  in  case  of  ERMS  
different   subgroups   were   found   (Suppl.   Figure   3).   This   findings   mirror   the   different   genetic  
landscape   characterizing   the   two  RMS   subtypes   as   well   as   the   larger   heterogeneity   of   ERMS  
tumors  [4]  At  the  level  of  individual  drugs,  different  response  patterns  were  detected.  A  first  set  of  
drugs   showed   general   toxicity   (at   least   40%   reduction   in   cell   viability   in   a   majority   of   the   cell  
cultures)   including   proteasome   inhibitors   (4),   HSP90   antagonists   (2),   anti-­PI3K   agents   (2),  
compounds  interfering  with  the  apoptotic  machinery  (Obatoclax  and  YM155),  the  dual  ALK/IGF1R  
inhibitor  AZD3463,   and   the  mTOR   inhibitor   Torin   2.  Other   drugs   showed  more   specific   activity  
patterns.   Among   them   are   3   out   of   4   Akt   inhibitors   including   GSK690693,   Afuresertib   and  
Ipatasertib,   which   especially   affected   aRMS   samples,   while   among   ERMS   samples   only   two  
RASWT  RTCs  (SJRHB012_RC  and  SJRHB012_SC)  but  not  the  corresponding  clones  were  highly  
sensitive   (Figure   4A).   Determination   of   IC50   values   of   GSK690693   and   Afuresertib   revealed  
sensitivities   at   therapeutically   applicable   concentrations   of   95-­281   nM   and   196-­212   nM,  
respectively   for   these   compounds   in   two   aRMS   RTCs   (Figure   4B).   Notably,   a   small   group   of  
drugs  was   especially   active   in  RTCs   compared   to   cell   lines.   These   include   anti-­topoisomerase  
chemotherapeutics   (doxorubin   and   etoposide)   in   ARMS,   the   menin-­MLL   inhibitor   MI-­2   and  
ponatinib  in  ERMS  (Figure  4A).  
At  the  level  of  individual  tumor  samples,  some  exceptional  behaviors  were  detected  such  as  the  
resistance   of   the   PAX7-­FOXO1   fusion   positive   tumor   (SJRHB013757_G1C)   against   all  
proteasome  inhibitors  (4),  Volasertib  (PLK1  inhibitor)  and  YM155  (survivin   inhibitor)  (Figure  4A).  
This  finding  again  underscores  the  relevance  of  personalized  drug  profiles.  Finally,  strong  degree  
of   overlap   between   two   DMEM   CLONES   derived   from   the   same   PDX   was   observed,   further  
corroborating  their  distinct  phenotype  (Figure  4A  and  Suppl.  Figure  3A).    
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As   proof-­of-­principle   for   reproducibility   of   our   discovery   drug   platform,   we   validated   additional  
compounds  anticipated   to   have  a   general   (Verdinexor   and  YM155)   or   individual   (ABT-­263  and  
Idasunutlin)   activity      (Figure   4B   and   Suppl.   Figure   3B).   The   IC-­50   values   were   in   general  
accordance  to  the  predicted  cell  viability  scores  (Figure  4B  and  Suppl.  Figure  3B,  lower  panels).  It  
is   worth   mentioning   that   Idasanutlin   exhibited   a   strong   activity   in   all   TP-­53wt   RTCs   tested   but  
failed   in   1/2  of  RMS  cell   lines  with   an   intact  TP-­53,   presumably   as   consequence  of   an   in   vitro  
selection   and/or   adaptation   process   required   to   establish   traditional   cell   lines   (Figure   4B   and  
Suppl.  Figure  3B).  
In   sum,   our   unbiased   drug   screen   revealed   the   need   of   using   functional   assays   to   interrogate  
druggable   targets,   which   cannot   be   fully   captured   across   the   limited   set   of   RMS   cell   lines  




Historically,  cancer  cell   lines  have  been  routinely  used  as  model  system  to  study   the  biology  of  
cancer.  Given   their   versatility   for  high-­throughput  approaches,   they  have  been  adopted  as  pre-­
clinical  platforms  to  readily  identify  therapeutic  targets  and  test  anti-­cancer  strategies.  Despite  the  
great   promise   of   cell   line-­based   screening   programs,   only   few   identified   agents   have   met   a  
clinical  success  [20].  Additionally,  the  current  paucity  of  tumor-­derived  cell  lines  highlights  a  major  
shortcoming  for  modeling   inter-­patient  cancer  heterogeneity   [17].  This   is  particularly  relevant   for  
the   rare  pediatric   tumors,   including  RMS,  where  cancer   research  continues   to   rely  on  a   limited  
panel  of  cell  lines  established  decades  ago  [21-­23].  This  low  success  rate  of  cell  cultivation  might  
reflect   the   inability   of   traditional   serum-­containing  media   to   adequately  mimic   the   physiological  
environment   of   living   tissues   [24].   An   alternative   strategy   to   overcome   in   vitro   limitations   is  
represented  by  PDX  models.  Recent  studies  in  RMS,  have  shown  that  PDX  faithfully  recapitulate  
molecular  and  phenotypic   features  of   the  original   tumor  biopsies  and  are  currently  employed   in  
drug  testing  programs  to  prioritize  effective  agents  for  childhood  cancers  [15,  19,  25].  However,  
the   narrow   PDX   populations   representative   of   each   tumor   type   and   the   restricted   number   of  
therapeutics   that  can  be  evaluated  annually  constitute  critical  caveats   in  current  drug  discovery  
and  development  pipelines.      
To  tackle  this  situation,  in  the  present  work  we  have  established  a  large  collection  of  PDX-­derived  
RTCs   using   a   serum-­free   culture   method   that   preserves   niche   factor   requirements,   patient-­
specific   genomic   alterations,   proliferative   capacity   and   tumorigenic   ability.   By   contrast,   we  
observed  a  general  difficulty  to  propagate  cells  in  serum-­containing  media,  consistent  with  the  low  
rate  of  establishment  of  cancer  cell  lines  achieved  in  the  past  with  standard  culture  protocols  [24].  
In  our  hands,  the  presence  of  serum  exhibited  a  strong  anti-­proliferative  effect,  induced  profound  
morphological   changes   and   in   some   cases   promoted   terminal   skeletal   muscle   differentiation.  
Similar   results   have   been   documented   for   primary   glioblastoma,   neuroblastoma   and   ovarian  
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tumor  cells,  suggesting  that  this  might  be  a  general  phenomenon  [26-­28].    We  speculate  that  the  
multitude  of  variable  components  of  the  serum  might  not  properly  recapitulate  the  fluid  that  cells  
are  exposed  to  in  their  natural  milieu  [29].  Accordingly,  2  out  of  3  successful  examples  of  serum-­
derived   cells   in   our   settings   were   associated   with   a   clonal   outgrowth   reminiscent   of   cells  
undergoing  growth  crisis  before  re-­gaining  a  proliferative  status  [26,  30].  The  selection  pressure  
imposed  by  this  culture  condition  resulted  in  the  emergence  of  de  novo  genetic  aberrations  and  in  
one  case   limited   the   tumorigenic  potential   of   the   cultured   cells.  This  occurrence   resembles   the  
loss  of  tumorigenicity  observed  in  primary  glioblastoma  cells  exposed  to  serum  [26].  Albeit  future  
experiments  are  needed  to  unravel  the  growth  inhibitor  factors  of  the  serum  and  clarify  the  stress-­
induced  growth  arrest,   recent   studies  have   suggested   that   both   senescence  and  differentiation  
can  take  place  [27,  31].  It  is  also  worth  mentioning  that  we  were  unable  to  generate  RTCs  in  three  
cases,  where  we  detected  outgrowth  of  mouse  cells,  indicating  that  further  attempts  to  refine  our  
culture  conditions  will  be  necessary  to  increase  the  array  of  RMS  cell  types  in  vitro.  Furthermore,  
our  in  vitro  “culture  discovery  platform”  revealed  that  semisolid  culture  conditions  (with  matrigel  or  
gelatin)  are  highly  beneficial  for  the  growth  of  RTCs,  probably  by  mimicking  the  cell-­extracellular  
matrix  (ECM)  contacts  occurring  in  vivo  and  thus  limiting  the  plastic  adaptation.  We  also  describe  
unpredictable  GF   sensitivities   and   identified   bFGF   as   the   crucial   factor   affecting   the   growth   of  
both  GF-­stimulated  and  GF-­inhibited  cells.  This  is  in  line  with  the  importance  of  FGF  signaling  in  
RMS   [32,   33].   Whether   specific   genetic   alterations   might   account   for   this   heterogeneity   of  
response  remains  elusive.  Alternatively,  it  is  possible  that  tumors  originated  from  different  sites  in  
the   body,   are   exposed   to   distinct   microenviroments   to   which   they   adapt.   Accordingly,   it   was  
shown   that,   colorectal   tumor  organoids  displayed   individual  dependencies  on  niche   factors   that  
might   reflect   their  original  anatomic  site,   tumor  stage  and  genomic  background  [34].  Finally,  we  
have  shown  a  broad  spectrum  of  responses  to  different  class  of  agents  across  our  set  of  RTCs  
derived   from   patients   with   distinct   clinical   course   and   RMS   subtype.  With   the   goal   in   mind   to  
identify  compounds  of  potential  clinical  benefit  for  individual  patients,  we  were  able  to  capture  not  
only   expected   drug   activities   (i.e.   idasanutlin   in   TP-­53wt   samples)   but   also   exquisite   patient-­
specific  sensitivities  (i.e.  ABT-­263)  or  refractory  responses  (i.e.  preteasome  inhibitors)  that  could  
not  be  anticipated  based  solely  on  genomic  data.  We  also  discovered  a  subset  of  patients  with  an  
AKT  responsive  phenotype  as  demonstrated  by  the  clear  overlap  of  several  AKT  inhibitors.  These  
latter   are   currently   investigated   in   phase   I/II   clinical   trials   for   adult   malignancies   [35].   Despite  
evidences  suggesting  that  AKT  iper-­phosphorylation  (AKT  ser473)  predicts  poor  overall  survival  
in  RMS,   little  attention  has  been   focused  on   the  mTOR/AKT  axis  blockade  so   far   [36].   Instead,  
our   findings   indicate   that   in   vitro   drug   profiling   is   a   suitable   approach   to   pre-­select   RMS   sub-­
groups  who  may  benefit  from  anti-­AKT  therapies.  Since  identification  of  “druggable”  mutations  in  
RMS   does   not   always   match   therapeutic   utility   [37],   we   propose   that   functional   testing   would  
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complement  current  genome-­based  technologies  or  other  diagnostic  tools  (i.e.  BH3  profiling  [38,  
39])  to  precisely  infer  drug  activity  for  precision  medicine.  
To   our   knowledge   our   data   provide   the   first   systematic   characterization   of   culture  methods   for  
efficient   derivation   and   maintenance   of   RTCs   in   vitro   and   demonstrate   the   adverse   effect   of  
serum-­based   protocols.  We   also   outline   the   feasibility   of   using   RTCs   to   functionally   inform   on  
personalized  treatment  strategies  and  in  a  clinically  relevant  time  frame.  
  
Materials  and  Methods  
  
Patient-­derived  samples  
The   PDX   samples   SJRHB012_R,   SJRHB012_S,   SJRHB013758_X1,   SJRHB013758_X2,  
SJRHB010463_X16,   SJRHB013759_X1   and   SJRHB013757_G1   were   obtained   from   St.   Jude  
Children’s  Research  Hospital  (USA)  [15].  RMS_ZH04_X  was  generated  from  a  tiny  tumor  biopsy  
collected  at  the  Mumbai  Children’s  Research  Hospital  in  agreement  with  local  institutional  ethical  
regulations   and   implanted   subcutaneously   in   NOD   scid   gamma   (NSG)   mice.   Once   tumors  
reached  a  size  of    ~1cm3,  xenografts  were  harvested  and  dissociated  for  cell  derivation  and  PDX  
propagation.   For   multiple   in   vivo   passages,   PDX   were   either   implanted   as   tumor   pieces   or  
injected  as  cell  suspension  subcutaneously  in  NSG  mice.  A  description  of  the  PDX  lines  used  in  
this  study  can  be  found  in  Suppl.  Table  S1.    
  
Tumor  dissociation  
PDXs  were  minced  with  scalpel,  suspended  in  2  ml  digestion  buffer  containing  1x  HBSS  (Sigma  
Aldrich),   200   U/ml   Dnase1   (Stemcell   Technologies   or   Roche   Diagnostics),   1   mM   MgCl2,   200  
ug/ml   Liberase   (Roche   Diagnostics)   and   incubated   at   37°C   for   20-­30   minutes.   Cells   were  
resuspended  in  18  ml  of  Dulbecco’s  Modified  Eagle  Medium  supplemented  with  10%  fetal  bovine  
serum   (heat   inactivated),   filtered   through   70   um   cell   strainer   and   centrifuged   at   300   g   for   5  
minutes.   Finally,   the   cell   pellet   was   washed   once   with   PBS   before   cell   counting.   For   freezing  
procedures,   digested   PDXs   or   minced   tumors   were   cryo-­preserved   in   either   FBS   (heat  
inactivated)  plus  10%  DMSO  or  Cryostor  (Stemcell  Technologies).  
  
Culture  screen  
1-­2  hours  before  mouse  sacrifice  and  PDX  collection,  18  wells  of  a  96-­well  plate  were  pre-­coated  
with  2%  gelatin  (Sigma  Aldrich)   for  40-­60  minutes  at  37˚C.  Afterwards,  18  additional  wells  were  
pre-­coated   with   10%   matrigel   (in   neurobasal   medium)   (Corning)   for   40-­60   minutes   at   room  
temperature.  Hence,  PDX  were   dissociated   in   single   cell   suspensions   and   counted   by   using   a  
mini   automated   cell   counter   (ORFLO).   For   cell   seeding,   30.000   cells   per   well   were   plated   in  
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triplicates  by  using  a  multichannel  pipette  before  cell   viability  was  assessed  1-­3  weeks   later  by  
WST-­1  assay  (Roche  Diagnostics)  according  to  the  manufacturer’s  instructions.  
  
Xenograft  studies    
For  establishment  of  cell-­derived  xenografts  (CDXs),  5x106  cells  were  suspended  in  100  ul  PBS  
and  injected  subcutaneously  (s.c.)  in  NOD  scid  gamma  (NSG)  mice.  Tumor  size  was  determined  
by  digital  calliper  measurements  of  2  diameters  (d1,  d2)  in  right  angles.  Total  tumor  volumes  were  
calculated   by   the   formula   V   =   (4/3)πr3   ;;   r   =   (d1   +   d2   )/4.  Mice  were   euthanized   once   tumors  
reached  the  maximum  allowable  size  (1  cm3)  or  with  weight   loss  over  20%  than  baseline  (body  
weight  was  monitored  daily  through  the  course  of  each  experiment).  
  
Cell  culture  and  cell  proliferation  
RD   (ATCC,   Manassas,   VA,   USA),   RHJT,   RH36   and   RH4   cells   (kindly   provided   by   Peter  
Houghton,   The   Research   Institute   at   Nationwide   Children’s   Hospital,   Columbus   OH)   were  
cultured   on   uncoated   plates   in   DMEM   supplemented   with   10%   fetal   bovine   serum   (heat  
inactivated),  1%  L-­glutamine  and  1%  penicillin-­streptomycin.  RTCs  were  cultured   in  Neurobasal  
medium  (Thermo  Fisher  Scientific)  supplemented  with  1%  glutaMAX  (Thermo  Fisher  Scientific),  
1%   penicillin-­streptomycin,   2x   B27   (Thermo   Fisher   Scientific),   bFGF   (20ng/ml,   Peprotech)   and  
EGF   (20ng/mL,   Peprotech).   Only   SJRHB012_RC   cells   were   maintained   without   GF   supply.  
Medium   was   replaced   tree   times   a   week.   Plates   were   pre-­coated   with   either   10%   matrigel  
(Corning)  for  40-­60  minutes  at  room  temperature  or  2%  gelatin  (Sigma  Aldrich)  for  40-­60  minutes  
at  37˚C,  according  to  the  optimal  culture  conditions  per  each  RTC  described  in  the  text.  All  cells  
were  cultured  in  5%  CO2  at  37°C.    
For  proliferation  assay,  cells  were  seeded  in  duplicate  for  each  culture  condition  and  split  at  the  
indicated   time   points   by   using   either   accutase   (Sigma   Aldrich)   or   trypsin   (1:1   with   PBS).   The  
cumulative  number  per  each  condition  was  calculated  by  multiplying  the  average  number  of  cells  




Cells  were  seeded  in  triplicate  on  flat-­bottomed,  white  384-­well  plates  and  after  24h  medium  was  
replaced  before  treatment  start.  Each  compound  (10  mM  stock  solution  dissolved  in  DMSO)  was  
pre-­diluted  with  medium  the  day  of  the  experiment  at  10  uM  concentration  and  1  ul  of  this  solution  
was  added  manually  to  each  well  containing  19  ul  of  medium  to  achieve  a  final  concentration  of  
500  nM.  DMSO  was  used  as  vehicle  control.  WST-­1  assay  was  performed  at  72h  time  point.  The  
average   number   of   leaving   cells   for   each   triplicate   was   normalized   to   untreated   cells   (vehicle  
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control)  and  data  are  shown  as  percentage  of  control.  The  drug  library  containing  204  drugs  was  
purchased  from  Selleck  and  details  are  shown  in  Supp.  Table  3.  
For  drug  validation,  cells  were  plated  in  triplicates  on  flat-­bottomed,  white  384-­well  plates  at  cell  
densities   ranging  between  3000   to  10000  cells   depending  on   the   cell   type  used.   24h  after   cell  
seeding,   medium   was   replaced   and   drug   was   added   by   using   HPD300   digital   dispenser   at  
concentrations   indicated   in   each   figure.   72h   after   treatment  WST-­1   assay   (Roche  Diagnostics)  
was   performed   according   to   the   manufacturer’s   instructions.   The   following   compounds   were  




SJRHB013757_G1C  and  SJRHB012_SC  cells  were  grown  on  tissue  culture  slides  (Corning)  pre-­
coated  with  10%  matrigel  or  2%  gelatin,   respectively.  After  washing  once  with  PBS,  cells  were  
fixed  with   4%   formalin   for   15  minutes,  washed  again  with  PBS  before   adding   0.1  M  Glycin   (in  
PBS)   for   5   minutes.   After   three   washing   steps   with   PBS,   cells   were   permeabilized   with   0.1%  
Triton  X-­100   (in  PBS)   for   15  minutes,   blocked   for   additional   15  minutes   in  PBS  containing  4%  
horse   serum   and   0.1%   Triton   X-­100   (blocking   buffer)   and   incubated   overnight   with   primary  
monoclonal  myosin  heavy  chain  antibody  (1:400  in  blocking  buffer,  DSHB)  at  4ºC.  The  day  after,  
cells  were  washed   three   times  with  PBS  and   incubated  with  Alexa-­488   (or  Alexa-­594)   labelled  
donkey  anti-­mouse  secondary  antibody  (Invitrogen)  diluted  1:250  in  PBS  plus  4%  horse  serum  for  
60   minutes   at   room   temperature   before   three   additional   washing   steps.   Finally,   slides   were  
dipped   in  water   and   nuclei   stained  with  DAPI   (Vector   Laboratories).   Images  were   acquired   by  
using  a  fluorescence  microscope  (Zeiss  Axio  Observer).  
  
Immunohistochemistry  
Following  mouse  sacrifice  and  tumor  collection,  tissue  was  fixed  in  paraformaldehyde  overnight,  
and  stored  in  70%  EtOH  at  +4°C  until  embedment.  Staining  was  performed  on  3µm  thick  sections  
from  blocks  of   formalin-­fixed,   paraffin-­embedded   (FFPE)   tissue  at   the  department  of  Pathology  
(University  of  Zurich)  as  previously  described  [40].  The  following  antibodies  were  used:  DESMIN  
(Dako,  M076029,  dilution  1:20)  and  MYOGENIN  (Novocastra,Leica,  PA0226,  dilution  1:20).  
  
aCGH  analysis  
Genomic   DNA   was   extracted   using   the   DNAse®   Blood&Tissue   Kit   (#69506)   following   the  
manufacturer’s  instructions.  The  aCGH  assay  was  performed  using  the  CytoScan™  HD  Array  Kit  
according   to   the  manufacturer’s   protocol   (Affymetrix,   Thermo   Fisher   Scientific,  MA,  USA).   The  
raw   data   of   each   single   sample   was   analyzed   with   the   Chromosome   Analysis   Suite   (ChAS)  
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Figure  1.  Identification  of  culture  medium  requirements  for  RTCs    
  
(A)  Model  used  to  generate  an  RTC-­based  pre-­clinical  platform.  Briefly,  established  PDXs  were  
collected   and   dissociated   to   derive   RTCs,   which   were   then   seeded   on   a   96-­well   plate   format  
under   different   culture   conditions   (see   text)   before   WST-­1   assay   was   performed.   Next,   the  
proliferation   rate   of   cells   under   standard   and   selected   culture   protocol  was  monitored   together  
with  aCGH  analysis.  Finally,  a  patient-­specific  drug  profile  was  applied  trough  a  high-­throughput  
drug   screen   followed   by   in   vivo   validation   of   the   top   candidates   on   the   original   PDX.   (B)   Cell  
culture   screen   results   of   indicated   RTCs.   Blue   and   orange   graph   bars   indicate   absence   or  
presence   of   supplemented   growth   factors   (GFs),   respectively   (mean  ±   sd).   (C)  Representative  
bright-­field  images  of  SJRHB013757_G1C  and  SJRHB010463_X16C  taken  before  WST-­1  assay.  
Scale   bar   200   µm.   (D)   IF   analysis   for   expression   of   myosin   heavy   chain   (MHC)   in  
SJRHB013757_G1C   cells   under   DMEM   or   PCM   (primary   culture   medium,   NB   condition)  
conditions.  Dapi  was  used   for  staining   the  nuclei.  Scale  bar  100  µm.  (E)  Representative  bright-­
field   images   of   SJRHB012_RC   in   presence   or   absence   of   GF   on   uncoated   or   gelatin-­coating  
conditions.  Scale  bar  200  µm.  
  
Table  1.  Table   indicating  known  genetic  alterations  of   the  RTCs  used   in   the  present  study  and  
the  effect  of  GF  on  cell   fitness.  The  GF  ratio   (+GF/-­GF)  was  calculated   for  cells  cultured  under  
NB   conditions   and   on   Matrigel   for   all   cell   types   but   SJRHB012_RC   and   SJRHB013758_X1C  
where  cell  viability  of  cells  cultured  on  gelatin  was  considered.  
  
Figure  2.  Proliferation  rate  of  RTCs  cultured  under  DMEM  or  NB  conditions  
  
(A)  Proliferation  rate  of  RTCs  cultured  under  DMEM  (black  line)  on  uncoated  plates  and  NB  (red  
line)   on   Matrigel   (RMS_ZH04_XC,   SJRHB010463_X16C,   SJRHB013759_X1C   and  
SJRHB13758_X2C)   or   gelatin-­coated   plates   (SJRHB13758_X1C   and   SJRHB012_RC).   Cell  
number  was  normalized  to  day  of  seeding  and  is  expressed  in  a  logarithmic  scale.  (mean  ±  sd).  
(B)  Growth  curves  of  RTCs  over  time  under  indicated  culture  conditions  (mean  ±  sd).  Please  note  
that   “NB”   in   these  graphs   indicates  neurobasal  medium  supplemented  with  1%  glutammax  and  
1%  penicillin-­streptomycin  but  without  B-­27.  (C)  Assessment  of  GF  dependency  upon  long-­term  
proliferation  of  GF-­inhibited  (upper  panel)  and  GF-­stimulated  cells  (lower  panel).  Each  data  point  
is  expressed  as  percentage  of  day  0  (mean  ±  sd).  On  the  right  side  of  each  graph,  representative  







Figure  3.  Copy  number  variants  analysis  of  RTCs  and  histological  characterization  of  
xenografts    
  
(A)  Copy-­number  variants   (CNVs)  analysis  of  RMS_ZH04   (upper  panel),  SJRHB012_R   (middle  
panel)   and   SJRHB012_S   (lower   panel)   for   the   original   PDXs   and   corresponding   NB-­derived  
RTCs   or   DMEM   clones.   (B,   left   panel)   Formalin-­fixed   paraffin-­embedded   (FFPE)   sections   of  
RMS_ZH04   primary   tumor,   corresponding   PDX   and   RTC-­derived   xenografts   were   stained   for  
H&E   (Hematoxylin   and   Eosin),   DESMIN   and   MYOGENIN.   (B,   middle   and   right   panel)   FFPE  
sections   of   SJRHB012_R   and  SJRHB012_S  PDX   and  matched  RTC-­   or   DMEM   clone-­derived  
xenografts.  Staining  for  H&E,  DESMIN  and  MYOGENIN  is  shown.  Scale  bar  200X  magnification.    
  
  
Figure  4.  Pharmacological  screen  on  RTCs  and  RMS  cell  lines  
  
(A)   Heat   map   depicting   the   activity   of   indicated   agents   used   at   final   concentration   of   500   nM  
across  the  RMS  cell  panel.  RMS  subtype,  fusion  status  and  cell  type  (RTC  or  cell  line)  are  shown  
above  each  column.  Each  color  in  the  heat  map  indicates  the  percentage  of  leaving  cells  relative  
to  vehicle  control:  0-­30%  (red),  30-­60%  (orange),  60-­80%  (light  blue)  and  >80%  (dark  blue).  (B,  
upper   panel)   Cell   viability   of   indicated   RTCs   or   cell   lines   treated   for   72h   with   increasing  
concentrations   of   each   drug   (ABT-­263,   afuresertib,   GSK690693,   and   idasanutlin)   (mean   ±   sd;;  
N=3).   (B,   lower   panel)   Table   indicating   corresponding   IC-­50   values   (Black:   undefined,   Blue:  
>1uM,  orange:  0.25-­1uM  and   red:  0-­0.25  uM)  calculated  by  WST-­1  assay.  Subtype  and  TP-­53  
status  for  each  cell  type  are  also  specified.  
  
Supplemental  Figures  
Supplemental  Table  1.  
  
A  description  of   the  PDX   lines  and  corresponding  RTCs  used   in   the  present  study.   Information  
regarding   the   subtype,   anatomic   site,   and   type   of   treatment   (if   any)   of   the   original   tumors   are  
shown.      
  
Supplemental  Figure  1  (relative  to  figure  1  and  2).  
  
(A)  Representative  bright-­field  images  of  RTCs  cultivated  in  NB  or  DMEM  conditions.  Outgrowing  
dmem_clones   are   also   shown   for   SJRHB012_SC   and   SJRHB012_RC   (upper   panel).   Images  
were  taken  at  40X  or  100X  magnification.  (B)  Tumor  growth  kinetic  of  SJRHB012_RC  (left  panel)  
and   SJRHB012_SC   (right   panel)   xenografts   derived   from   matched   NB   cells   (red   line)   or  
dmem_clones   (black   line).   (C)   Representative   bright-­field   images   of   SJRHB012_RC,  
SJRHB012_SC  and  RMS-­ZH04_XC  cells  at  passage  3  under  indicated  culture  conditions.  Scale  
bar   100X   magnification.   (D,   upper   panel)   Representative   light-­microscopy   images   of  
SJRHB012_RC  at  passage  1   (7  days   from  day  of  plaiting)   in  presence  or  absence  of   indicated  
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GF.  (D,  lower  panel)  IF  for  MYOSIN  HEAVY  CHAIN  (MHC)  expression  in  SJRHB012_RC  cells  at  
the  same  time  point.  Dapi  was  used   to  stain   the  nuclei.   Images  show  overly  of  DAPI  and  MHC  
staining.  Scale  bar  50  µm.  
  
Supplemental  Figure  2  (relative  to  figure  3).  
  
(A)  Copy-­number  variants  (CNVs)  analysis  of  SJRHB13758  PDX  and  corresponding  RTCs  under  
NB  or  DMEM.   (B)  Table  depicting   the  percentage  of  mouse  cells  detected  by  DAPI  staining  of  
indicated  RTCs.  
  
Supplemental  Figure  3  (relative  to  figure  4).  
  
(A)   Clustering   analysis   of   the   drug   response   profile   shown   in   figure   4.   The   activity   of   the  
compounds  (row)  is  shown  for  each  sample  (column).  (B,  upper  panel)  Cell  viability  of   indicated  
RTCs   or   cell   lines   treated   for   72h  with   increasing   concentrations   of   each   drug   (AZ20,   YM155,  
verdinexor,   idasanutlin)   (mean   ±   sd).   (B,   lower   panel)   Table   indicating   corresponding   IC-­50  
values  (Black:  undefined,  Blue:  >1uM,  orange:  0.25-­1uM  and  red:  0-­0.25  uM)  calculated  by  WST-­
1  assay.  Subtype  and  TP-­53  status  for  each  cell  type  are  also  specified.  
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SJRHB010463_X16C SJRHB013759_X1C RMS-ZH04_XC SJRHB013757_G1C SJRHB13758_X1C SJRHB13758_X2C SJRHB012_RC SJRHB012_SC
NO COATING
- DMEM 100 100 100 100 100 100 100 100
+ DMEM 143.28633 100.66277 108.745225 226.5208 112.6048667 91.35102 122.6057572 93.80551414
- F-10 14.33978825 14.40550567 38.68501 43.65427 72.64595333 59.281345 36.92284888 79.38370446
+ F-10 18.13584625 20.26559633 19.416395 115.6674 58.70552667 54.04034 22.79631607 61.04767599
- NB 0.43415545 24.00341667 27.3079 39.43107 66.70999 47.061345 94.74028925 16.88459187
+ NB 1.4654645 111.5079967 52.03451 79.12473 61.3214 86.42069 30.45999425 41.35088759
MATRIGEL
- DMEM 109.3724025 99.07643 117.01555 121.7506 138.7735 134.79435 91.68912643 113.7840817
+ DMEM 190.1150525 102.04987 125.9591 293.4573 131.1431333 126.95085 162.1196676 107.2258965
- F-10 28.90856025 12.96668667 51.43482 49.0372 84.16536333 66.808995 23.81132526 61.31859762
+ F-10 14.4909775 15.86510967 19.63866 102.6477 60.79662 63.774855 6.243846331 59.46330499
- NB 8.377257 63.12761 57.02533 71.94749 66.90718667 125.25335 121.8345388 20.62598575
+ NB 143.7415725 307.92 125.7676 172.2101 54.00627667 133.70855 84.96755659 95.44013311
GELATIN
- DMEM 93.52682 115.2651633 107.7371 120.9847 140.58068 167.48 144.494349 123.7064537
+ DMEM 110.9570425 121.5720967 104.84925 267.046 160.1919 127.87035 129.9856156 126.562512
- F-10 25.111923 55.67869333 48.340285 58.20569 43.15438333 77.620855 80.06798513 72.7524233
+ F-10 11.551761 48.17922333 18.5549485 124.9672 32.37836333 53.725055 67.74864823 68.54139239
- NB -1.552923125 49.98456333 32.287195 32.47265 108.4531233 111.80429 91.4576457 21.63124264










Catalog No. Product Name Target
S1005 Axitinib VEGFR, PDGFR, c-Kit
S1023 Erlotinib HCl (OSI-744) EGFR
S1042 Sunitinib Malate VEGFR, PDGFR, c-Kit, Flt
S1060 Olaparib (AZD2281, Ku-0059436) PARP
S1082 Vismodegib (GDC-0449) Hedgehog, P-gp
S1119 Cabozantinib (XL184, BMS-907351) VEGFR, c-Met, Flt, Tie-2, c-Kit
S1164 Lenvatinib (E7080) VEGFR
S1267 Vemurafenib (PLX4032, RG7204) Raf
S1524 AT7519 CDK
S1570 KU-60019 ATM
S2061 Lovastatin HMG-CoA Reductase
S1006 Saracatinib (AZD0530) Src, Bcr-Abl
S1025 Gefitinib (ZD1839) EGFR
S1046 Vandetanib (ZD6474) VEGFR
S1065 GDC-0941 PI3K
S1092 KU-55933 (ATM Kinase Inhibitor) ATM
S1120 Everolimus (RAD001) mTOR
S1168 Valproic acid sodium salt (Sodium valproate) GABA Receptor, HDAC
S1362 Rigosertib (ON-01910) PLK
S1525 MK-1775 Wee1
S1574 BIRB 796 (Doramapimod) p38 MAPK
S2151 LDE225 (NVP-LDE225,Erismodegib) Smoothened
S1007 FG-4592 HIF
S1028 Lapatinib (GW-572016) Ditosylate EGFR, HER2




S1171 CYC116 Aurora Kinase, VEGFR
S1378 Ruxolitinib (INCB018424) JAK
S1526 Quizartinib (AC220) Flt
S1575 RO4929097 Y-Secretase
S2163 PF-4708671 S6 Kinase
S1011 Afatinib (BIBW2992) EGFR
S1029 Lenalidomide (CC-5013) TNF-alpha
S1048 VX-680 (Tozasertib, MK-0457) Aurora Kinase
S1068 Crizotinib (PF-02341066) c-Met, ALK
S1100 MLN8054 Aurora Kinase











S1013 Bortezomib (PS-341) Proteasome
S1033 Nilotinib (AMN-107) Bcr-Abl
S1049 Y-27632 2HCl ROCK
S1069 AUY922 (NVP-AUY922) HSP
S1107 Danusertib (PHA-739358) Aurora Kinase, FGFR, Bcr-Abl, c-RET, Src
S1133 Alisertib (MLN8237) Aurora Kinase
S1193 Thalidomide Others
S1452 Ispinesib (SB-715992) Kinesin
S1533 R406 (free base) Syk
S1782 Azacitidine DNA/RNA Synthesis
S2181 MLN9708 Proteasome
S1014 Bosutinib (SKI-606) Src
S1035 Pazopanib HCl
S1052 Elesclomol (STA-4783) HSP
S1070 PHA-665752 c-Met
S1113 GSK690693 Akt
S1134 AT9283 Bcr-Abl, JAK, Aurora Kinase
S1200 Decitabine DNA/RNA Synthesis
S1486 AEE788 (NVP-AEE788) EGFR, Flt, VEGFR, HER2
S1534 Org 27569 Cannabinoid Receptor
S1802 Acadesine AMPK
S2198 SGI-1776 free base Pim
S1004 Veliparib (ABT-888) PARP
S1021 Dasatinib Src, Bcr-Abl, c-Kit
S1040 Sorafenib Tosylate VEGFR, PDGFR, Raf
S1055 Enzastaurin (LY317615) PKC
S1078 MK-2206 2HCl Akt
S1116 Palbociclib (PD-0332991) HCl CDK
S1153 Roscovitine (Seliciclib,CYC202) CDK
S1233 2-Methoxyestradiol (2-MeOE2) HIF
S1490 Ponatinib (AP24534) Bcr-Abl, VEGFR, FGFR, PDGFR, Flt
S1567 Pomalidomide TNF-alpha, COX
S2013 PF-573228 FAK
S1018 Dovitinib (TKI-258, CHIR-258) c-Kit, FGFR, Flt, VEGFR, PDGFR
S1039 Rapamycin (Sirolimus) mTOR
S1053 Entinostat (MS-275) HDAC
S1075 SB216763 GSK-3
S1114 JNJ-38877605 c-Met
S1147 Barasertib (AZD1152-HQPA) Aurora Kinase
S1205 PIK-75 PI3K, DNA-PK
S1487 PHA-793887 CDK
S1541 EX 527 (Selisistat) Sirtuin
S1971 Nicorandil Others

















S8031 NSC 23766 Rac
S8044 BMS-345541 I B/IKK
S8057 Pacritinib (SB1518) JAK
S2235 Volasertib (BI 6727) PLK
S2673 Trametinib (GSK1120212) MEK
S2742 PHA-767491 CDK
S2820 TAE226 (NVP-TAE226) FAK
S3021 Rimonabant Cannabinoid Receptor
S7050 AZ20 ATM/ATR
S7097 HSP990 (NVP-HSP990) HSP (e.g. HSP90)




S2243 Degrasyn (WP1130) DUB, Bcr-Abl
S2680 Ibrutinib (PCI-32765) Src
S2759 CUDC-907 HDAC, PI3K
S2824 TPCA-1 IKK







S2247 BKM120 (NVP-BKM120, Buparlisib) PI3K
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While   childhood   cancers   are   generally   uncommon,   they   represent   the   first   cause   of   disease-­
related  death   in  children   (≤20  years  old)   [1].  The  mainstay  of   therapy   for  pediatric  patients  with  
solid   tumors   consists   of   surgery,   radiotherapy   and   standard   chemotherapy.   Although   such  
approach   remains  one  of   the  greatest  examples  of   success   in   the  clinic,   cancer   is  still   fatal   for  
approximately  90,000  children  and  adolescents  every  year  worldwide  [2,  3].    
Rhabdomyosarcoma  (RMS)  is  the  most  common  soft-­tissue  sarcoma  in  children  and  includes  two  
main   subtypes   named   alveolar   (ARMS)   and   embryonal   (ERMS)   RMS.   The   traditional   first-­line  
chemotherapy   regimen   is   based   on   the   VAC/VAI   protocol,   which   combines   vincristine,  
actinomycin   D   and   cyclophosphamide   or   ifosfamide   [4].   Despite   advances   in   RMS   care,   cure  
rates  have  reached  a  plateau  over  the  last  three  decades  [5,  6].  Presently,  30%  of  RMS  patients  
continue  to  experience  relapse  disease  with  a  median  surivival  of  only  ~10  months  from  the  time  
of   first   recurrence   [7,  8].  The  treatment  plan   for   this  group  of  patients   is  not  well  defined  and   in  
most   of   the   cases   intensification   of   chemotherapy   (with   the   addition   of   topoisomerase   I   and   II  
antagonists)   is   applied   [4].   It   was   estimated   that   even  when   response   occurs,   one   third   of   the  
survivors  experience  at  least  one  severe  or  life  threatening  effect  such  as  organ  dysfunctions  or  
development   of   second   malignant   neoplasms   (SMNs)   [9-­11].   Hence,   resistance   to   cytotoxic  
chemotherapeutics   followed   by   long-­term   sequelae   represent   a   major   challenge   for   the  
achievement  of  a  complete  cure.    
One   possibility   to   counteract   chemoresistance   and   limit   aggressive   therapies   is   to   define   new  
combinatorial   treatments   strategies.   However,   a   priori   identification   of   druggable   interaction  
networks   is   hindered   by   the   relative   homogenous   genetic   landscape   of   RMS   and   therefore  
functional   pre-­clinical   platforms   are   urgently   needed   [12,   13].   Recently,   we   and   others   have  
shown   the   feasibility   of   using   RMS   PDX   models   and   primary   cultures   (RPCs)   to   guide  
personalized  therapeutic  strategies  (manuscript  1  and  [14,  15]).  
In  the  present  study,  we  modeled  chemorefractory  disease  by  taking  advantage  of  RPCs  derived  
from   diagnostic/relapse   pairs   of   ERMS   tumors.   We   first   confirmed   that   our   in   vitro   culture  
conditions  preserved  the  differential  chemo-­response  in  recurrent  compared  to  diagnostic  RPCs  
of   the   same   patient.   We   then   employed   in   vitro   high-­throughput   drug   screens   to   identify  
chemosensitizing  compounds   for  patients  with  poor  outcome.  Among   the   top  scoring  drugs,  we  
discovered   the  BH3-­mimetic  ABT-­263,  which  was   further   validated   in   vivo   on   the  original  PDX.  
Mechanistic   studies   revealed   that  ABT-­263/standard   chemotherapy  exploits   the  BCL-­XL/MCL-­1  
axis   and   in   a   NOXA-­dependent   manner   in   recurrent   ERMS.   Altogether,   we   discovered   new  
combinatorial  therapeutic  modalities  that  might  be  evaluated  in  clinical  trials  as  escape  routes  for  







Characterization  of  chemo-­resistant/sensitive  ERMS  models.  
To  discover  mechanisms  of  sensitization   to  standard-­of-­care   therapies   in  ERMS,  we  adopted  a  
pre-­clinical  platform,  which  combines  PDXs  and  matched  primary  cultures   (RPCs)  derived   from  
pre-­treatment  and  post-­relapse  tumor  biopsies  of  the  same  patient  (Figure  1A  and  manuscript  1).  
Of   note,   our   in   vitro   model   closely   preserves   the   molecular   and   phenotypic   heterogeneity  
observed  in  the  primary  tumors  and  PDXs  (manuscript  1).  Hence,  we  asked  weather  RPCs  from  
relapse   and   diagnostic   patients   displayed   a   different   sensitivity   to   conventional   chemo-­
therapeutics.   To   this   end,   we   performed   dose   escalation   experiments   following   72h   treatment  
with  a  panel  of  agents  (doxorubicin,  etoposide,  actinomycin  D  and  vincristine)  commonly  used  for  
the  management  of  RMS  patients  and  also  according   to   the  available  clinical   information  of   the  
samples  we  employed  in  the  current  study  (Figure  1B  and  1C  and  manuscript  1).  WST-­1  assay  
was  used  as  read-­out  of  cell  viability  and  data  were  normalized   to  vehicle  control.   Interestingly,  
we  observed  a  clear  refractory  response  for  SJRHB13758_X2C  (relapse  cells  from  patient  #3)  to  
both   topoisomerase   II   targeting  agents      (IC50doxrubicin  >  33.8   fold,   IC50etoposide  >  39.9   fold)  and   to  
etoposide   only   (IC50etoposide   >   3.3   fold)   for   SJRHB012_ZC   (relapse   cells   from  patient   #2)  when  
compared   to   the   corresponding   diagnostic   RPCs   (Figure   1B   and   1C).   Moreover,   vincristine  
exhibited  mostly  a  cytostatic  effect   in  either  diagnostic  or   recurrent  cells  and  no  difference  was  
observed   in   the  response  to  actinomycin  D  (Suppl.Figure  1A).  Such  response  profile   is  partially  
consistent  with  the  treatment  regimen  initially  applied  to  the  patients  (manuscript  1).    
Altogether,  we  validated  the  chemoresistant  phenotype  of  recurrent  RPCs,  which  we  selected  as  
model  to  unravel  new  combinatorial  options  for  patients  with  poor  outcome.  
  
A   drug   screening   approach   identifies   ABT-­263   as   potential   novel   sensitizer   of   standard  
chemotherapy  in  ERMS.  
Failure   of   conventional   treatment   for   high-­risk   group  ERMS  patients   remains   a  major   unsolved  
clinical  problem  to  date.  Therefore,   to   identify  “ready  to  use”  sensitizing  drugs  towards  standard  
chemotherapy,  we  combined  a  drug  library  containing  204  FDA-­approved  drugs  or  compounds  in  
clinical  development   (500  nM)  with  standard  cytotoxic  agents   (doxorubicin  ~IC-­20  or  etoposide,  
~IC-­30)   in   SJRHB13758_X2C   cells   which   served   as   recurrent   and   resistant   model   of   ERMS  
(Figure   1A).   Cell   viability   was   assessed   72   hours   post-­treatment   and   top   hits   were   filtered   by  
considering  only  drugs  showing  at   least  40%  reduction  of  cell  survival   in  combination  compared  
to   single   treatment.   Based   on   these   criteria,   we   identified   only   few   candidates   in   each  
combinatorial  screen  (3  drugs  in  combination  with  etoposide  and  6  with  doxorubicin),  of  which  5  
out  of  9   target  growth   factor  signaling   followed  by  cell  death  pathways  (2  out  of  9)   (Figure  2A).  
Nevertheless,  we   focused  our  attention  on  ABT-­263,   a  multiple  BCL-­2/BCL-­XL/BCL-­W   inhibitor  
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(orally  available),  for  several  reasons:  1)  it  was  the  only  candidate  shared  between  the  2  screen  
results,   2)   it   has   already   entered   into   clinical   trials   for   different   cancer   entities   [16-­19],   3)   we  
reasoned  that   interfering  directly  with  the  apoptotic  machinery  might  overcome  the   limitations  of  
upstream  kinase  inhibitors  4)  and  its  chemosensitizer  function  has  not  been  explored  in  RMS  yet.  
Therefore,   we   initially   tested   the   single   agent   activity   of   ABT-­263   in   a   panel   of   ERMS   cells  
including   primary   cultures   (RPCs),   RD   cell   line   and   normal   primary   human   foreskin   fibroblasts  
(HFF).   Cells   were   treated   for   72   hours   with   increasing   concentrations   of   the   drug   (Figure   2B,  
upper  panel).  Cell  viability   results   revealed   that   relapse  cells  were  generally  poor   responsive   to  
the   drug   (IC-­50:   1-­69-­14.63   uM)   whereas   no   effect   was   observed   in   HFF   cells.   In   contrast,   a  
strong  response  was  detected  for  SJRHB13758_X1C  (diagnostic  cells   from  patient  #3)  showing  
an  IC50  in  the  nanomolar  range  (~150  nM)  (Figure  2B,  lower  panel).  To  unravel  this  discrepancy  
in  the  drug-­response  we  performed  protein  analysis  for  both  pro-­survival  and  pro-­apoptotic  BCL-­2  
family   members   in   ABT-­263-­naive   and   -­resistant   cells   but   we   were   unable   to   correlate   the  
expression   of   these   proteins  with   the   response   to   the   inhibitor   (Figure   2C).  However,   BCL-­XL,  
BCL-­2,   MCL-­1,   BAK,   BIM   and   NOXA   were   widely   expressed   across   the   cell   types   examined  
although  to  different  levels.  Only  BAX  could  not  be  detected  in  SJRHB13758_X2C  cells,  a  feature  
previously  shown  to  be  associated  with  chemo-­resistant  tumors  [20,  21].    
In   sum,   these   findings   suggest   that   ABT-­263   has   a   limited   single   agent   activity   across   ERMS  
recurrent  cells  but  represents  a  potential  ‘partner’  compound  of  conventional  therapy.  
  
Treatment  with  ABT-­263  restores  chemo-­sensitivity  in  ERMS  recurrent  cells  
In  order  to  validate  our  screen  results,  we  performed  combinatorial   treatments  in  various  ERMS  
relapse   cells   with   ABT-­263   (250   nM   and   500   nM)   and   a   set   of   chemotherapeutics   (i.e.  
doxorubicin,   etoposide   and   vincristine)   tested   in   an   8-­point   dose-­response   curve.   Again   cell  
viability   was   normalized   to   vehicle   control   per   each   data   point.   As   expected,   ABT-­263   alone  
showed  a  negligible  effect  on  cell  survival  (ranging  between  6.72%  to  32.5%  reduction)  whereas  
the  combination  with  standard  chemotherapy  was  highly  effective  across  3  different  recurrent  cell  
types   (Figure   3A   and   Supp.   Figure   2A).   Calculation   of   the   combination   index   (CI)   revealed   a  
strong  synergistic  effect  of  ABT-­263  with  doxorubicin  and  vincristine  and  to  a   lesser  extent  with  
etoposide   (Suppl.   Figure   2B).   To   demonstrate   the   cytotoxic   activity   of   the   ABT-­263/standard  
chemotherapy   combination,   we   monitored   caspase   3/7-­activity   upon   co-­treatment   of   ABT-­263  
with   doxorubicin   (3-­6   hours   time   point),   vincristine   (9   hours   time   point)   and   etoposide   (24-­48  
hours   time   point)   (Figure   3B   and   Suppl.Figure   2C).   Our   analysis   revealed   that   both  
SJRHB13758_X2C   and   SJRHB012_ZC   cells   showed   an   elevated   cell   death   in   co-­treatment  
experiments   reaching   between   ~2-­   and   ~10-­   fold   increase  when   compared   to   ABT-­263   alone.  
These   findings   were   further   corroborated   by   western   blot   analysis,   which   showed   increased  
protein  levels  of  known  apoptotic  markers  such  as  cleaved  PARP  and  CASPASE  3  in  co-­treated  
Manuscript 2 
	  79	  
cells   (Figure   3C   and   Suppl.Figure   2D).   Taken   together,   these   data   indicate   that   ABT-­263  
enhances   the   effect   of   conventional   chemotherapeutics   by   augmenting   cell   death   in   recurrent  
RPCs.  
  
NOXA  partially  mediates  ABT-­263/standard  chemotherapy-­induced  cell  death    
Next,   we   investigated   which   pro-­apoptotic   player   is   engaged   by   ABT-­263/standard  
chemotherapy.  To  this  aim,  we  used  a  lentiviral-­based  crispr-­Cas9  system  to  knock-­out  two  main  
BH3-­only   proteins   namely   BIM   (1   sgRNA)   and   NOXA   (2   sgRNAs),   which   are   well   known  
antagonistic   partners   of   the   pro-­survival   BCL-­2   family   members   (Figure   4A,   left   panel).   Cells  
transduced   with   a   scramble   sgRNA   sequence   were   used   as   negative   control.   Silencing   was  
validated  on  protein  level  by  western  blot  7  days  after  transduction  (Supp.  Figure  3A,  right  panel).  
We   then   assessed   the   caspase   activity   upon   short-­term   co-­treatment   of   ABT-­263   with  
conventional  chemotherapeutics  (Figure  4B  and  Suppl.  Figure  3A).  Unlike  BIM  knock-­out,  NOXA  
depletion   significantly   impaired   the   cooperative   effect   of   ABT-­263   with   either   vincristine   or  
doxorubicin   when   compared   to   scramble   control   cells   (Suppl.   Figure   3A   and   Figure   4B).  
Accordingly,  NOXA  protein  levels  were  transiently  and  shortly  (6-­9  h)  upregulated  upon  exposure  
to   these  cytotoxic  agents   (Figure  4D).  This   is  consistent  with   the  pick  of  cell  death  achieved  at  
these  early   time  points   in   co-­treatment  experiments   (Figure  3B).  However,  although  ablation  of  
NOXA  could  still  counteract  the  effect  of  ABT-­263/vincristine  at  later  time  points  (72h),  it  was  no  
longer  sufficient  to  affect  the  cytotoxic  activity  of  ABT-­263/doxorubicin  (Figure  4C).  Therefore,  late  
compensatory   mechanisms   might   take   place   to   mediate   the   combinatorial   effect   of   ABT-­
263/doxorubicin.  Additionally,  the  regulation  of  NOXA  is  likely  to  be  independent  from  P53,  since  
SJRHB13758_X2C  cells  do  not  express  a  functional  P-­53  as  demonstrated  by  the  lack  of  activity  
of   idasunutlin,  a  MDM2  antagonist   (Supp.  Figure  3B).   In  contrast,   the  corresponding  diagnostic  
cells,  which  harbor  a  TP-­53wt  were  rather  sensitive  (IC50  ~1uM).  In  sum,  these  findings  suggest  
that  NOXA  is  a  functional  mediator  of  ABT-­263/standad  chemotherapy-­induced  cell  death.  
  
ABT-­263/stadard  chemotherapy  blocks  the  BCL-­XL/MCL-­1  axis  
With   the   idea   that   the   apoptotic  machinery   is   altered   by   ABT-­263/standard   chemotherapy,   we  
embarked   on   identifying   which   pro-­survival   factors   are   implicated   in   this   interaction.   First,   we  
sought   to  determine   the  specific   target  of  ABT-­263  by  using  selective   inhibitors  of  either  BCL-­2  
(ABT-­199   or   venetoclax)   or   BCL-­XL   (A-­1331852)   at   concentrations   of   500   nM   and   1uM   each  
(Figure   5A).   Upon   24h   co-­treatment   with   increasing   concentrations   of   cytotoxic   agents  
(doxorubicin  or  vincristine),  we   found   that  only  BCL-­XL   inhibition  could  phenocopy   the  effect  of  
ABT-­263  (Figure  5A  and  Suppl.  Figure  4A).  Accordingly,  crispr/Cas9-­mediated  down-­regulation  of  
BCL-­XL  by  2  independent  sgRNAs  sensitized  SJRHB13758_X2C  cells  to  vincristine-­induced  cell  
death  at   the   same   time  point   (24h)   (Figure  5B  and  Suppl.   Figure  4B).   In   contrast,   depletion  of  
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BCL-­2,  MCL-­1  and  BCL-­W  did  not  exhibit  any  effect  pointing  to  BCL-­XL  as  the  main  BCL-­2  pro-­
survival  member  mediating   the  ABT-­263   response   (Figure  5B  and  Suppl.  Figure  4B).  Next,  we  
attempted  to  dissect  the  potential  anti-­apoptotic  factor  affected  by  the  standard  chemotherapy.  To  
this   aim,   we   exposed   the   established   knock-­out   cells   to   increasing   concentrations   of   ABT-­263  
and  assessed  cell  viability  24h  later.  Remarkably,  only  cells  lacking  MCL-­1  were  highly  sensitive  
to  the  drug,  corroborating  previous  reports  (Figure  5C)  [22].  Thus  we  reasoned  that  MCL-­1,  which  
is   well   known   to   be   specifically   engaged   by   NOXA   represents   a   good   candidate   target   of  
chemotherapy.  To  pursue   this   hypothesis,  we  analyzed  MCL-­1  protein   levels   upon  doxorubicin  
treatment  with  or  without  ABT-­263  in  both  SJRHB13758_X2C  and  SJRHB012_ZC  recurrent  cells.  
Notably,   this   analysis   revealed   a   striking   down-­regulation   of   MCL-­1   expression   upon  
chemotherapy  exposure  in  both  RPCs  (Suppl.  Figure  4C).  Only  minor  effects  were  observed  for  
BCL-­XL   or   BCL-­2   expression,   indicating   that   this   is   not   a   general   cytotoxicity   induced   by  
doxorubicin   (Suppl.  Figure  4C).  Hence,   these  data  suggest  a  model  where  BCL-­XL  and  MCL-­1  
are   the   two   major   factors   mounting   the   anti-­apoptotic   response   in   recurrent   ERMS   cells.   To  
demonstrate  that  this  is  a  vulnerable  axis,  we  pharmacologically  inhibited  both  BCL-­XL  and  MCL-­
1   by   using   specific   inhibitors   (MCL1i   and   BCL-­XLi)   tested   at   4   different   concentrations.  
Impressively,   this  drug  pair  showed  a  sever  growth   inhibition  and  exhibited  a  strong  synergistic  
effect   in   three   recurrent  RPCs,  mimicking   the  ABT-­263/standard  chemotherapy   (Figure  5D  and  
Suppl.  Figure  4D).  Altogether,  we  showed  that  simultaneous  blockade  of  BCL-­XL  and  MCL-­1   is  
particularly  effective  in  recurrent  RPCs  and  might  be  exploited  by  ABT-­263  and  the  standard-­of-­
care  therapy.    
  
Assessment   of   BCL-­XL   expression   and   response   to   ABT-­263/stadard   chemotherapy   in  
vivo  
Based  on  the  chemosensitization  effect  of  ABT-­263-­mediated  inhibition  of  BCL-­XL,  we  aimed  to  
confirm  the  clinical  relevance  of  BCL-­XL  in  a  large  cohort.  Therefore,  we  analyzed  BCL-­XL  mRNA  
levels  from  two  independent  datasets  of  primary  RMSs  publicly  available  through  the  R2  platform  
(Figure  6A).  As  control,  we  used  normal  skeletal  muscle  tissues.  Consistent  with  the  importance  
of  BCL-­XL  in  our  RPCs,  we  found  a  statistical  significant  increase  of  BCL-­XL  expression  in  RMS  
tumors   compared   to   control   samples,   whereas   BCL-­2   and   BCL-­W   were   significantly   down  
regulated  (Figure  6A).  These  findings  prompted  us  to  evaluate  the  functional  role  of  BCL-­XL  in  a  
pre-­clinical   in  vivo  model  of  RMS  resistant   to  conventional   therapies.  Hence,  we  tested  whether  
BCL-­XL   blockade   sensitizes   a   chemorefractory   and   fast-­growing   PDX   (SJRHB13758_X2)   to  
doxorubicin  in  vivo.  Since  selective  BCL-­XL  antagonists  are  still  in  early  pre-­clinical  development,  
we   chose   ABT-­263,   which   is   already   in   clinical   evaluation.   To   this   end,   immunocompromised  
NOD  scid  gamma  (NSG)  mice  were  engrafted  subcutaneusly  with  1*106  dissociated  tumor  cells  
from  the  original  SJRHB13758_X2  PDX.  Mice  with  palpable  tumors  (~100  mm3)  were  randomized  
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to   4   groups   (6   mice   each):   vehicle,   ABT-­263   treatment,   doxorubicin   arm   and   combination.  
Additionally,   to   limit   the   risk   of   thrombocytopenia   associated   with   ABT-­263   administration,   we  
used  a  therapy  schedule  that  reduces  both  doses  (80  mg/Kg)  and  time  of  treatment  (three  days  a  
week)   compared   to   previous   reports   (Figure   6B,   left   panel).   However,   after   only   one   cycle   of  
therapy,  mice   had   to   be   scarified   due   to   doxorubicin-­induced  body  weight   loss.   In   contrast,   no  
overt   toxicities  were  detected   in   vehicle  or  ABT-­263   cohorts.   In   this   short   time   frame  when  we  
could  monitor  tumor  growth,  we  observed  a  trend  for  a  reduced  tumor  kinetic  in  the  combination  
arm  compared  to  single  agent  or  vehicle  groups  although  it  did  not  reach  statistical  significance  
(Figure   6B,   right   panel).   Taken   together,   these   data   suggest   that   BCL-­XL   is   generally   over-­
expressed  in  RMS  patients  and  its  inhibition  represents  a  promising  strategy  to  couple  with  first-­
line   therapies.   However,   establishment   of   less   aggressive   treatment   protocols   are   needed   to  




Standard   chemotherapy   regimens   are   routinely   applied   for   the   management   of   RMS   patients  
leading  to  extraordinary  cure  rates  in  low-­risk  groups.  Unfortunately,  the  outcome  for  patients  who  
experience  metastasis   and/or   relapse   disease   remains   dismal.   The   estimated   long-­term  event-­
free  survival  (EFS)  rate  for  this  category  is  in  the  range  of  15%  to  35%,  and  no  further  progress  
has   been  made   in   the   last   decades   [23].   Different   combinations   of   dubulking   agents   including  
VAC/VAI,  VAC  plus   topoisomerase   inhibitors  or  VAC  plus  carboplatin   failed   to  show  substantial  
clinical  benefit   in  previous  clinical  trials  [23].  Hence,  the  search  of  novel  combinatorial  options  is  
highly  warranted  in  the  field.  To  this  end,  in  the  present  study  we  performed  an  unbiased  chemo-­
sensitizing  screen  by  combining  standard-­of-­care  therapeutics  and  a  targeted  compound  library  in  
a  chemoresistant  relapsed  RPC  model.  We  identified  ABT-­263  as  the  top-­scoring  drug  capable  of  
restoring   vulnerability   to   a   wide   range   of   cytotoxic   agents   (i.e.   doxorubicin,   etoposide   and  
vincristine).  
ABT-­263  resembles  the  structure  of  the  BH3-­only  BAD,  thus  is  designed  to  induce  apoptosis  by  
neutralizing   the  pro-­survival   function  of   the  BCL-­2   family  members  BCL-­2,  BCL-­XL  and  BLC-­W  
[24].   Such   BH3-­mimetic   (ABT-­263   or   its   predecessor   ABT-­737)   has   been   previously   shown   to  
potentiate  the  efficacy  of  a  variety  of  clinically  relevant  compounds  in  a  large  set  of  cancer  entities  
[24-­29].  However,  its  role  in  the  context  of  sensitization  to  first-­line  chemotherapy  in  RMS  remains  
elusive.   Here,   we   provide   compelling   evidence   that   ABT-­263   augments   the   cytotoxicity   of  
conventional  chemotherapeutics   in   two  different   recurrent  RPC  models   regardless  of   the  TP-­53  
status.  Strong  single  agent  activity   for  ABT-­263  was  detected   in  only  1  out  of  5  RMS  cell   types  
tested,  corroborating  the   in  vivo  findings  of  the  pediatric  preclinical  testing  program  (PPTP)  [30].  
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From   a   mechanistic   standpoint,   we   show   that   the   pro-­apoptotic   BH3-­only   NOXA  mediates,   at  
least  in  part,  the  combinatorial  effect  of  ABT-­263/standard  chemotherapy.  
NOXA  is  known  to  specifically  bind  to  MCL-­1  but  not  BCL-­XL  or  BCL-­2  [31],  and  down-­regulation  
of  MCL-­1  sensitizes  cells   to  ABT-­263   (Figure  5C  and   [22,  32]).  Consequently  NOXA  knock-­out  
significantly   reduced   the  ABT-­263-­induced   cell   death   and   thus  mitigated   its   chemosensitization  
effect,   probably   by   re-­enforcing   MCL-­1   function   and/or   stability.   On   the   other   hand,   single  
chemotherapy   treatment   induced   a   transient   up-­regulation   of   NOXA   and   a   dramatic   down-­
regulation  of  MCL-­1.  The  time  window  when  this  latter  occurred  (between  3h  and  9h),  correlated  
with   the   pick   of   cell   death   observed   in   co-­treatment   experiments.   Notably,   BCL-­XL   or   BCL-­2  
protein   levels   were   not   affected.   Hence,   we   hypothesize   that   the   chemotherapy-­induced  
perturbation  of  the  steady-­state  levels  of  NOXA  strongly  affects  the  MCL-­1-­mediated  sensitivity  to  
ABT-­263.  Cells  with  a  MCL-­1  blockade  would   then   rely   on  either  BCL-­2  or  BCL-­XL   to   survive,  
thus  their  inhibition  by  ABT-­263  will  lead  to  cell  death.  Such  model  is  supported  by  the  fact  that  (i)  
chemotherapy-­mediated  down-­regulation  of  MCL-­1  has  been  documented  in  cancer  [27,  33],  (ii)  
NOXA  can  promote  MCL-­1  degradation  [34]  and  (iii)  NOXA  over-­expression  can  sensitize  cells  to  
BH3-­mimetics   [35,   36].   Although   BIM   has   also   been   proposed   as   a   key   determinant   of   the  
sensitivity  to  ABT-­263  [37],  we  did  not  find  any  cell  death  alteration  in  BIM  knock-­out  cells  treated  
with  either  ABT-­263  alone  or  with  chemotherapy.  However,  we  cannot  rule  out  the  involvement  of  
NOXA-­independent  mechanisms  since  depletion  of  NOXA  did  not  completely  abrogate  the  ABT-­
263/chemotherapy  effect.   Importantly,   the  RPC  model  used  (SJRHB13758_X2C)  harbor  mutant  
TP-­53  and  does  not  respond  to  the  MDM2/P53  inhibitor  idasanutlin.  Since  NOXA  is  a  well-­known  
P53  target  [38],  it  remains  subject  of  further  studies  to  unravel  the  mode  of  regulation  of  NOXA  in  
this  context.  
Following   a   model   where   chemotherapy   blocks   MCL-­1,   we   also   dissected   the   direct   target   of  
ABT-­263.  We  found  that  inhibition  of  BCL-­XL  is  likely  to  contribute  to  the  cooperativity  of  ABT-­263  
with  standard  chemotherapy.  This  has  been  proven  by  the  increased  sensitivity  of  RPCs  towards  
doxorubicin   and/or   vincristine   upon   pharmacological   and   genetic   interference   of   BCL-­XL.   In  
contrast,   BCL-­2   appeared   to   be   largely   dispensable   for   the   observed   phenotype.   This  
underscores  a  new  function  for  BCL-­XL  in  ERMS  besides  its  well-­recognized  role  as  modulator  of  
the   anti-­apoptotic   function   of   PAX3-­FOXO1   in   ARMS   [39].   Finally,   we   demonstrated   that  
simultaneous  inhibition  of  BCL-­XL  and  MCL-­1  by  selective  targeting  compounds  phenocopies  the  
combinatorial  effect  of  ABT-­263/standard  chemotherapy.  Thus,  this  axis  represents  a  “druggable”  
vulnerability  in  recurrent  RPCs  resembling  the  strong  genetic  and  pharmacological  interaction  of  
BCL-­XL  and  MCL-­1  recently  shown  in  chronic  myeloid  leukemia  (CML)  but  with  only  minor  effects  
in  normal  counterparts   [40].  However,   it   is  noteworthy  that  pre-­clinical  and  phase  II  studies  with  
ABT-­263   as   single   agent   revealed   that   thrombocytopenia   is   a  major   drawback   that   limits   dose  
escalation  [41].  Hence  we  attempted  to  translate  our  findings  in  a  clinically  relevant  in  vivo  model  
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by   taking   into   consideration   the   on-­target   toxicities   associated   with   ABT-­263.   However,   we  
noticed  a  severe  body  weight  loss  in  mice  due  to  doxorubicin  administration  that  was  no  additive  
in  presence  of  the  BH3-­mimetic  (data  not  shown).  Although  we  used  doses  of  chemotherapy  that  
are   considered   low   in   mice   (2mg/Kg),   it   is   possible   that   mouse   strain,   gender,   age,   and  
administration   route  might  have  contributed   to   this  unexpected  phenotype.  Nevertheless,   in   the  
short   time  frame  available   for   treatment  (1  week)  we  observed  a  clear   trend  for  a   tumor  growth  
reduction  in  the  co-­treatment  compared  to  single  agents  or  vehicle  control.  This  will  motivate  us  to  
establish  safer  treatment  schedules  to  test  this  therapeutic  combination  for  a  longer  time  period  in  
vivo.  
In  conclusion,  we  demonstrated  that  our  previously  established  pre-­clinical  platform  (manuscript  
1)   is   amenable   to   capture   novel   combinatorial   options   for   recurrent   RMS   patients   where  
responses  to  conventional  therapies  are  failing.  As  proof-­of-­principle,  we  describe  ABT-­263  to  be  
a  novel  sensitizer  toward  standard  chemotherapy  in  ERMS  and  provide  mechanistic  insights  into  
their  mode  of  action.    
  
Materials  and  Methods  
  
Patient-­derived  samples  
ERMS   PDX   samples   SJRHB012_X,   SJRHB012_Y,   SJRHB012_Z,   SJRHB013758_X1   and  
SJRHB013758_X2   were   obtained   from   the   St.   Jude   Children’s   Research   Hospital   (USA)   and  
processed   according   to   the   procedures   reported   previously   in.   [15]   and   (manuscript   1).   A  
description  of  the  PDX  lines  used  in  this  study  can  be  found  in  manuscript  1  (Supp.  Table  1).    
  
Xenograft  studies  and  in  vivo  treatments  
1x106   cells   from   dissociated   SJRHB013758_X2   PDX   were   suspended   in   100   ul   of   PBS   and  
injected  subcutaneously   in  male  NOD  scid  gamma  (NSG)  mice.  Once  tumors  reached  a  size  of  
around   100   mm3,   mice   were   randomized   to   vehicle   (control   group),   ABT-­263   only,   standard  
chemotherapy   only   (doxorubicin)   and   combinatorial   treatment   arm   (6   animals   per   group).  
Treatments  schedules  are  indicated  in  the  figure  legends.  ABT-­263  (ApexBio)  was  dissolved  in  a  
mixture  of  10%  EtOH,  30%  PEG-­400  (Lipoid)  and  60%  phosal  50  PG  (Sigma  Aldrich)  and  was  
given  orally  1.5  h  after  standard  chemotherapy  for  combination  experiments.  Compound  solution  
was  prepared  fresh  before  drug  administration  and  any  remaining  solution  was  routinely  stored  at  
+4°C  for  no  longer  than  1  week  after  dissolving.  Doxorubicin  (Sandoz)  was  injected  intravenously  
(i.v.)   and   stored   at   +4°C.   Tumor   size   was   determined   by   digital   calliper   measurements   of   2  
diameters   (d1,   d2)   in   right   angles.   Total   tumor   volumes   were   calculated   by   the   formula   V   =  
(4/3)πr3  ;;  r  =  (d1  +  d2  )/4.  Mice  were  euthanized  once  tumors  reached  the  maximum  allowed  size  
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(1000  mm3)  or  with  weight  loss  over  20%  than  baseline  (body  weight  was  monitored  daily  through  
the  course  of  each  experiment).  
  
Cell  culture,  cell  viability  and  chemicals  
RD  (ATCC,  Manassas,  VA,  USA),  HEK293T  (ATCC,  LGC  Promochem,  Molsheim,  France)  and  
HFF   (purchased   from  System  Biosciences,  CA,  US)  cells  were  cultured   in  Dulbecco’s  modified  
Eagle’s  medium  supplemented  with  10%   fetal  bovine  serum   (heat   inactivated),  1%  L-­glutamine  
and  1%  penicillin-­streptomycin.  RPCs  were  maintained  as  previously  described   (manuscript  1).  
All   cells   were   cultured   in   5%  CO2   at   37°C.   For   cell   viability,   cells   were   plated   in   triplicates   or  
duplicates   in  96  or  384-­well  plates  at  cell  densities  optimized  per  each  cell   type   (Supplemental  
Table  S1).  24h  after  cell  seeding,  medium  was  replaced  and  drug  was  added  by  using  HPD300  
digital   dispenser   at   concentrations   indicated   in   each   figure.   After   treatment   (at   various   time  
points),   WST-­1   assay   (Roche   Diagnostics)   was   performed   according   to   the   manufacturer’s  
instructions.  A  list  of  the  compound  details  used  in  this  study  is  available  in  (Supplemental  table  
S3  manuscript  1).  
  
Drug  screen  
3000  SJRHB013758_X2C  cells  were  seeded  in  duplicate  in  384-­well  plate  and  after  24  h  medium  
was  changed  before  treatment  start.  Each  compound  (10  mM  stock  solution  dissolved  in  DMSO)  
was  pre-­diluted  with  medium  the  day  of   the  experiment  at  10  uM  concentration  and  1  ul  of   this  
solution  was  added  manually  to  19  ul  of  medium  per  well  to  achieve  a  final  concentration  of  500  
nM.  Finally,  either  doxorubicin  (IC-­20)  or  etoposide  (IC-­30)  were  added  by  using  HPD300  digital  
dispenser.  DMSO  and  water   solution   containing   0.3%   tween   20   (Sigma  Aldrich)  were   used   as  
vehicle  controls  for  etoposide  and  doxorubicin,  respectively.  WST-­1  assay  was  performed  at  72  h  
time  point  and  cell  viability   for  each  well  was  normalized  to  untreated  cells  (vehicle  control)  and  
data  are  shown  as  percentage  of  control.  The  drug   library  containing  204  drugs  was  purchased  
from  Selleck  and  details  are  shown  in  (Supplemental  table  S3  manuscript  1).  
  
Caspase  3/7-­activity  assay  
Cells  were  seeded  in  white  384-­well  plates  with  clear  bottom  (Greiner  Bio-­One).  Caspase  activity  
was  determined  at   indicated  time  points  by  Caspase-­Glo  3/7  Assay  (Promega)  according  to  the  
manufacturer’s   instructions.   Luminescence   was   measured   using   the   multidetection   microplate  
reader  Synergy  HT  (Bio-­Tek  Instruments).  
  
Western  blotting  
Total  protein  from  cell  lysates  was  extracted  using  RIPA  buffer  (50  mM  TrisCl  (pH  7.5),  150  mM  
NaCl,  1%  NP-­40,  0.5%  Na-­deoxycholate,  1  mM  EGTA,  0.1%  SDS,  50  mM  NaF,  10  mM  sodium  
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β-­glycerolphosphate,   5   mM   sodium   pyrophosphate,   1   mM   sodium   orthovanadate   and  
supplemented  with  Complete  Mini  Protease  Inhibitor  Cocktail  (Roche).  To  load  equal  amounts  of  
proteins  per  sample,   relative  protein  quantification  was  calculated  using   the  Pierce  BCA  protein  
Assay   Kit   (Thermo   Fisher   Scientific,   LuBioScience).   Proteins   were   separated   using   NuPAGE  
4%–12%  Bis-­Tris  SDS–PAGE  pre-­cast  gels   (Life  Technologies)   for  about  1-­1.5  hours  at  120  V  
(constant  voltage)  and  transferred  to  nitrocellulose  membranes  (GE  Healthcare  Life  Sciences)  for  
3  h  at  33  V.  After  blocking  with  5%  milk  powder  in  TBS/0.1%  Tween  for  50  minutes,  membranes  
were   incubated   overnight   at   4°C   with   the   primary   antibody.   The   day   after,   membranes   were  
washed  twice  with  TBS/0.1%  Tween  and  incubated  with  secondary  antibody  for  50  minutes.  After  
2   additional   washing   steps,   the   specific   proteins   were   detected   by   using   Amersham   ECL  
Detection   reagent   (GE   Healthcare   Life   Sciences)   or   SuperSignal   West   Femto   Maximum  
Sensitivity   Substrate   (Thermo   Scientific).   A   description   of   the   antibodies   used   throughout   the  
study  can  be  found  in  (Supplemental  table  S2).  
  
Expression  analysis  using  R2  database  
  
All  data  used  are  accessible  through  the  open  access  platform  R2  for  visualization  and  analysis  
of   the   microarray   data   (http://r2.amc.nl).   The   following   datasets   were   used:   Normal   Muscle  




Data   analysis   was   performed   using   GraphPad   Prism   (version   6).   Significance   was   calculated  
using  Student’s  t-­test  (unpaired,   two  tailed)  or  multiple  t-­test.  For  BCL-­XL  expression  from  RMS  
and   normal   tissue   datasets,   one-­way   ANOVA   was   used   for   multiple   comparisons.   Differences  
were  considered  statistically  different  if  P<0.05.  The  number  of  biological  replicates  (N)  per  each  
experiment  is  indicated  in  the  figure  legends.    Drug  interaction  was  analyzed  by  using  the  Chou-­
Talalay   method   [42].   A   visualized   shiny   app   to   evaluate   drug-­drug   interaction   was   used   to  
calculate   the   combination   index   (CI)   and   is   freely   available   from  





Plasmids,  transfection  methods  and  lentiviral  transduction  
pLentiCRISPR-­EGFP  (empty  backbone)   (Addgene  #  75159)  and  pLentiCRISPR-­tagBFP  (empty  
backbone)  (Addgene  #  75160)  were  a  gift  from  Beat  Bornhauser.  SgRNAs    (sequences  are  listed  
in  Supplemental  table  S3)  targeting  exon  regions  shared  across  all  the  predicted  isoforms  for  the  
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selected  gene  were  designed  by  using  the  online  CRISPR  design  tool  (http://crispr.mit.edu/)  and  
top   candidates  with   a   score   over   80  were   chosen.   For   cloning,   double-­stranded   sgRNA  oligos  
were  inserted  into  pLentiCRISPR  vectors  by  digestion  with  ESP3I  (Thermo  Scientific)  and  ligation  
with   a   T4   ligase   (Themo   Scientific).   For   lentiviral   particle   production,   pVSV-­G,   pMDL,   pREV  
(kindly   provided   by   Oliver   Pertz,   Department   of   Biomedicine,   University   of   Basel,   Switzerland)  
and  pLentiCRISPR  vectors  were  co-­transfected  into  HEK293T  cells  using  calciumphosphate.  48h  
after   transfection,   the   virions   from   supernatant   cultures  were   collected   and   concentrated   using  
Amicon   Ultra   tubes   (Ultracel   100k,   Millipore).   SJRHB013758_X2C   cells   were   transduced   with  
LentiCRISPR   constructs   at   MOI   of   0.7-­0.9   and   24h   after   medium   was   changed.   7   days   post-­
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Figure   1.  Characterization   of   the   response   towards   chemotherapeutic   agents   in   pairs   of  
diagnostic/recurrent  ERMS  RPCs.  
(A)  Model  used   to  study  chemosensitization  mechanisms   in  ERMS.  Tumor  biopsies   taken   from  
the   patient   at   the   diagnosis   and   relapse   were   implanted   in   mice   to   generate   PDXs.   Freshly  
derived   RPCs   were   used   to   test   the   response   towards   standard   chemotherapy.   Hence,   high-­
throughput   drug   screens  were   performed  on   chemoresistant  RPCs   to   identify   potential   chemo-­
sensitizers.   (B   and   C)   Viability   assay   in   pairs   of   diagnostic   (blue)/relapse   (black)   RPCs   from  
patient  #2   (B)  and  patient  #3   (C)   treated   for  72h  with  doxorubicin   (upper  panel)   and  etoposide  
(lower   panel)(mean   ±   SD;;  N=3).  Graph   bars   indicate   the   corresponding   IC-­50   values   for   each  
drug  (mean  ±  SEM).  *P≤0.05;;  **P≤0.01;;  **P≤0.001;;  NS,  not  significant.  
  
Figure   2.   A   drug   screen   approach   identifies   ABT-­263   as   sensitizer   to   standard  
chemotherapy  in  ERMS.  
(A)   Drug   screen   results   showing   the   top   hit   compounds   that   modulate   the   sensitivity   of  
doxorubicin   (light   green   circle)   and   etoposide   (light   blue   circle).   The   common   candidate   (ABT-­
263)   is  highlighted   in   the   intersection.  Black  and  red  bars   indicate   the  effect  of   the   inhibitors  as  
single  agent  and  in  combination,  respectively.  (B)  Dose  titration  curves  for  ABT-­263  performed  in  
ERMS   cells   (N=3)   and  HFF   (human   foreskin   fibroblasts)   (N=2)   after   72h   treatment   (left   panel)  
(mean   ±   SD).   The   IC-­50   values   are   shown   for   each   cell   type   (lower   panel).   (C)  Western   blot  
analysis  showing  expression  of  indicated  proteins  in  HFF  and  ERMS  cells.  b-­ACTIN  was  used  as  
loading  control.  
  
Figure   3.   ABT-­263   synergizes   with   conventional   therapy   to   induce   cell   death   in   ERMS  
recurrent  samples.  
(A)   Viability   of   ERMS   recurrent   cells   treated   with   increasing   concentrations   of   etoposide,  
doxorubicin   and   vincristine   as   single   arm   treatment   (black)   or   in   combination   with   ABT-­263  
(500nM  and  250  nM,  dark  and  light  blue  lines,  respectively)  for  72h.  The  cell  type  used  is  shown  
above   each   graph.   (Mean   ±   SD;;   N=2-­3).   (B)   Caspase   3/7-­activity   assay   performed   in  
SJRHB13758_X2C   (upper   and   lower   panel)   and   SJRHB012_ZC   (middle   panel)   following  
treatment  with  the  indicated  chemotherapeutics  with  or  without  ABT-­263.  (Mean  ±  SD;;  N=3).  (C)  
Western  blot  analysis  showing  protein  levels  of  PARP,  cleaved  PARP  and  cleaved  CASPASE  3  
in   SJRHB13758_X2C   (upper   and   lower   panel)   and   SJRHB012_ZC   (middle   panel)   after   short-­
term  exposure  to  single  or  combinatorial  treatments  with  the  indicated  compounds.  GAPDH  was  






Figure  4.  ABT-­263  sensitizes  ERMS  cells  to  chemotherapy  via  NOXA.  
  
(A)   Representation   of   the   experimental   workflow   aimed   at   the   identification   of   the   BH3-­only  
protein   mediating   the   effect   of   ABT-­263/chemotherapy.   (B)   Caspase   3/7   assay   performed   on  
SJRHB13758_X2C  NOXA-­/-­  upon  treatment  with  vincristine  (VCR)  (upper  panel)  and  doxorubicin  
(lower  panel)  with  or  without  ABT-­263  (500nM  and  250nM)  at  the  indicated  time  points.  (Mean  ±  
SD;;   N=3);;*P≤0.05;;   **P≤0.01;;   ***P≤0.001;;   ****P≤0.0001.   (C)   WST-­1-­assay   performed   on  
SJRHB13758_X2C   NOXA-­/-­   upon   treatment   with   vincristine   (VCR)   (left   panel)   and   doxorubicin  
(right  panel)  with  or  without  ABT-­263  (500nM  and  250nM)  at   the   indicated  time  points.  (Mean  ±  
SD;;   N=3-­4;;)   *P≤0.05;;   **P≤0.01;;   ***P≤0.001;;   ****P≤0.0001.   (D)   SJRHB13758_X2C   treated   with  
either  vincristine  (left)  or  doxorubicin  (right)  for  3,6,9,24  and  48  hours  (h),  were  collected  at  time  
points  for  western  blot.  NOXA  and  GAPDH  protein  levels  are  shown.  
  
Figure  5.  Chemotherapy  and  ABT-­263  target  MCL-­1  and  BCL-­xl,  respectively.  
  
(A,  left  panel)  Cell  viability  analysis  of  SJRHB13758_X2C  cells  co-­treated  with  ABT-­199  (BCL-­2i)  
and  doxorubicin   (upper   panel,  N=2)  or   vincristine   (lower  panel,  N=3)   for   24h   (mean  ±  SD).   (A,  
right   panel)  Cell   viability   analysis   of   SJRHB13758_X2C   cells   co-­treated  with   A-­1331852   (BCL-­
XLi)  and  doxorubicin  (upper  panel,  N=3)  or  vincristine  (lower  panel,  N=3)  for  24h  (mean  ±  SD).  A  
schematic   view   depicting   the   strategy   used   is   shown  on   the   left   of   each   graph.   (B)  Schematic  
representation   showing   the   approach   used   to   identify   the   target   of   chemotherapy   (left   panel).  
Indicated   protein   levels   from   scramble   control   (sg_SC),   MCL-­1,   BCL-­2   and   BCL-­XL   knock-­out  
cells  (sg1  and  sg2)  are  shown.  b-­ACTIN  was  used  as  loading  control.  (C)  Cell  viability  performed  
on   SJRHB13758_X2C   knock-­out   cells   for   BCL-­2,   BCL-­XL,   BCL-­W   and  MCL-­1   upon   treatment  
with  ABT-­263  for  24h.  (Mean  ±  SD;;  N=2-­3).  (D)  Dual  inhibition  of  MCL-­1  and  BCL-­XL  via  MCL-­1i  
(A-­1210477)   and   BCL-­XLi   (A-­1331852),   respectively   (left   panel).   SJRHB13758_X2C   and  
SJRHB012_ZC  cells  were  treated  with  increasing  concentrations  of  BCL-­XLi  and  MCL-­1i  for  72h  
before  cell  viability  was  analyzed  (right  panel).  (Mean  ±  SD;;  N=3).  
  
Figure  6.  Clinical  relevance  of  BCL-­XL  and  in  vivo  treatment  with  ABT-­263/doxrubicin.  
  
(A)  Expression  analysis  for  BCL-­XL,  BCL-­2  and  BCL-­w  for  two  different  RMS  collections  (N=147  
and  N=30)  and  normal  skeletal  muscle  tissues  (N=40).  (B)  Treatment  plan  for  in  vivo  assessment  
of  ABT-­263/doxorubcin  (left  panel)  and  tumor  growth  of  mice  (n=6)  treated  with  vehicle,  ABT-­263  
(80mg/Kg   orally),   doxorubicin   (2   mg/kg   i.v.)   or   ABT-­263   plus   doxorubicin   (right   panel).   Tumor  









Figure   S1   (related   to   Figure   1).   Characterization   of   the   response   towards  
chemotherapeutic  agents  in  pairs  of  diagnostic/recurrent  ERMS  primary  cultures.    
  
(A)  Cell  viability  assay  of  diagnostic  (blue)/relapse  (black)  cells  derived  from  patient  #3  upon  72h  
treatment   with   the   indicated   cytotoxic   agents   (mean   ±   SD).   Histogram   graphs   represent   IC-­50  
values  for  each  drug  (mean  ±  SEM,  N=2).  NS,  not  significant.  
  
Figure  S2   (related   to  Figure   3).  ABT-­263  synergizes  with   conventional   therapy   to   induce  
cell  death  in  ERMS  recurrent  samples.    
  
(A)  Cell  viability  analysis  of  RD  cell   line  co-­treated  with  increasing  concentrations  of  doxorubicin  
with  or  without  ABT-­263  (250nM  and  500nM)   for  72h  (mean  ±  SD,  N=3).   (B)  Calculation  of   the  
combination   index   (CI)   for   SJRHB13758_X2C   and   SJRHB012_Z   cells   upon   72h   co-­treatment  
with   ABT-­263   and   indicated   chemotherapeutics   at   various   concentrations.   CI>1   indicates  
antagonism  (red),  1-­08  additivity  (dark  green)  and  <0.8    synergism  (light  green).  (C)  Caspase  3/7-­
activity   assay   performed   on  SJRHB012_ZC  and  SJRHB13758_X2C   cells   co-­treated  with  ABT-­
263  and  etoposide  at  24h  and  48h,  respectively.  (Mean  ±  SD;;  N=3).  (D)  Time  course  analysis  of  
protein   levels   from   SJRHB13758_X2C   cells   treated   with   vincristine   (0.1   and   1uM),   ABT-­263  
(500nM)  or  both  at  indicated  time  points  (h).  GAPDH  was  used  as  loading  control.  
  
Figure  S3  (related  to  Figure  4).  ABT-­263  sensitizes  ERMS  cells  to  chemotherapy  via  NOXA.  
  
(A,  left  panel)  Caspase  3/7-­activity  assay  performed  in  SJRHB13758_X2C  cells  transduced  with  
sgSC  (control)  or  sgBIM  and  treated  for  24h  with  vincristine  alone  or  in  combination  with  ABT-­263  
(250  and  500nM)  (mean  ±  SD,  N=3).  (A,  right  panel)  Western  blot  analysis  for  validation  of  NOXA  
and   BIM   down-­regulation   at   protein   level.   b-­ACTIN   was   used   as   loading   control.   (B)   Dose  
response   curve   of   SJRHB13758_X1C   (diagnostic,   blue   line)   and   SJRHB13758_X1C   (relapse,  
black   line)   cells   exposed   to   increasing   concentrations   of   idasanutlin   (mean   ±   SD;;   N=3).  
Corresponding  IC-­50  values  per  each  sample  are  indicated  in  the  table.  
  
Figure   S4   (related   to   Figure   5).   Chemotherapy   and   ABT-­263   target   MCL-­1   and   BCL-­xl,  
respectively.  
  
(A)  Cell  viability  analysis  of  SJRHB_ZC  (left  panel)  and  SJRHB_YC  (right  panel)  cells  co-­treated  
with   A-­1331852   (BCL-­XLi)   and   chemotherapeutics   (doxorubicin   or   vincristine)   for   24h   (mean   ±  
SD;;   N=2-­3).   (B)   Experimental   model   used   to   identify   the   target   of   ABT-­263   (left   panel).  
SJRHB13758_X2C   cells   containing   sgRNAs   targeting   BCL-­XL   (N=4),   BCL-­2   (N=2),   MCL-­1  
(N=2),  BCL-­W  (N=2)  and  scramble  control  (SC,  N=4)  were  treated  with  different  concentrations  of  
vincristine  (VCR)  7  days  after  transduction.  Caspase  3/7-­activity  assay  was  performed  24h  after  
treatment  start.  (Mean  ±  SD;;  *P≤0.05;;  ns,  not  significant).  (C)  Western  blot  analysis  showing  the  
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expression   of   indicated   proteins   after   treatment   with   ABT-­263   and/or   doxorubicin   in  
SJRHB13758_X2C   and   SJRHB_ZC   cells   at   the   indicated   time   points.   b-­ACTIN   was   used   as  
loading   control.   (D)   Cell   viability   analysis   of   co-­treated   SJRHB_YC   cells   with   increasing  
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RELAPSE       (SJRHB13758_X2C) 
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DOXORUBICIN + BCLXLi (1uM)
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DOXORUBICIN (2 mg/Kg) 





	  	  	  
Supplemental Figure 1
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Cell type 384-well plate Volume (ul) for 384-well plate Pre-coated 96-well plate Volume (ul) for 96-well plate Pre-coated
RD 2000 20 No not performed not performed not performed
HFF 2000 20 No not performed not performed not performed
SJRHB012_X 4000 20 Yes, 2 % gelatin 10000 100 Yes, 0.2% gelatin
SJRHB012_Y 12000 20 Yes, 2 % gelatin not performed not performed not performed
SJRHB012_Z 3000 20 Yes, 2 % gelatin 10000 100 Yes, 0.2% gelatin
SJRHB13758_X1C 4000 20 Yes, 2 % gelatin 15000 100 Yes, 0.2% gelatin
SJRHB13758_X2C 3000 20 Yes, 2 % gelatin 10000 100 Yes, 0.2% gelatin
Supplemental Table S1
PRIMARY ANTIBODIES
Detected Protein Applications Molecular Weight (kDa) Species Clonality Dilution Catalog Number (#) Company
BAX WB 20 Rabbit Monoclonal 1:1000 5023S Cell signaling
BCL-XL WB 28 Rabbit Polyclonal 1:1000 2762S Cell signaling
BCL-2 WB 26 Mouse Monoclonal 1:1000 M0887 Dako
MCL-1 WB 40 Rabbit Monoclonal 1:1000 5453T Cell signaling
-ACTIN1 WB 45 Mouse Monoclonal 1:1000 12262S Cell signaling
BAK WB 25 Rabbit Monoclonal 1:1000 6947S Cell signaling
BIM WB 23-15-12 Rabbit Monoclonal 1:1000 2933S Cell signaling
NOXA WB 10 Rabbit Monoclonal 1:1000 14766S Cell signaling
PARP WB 89-116 Rabbit Polyclonal 1:1000 9542S Cell signaling
CLEAVED CASPASE 3 WB 17-19 Rabbit Monoclonal 1:1000 9664P Cell signaling
GAPDH WB 37 Rabbit Monoclonal 1:1000 2118S Cell signaling
SECONDARY ANTIBODIES
Anti-Mouse IgG1 WB 1:2500 7076S Cell signaling






GENE sgRNA sequence (de-PAM-end) Backbone vector used
SCRAMBLE GCACTACCAGAGCTAACTCA pLentiCRISPR-EGFP (Addgene, #75159) andpLentiCRISPR-tagBFP (Addgene, #75160)
MCL-1 sg1 CTCAAAAGAAACGCGGTAAT pLentiCRISPR-EGFP (Addgene, #75159)
MCL-1 sg2 TGGAGACCTTACGACGGGTT pLentiCRISPR-EGFP (Addgene, #75159)
BCL-XL sg1 CAGTGGCTCCATTCACCGCG pLentiCRISPR-EGFP (Addgene, #75159)
BCL-XL sg2 GGGTTGCCATTGATGGCACT pLentiCRISPR-EGFP (Addgene, #75159)
BCL-2 sg1 GAGAACAGGGTACGATAACC pLentiCRISPR-EGFP (Addgene, #75159)
BCL-2 sg2 GTCGCAGAGGGGCTACGAGT pLentiCRISPR-EGFP (Addgene, #75159)
BCL-w sg1 ATGAGTTCGAGACCCGCTTC pLentiCRISPR-EGFP (Addgene, #75159)
BCL-w sg2 GACCTGGGTGAAGCGTTGTT pLentiCRISPR-EGFP (Addgene, #75159)
NOXA sg1 ACGCTCAACCGAGCCCCGCG pLentiCRISPR-tagBFP (Addgene, #75160)
NOXA sg2 TCGAGTGTGCTACTCAACTC pLentiCRISPR-tagBFP (Addgene, #75160)
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Rhabdomyosarcoma  (RMS)   is   the  most   frequent  soft-­tissue  sarcoma   in  children,  accounting   for  
about   4-­8   %   of   all   pediatric   tumors.   RMS   comprises   embryonal   rhabdomyosarcoma   (ERMS,  
60%),  alveolar  Rhabdomyosarcoma  (ARMS,  20%)  and  other  subtypes   (20%),  showing  different  
histological,   genetic   and   clinical   features   [1].   Indeed,   70-­80%   of   the   alveolar   subtype   is  
characterized   by   specific   chromosomal   translocations   which   lead   to   the   generation   of  
PAX3/PAX7-­FOXO1  fusion  proteins,  considered  clinically  relevant  in  the  aetiology  and  prognosis  
of   the   disease   [2,   3].   ERMS   is   the   most   common   subtype   of   RMS   and   has   frequent   loss   of  
heterozygosity  (LOH)  and  loss  of  imprinting  (LOI)  at  11p15.5  locus.  It  is  mostly  diagnosed  in  the  
head,   neck   and   genitourinary   region   of   children   and   rarely   metastasises   even   if   the   overall  
survival   for   patients   with   recurrent   disease   is   less   than   30%   [4,   5].   To   date,   chemotherapy,  
radiotherapy   and   surgery   are   the   current   treatments   for   RMS.   Despite   improvements   in   the  
survival  rate  of  patients  with  localized  disease,  the  outcome  for  high-­risk  groups  remains  poor  [6].  
One   of   the   approaches   used   in   the   clinic   to   overcome   this   poor   prognosis   includes   intensive  
chemotherapy   given   the   better   tolerability   of   children   compared   to   adults.   However,   these  
treatments  are  often  associated  with  long-­term  side  effects  such  as  secondary  malignancies  and  
organ  dysfunctions   [7].  Therefore,   there   is  a  need   to   improve  current   therapies,   for  example  by  
looking  at  new  targets  involved  in  the  aetiology  and  maintenance  of  RMS  [8].  To  this  end,  a  valid  
avenue  is  offered  by  embryonic  signalling  pathways  such  as  Notch,  Wnt  and  Hedgehog,  mainly  
active  during  embryogenesis  but  often  deregulated  in  cancer,  with  a  high  propensity  for  childhood  
malignancies   [9,   10].   Among   these,   Hedgehog   (Hh)   is   the   most   studied   signalling   pathway   in  
ERMS.  In  physiological  conditions,  Hh  signalling  is  activated  by  three  mammalian  ligand  variants  
SHH,  IHH  and  DHH,  which  bind  to  the  negative  regulator,  patched  (PTCH)  receptor.  This  leads  to  
the  de-­repression  of  smoothened  (SMO)  co-­receptor,  which  can  accumulate  on   the  mammalian  
primary  cilium  and  release  the  downstream  GLI  (GLI1,  GLI2  and  GLI3)  transcription  factors  from  
suppressed  of   fused  (SUFU)   inhibition.  GLI1   is   the  main  effector  of  Hh  signalling,  while  GLI3   is  
mostly   a   repressor   and   GLI2   can   behave   as   repressor   and   activator.   Three   main   reasons  
underscore   the   importance   of   Hh   in   ERMS   tumorigenesis.   First,   individuals   with   germline  
mutations   in  Ptch1  (Gorline  syndrome)  are  predisposed   to  ERMS  [11,  12].  Second,  Hh  gain-­of-­
function  gene  expression  signature   is  highly  prevalent   in  human  primary  ERMS  tumors   [13-­15].  
Third,  GLI1  over-­expression  and/or  genetic  inactivation  of  Sufu  have  been  reported  in  ERMS  [14].  
These  observations   together  with   the   relevant   role  of  Hh   in   the  generation  and  maintenance  of  
stem  cell  pools  during  embryogenesis,  suggest  a  key  role   in  ERMS  pathogenesis.  According   to  
this,   we   have   previously   shown   the   existence   of   high   tumorigenic   sub-­populations  with   cancer  
stem  cell   (CSC)-­like  proprieties   in  ERMS   [16]   and   the   key   role  of  Hh   in  modulating   these   self-­
renewal  compartments  [17].  Since  CSCs  are  also  known  to  drive  relapse  disease,  we  reasoned  
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that   targeting  Hh   signalling   in   combination  with   conventional   therapies  might   represent   a   valid  
avenue  to  counteract  chemoresistance.    
Here,  we   show   that  Hh   signalling   is   iper-­activated   in   three   independent   recurrent  PDX  models  
compared  to  matched  diagnostic  samples.  Consequently,  chemical  inhibition  of  upstream  (SMO)  
as   well   as   downstream   (GLI)   Hh   players   strongly   improves   the   effects   of   standard  
chemotherapeutics.  Although  this  represents  a  promising  approach,  further  investigations  on  the  
mechanism  of  action  of  anti-­Hh  compounds  are  required  since  we  were  unable  to  recapitulate  the  




Hh  signaling  is  over-­activated  in  relapse  PDX  samples  
In  our  previous  study  we  showed  that  Hh  signaling   is  an   important  driver  of  stemness   in  ERMS  
tumor-­initiating  cells  (TICs),  which  are  also  considered  to  be  responsible  for  chemoresistance  [17,  
18].   Therefore,  we   took   advantage   of   our   recently   described   pairs   of   diagnostic/recurrent   PDX  
samples   to   study   whether   relapse   disease   can   be   associated   with   changes   in   Hh   signaling  
activity  (manuscript1).  To  test  this,  we  evaluated  the  expression  of  Hh  target  genes  (GLI1,  HHIP  
and  PTCH1)  by  quantitative  real-­time  PCR  (qRT-­PCR)  for  each  of  these  paired  models  (derived  
from   three   ERMS   patients)   and   compared   the   mRNA   levels   (2-­∆CT)   between   diagnostic   and  
relapse  tumors  (Figure  1  A).  Remarkably,  all  recurrent  samples  had  increased  expression  of  GLI1  
(between   2.62-­   to   8.59-­   fold)   and   HHIP   (between   5.6-­   to   12-­   fold)   whereas   PTCH1   was   up-­
regulated   only   in   relapsed   patient   #1   (>   3.18   fold   change)   and   patient   #2   (>   1.47-­fold).  
Accordingly,   immunoblot   analysis   confirmed  GLI1   over-­expression   (ranging   from   2.35   to   15.64  
fold  change)  in  all  recurrent  PDXs  relative  to  diagnostic  samples  within  the  same  patient  (Figure  1  
B).  Next,   to   further   investigate   the   functional   contribution  of  Hh  pathway   to   chemoresistance   in  
vitro,   we   derived   diagnostic   (SJRHB011_YC)   and   recurrent   (SJRHB011_XC)   primary   cultures  
from  patient  #1  (PDX)  and  tested  whether  the   in  vitro  system  recapitulates  the  same  expression  
pattern  observed  in  vivo.  As  expected,  qRT-­PCR  analysis  revealed  increased  expression  of  GLI1,  
HHIP  and  PTCH1   in  SJRHB011_XC  compared   to  SJRHB011_YC  at   similar  extends  as   in   vivo  
(Figure  1  C,  upper  panel).  Furthermore,  GLI1  protein  expression  was  also  increased  similarly  to  
the  initial  paired  PDX  sample  (Figure  1  C,  lower  panel).  Since  Hh  is  a  ligand-­based  pathway,  we  
asked  whether  increased  Hh  signaling  activation  in  relapsed  cells  is  associated  with  higher  ligand  
expression.   To   this   aim,   we   analyzed  mRNA   levels   of   SHH,   IHH   and   DHH   by   qRT-­PCR   and  
found   that   both   DHH   and   SHH   are   relatively   higher   in   SJRHB011_XC   compared   to  
SJRHB011_YC  cells  although  the  basal  levels  were  consistently  low  (Figure  1  D).    In  sum,  these  
results   indicate  an  Hh  gain-­of-­function  gene  expression  signature  in  recurrent  samples,  which  is  
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conserved  also  in  one  example  of  paired  PDX-­derived  cells,  leading  us  to  investigate  further  the  
role  of  Hh  pathway  in  the  context  of  chemo-­resistance.    
  
Pharmacological   inhibition   of   Hh   signaling   sensitizes   ERMS   cells   to   standard  
chemotherapy  
The  observed  aberrant  activity  of  Hh  pathway  in  recurrent  ERMS  samples  prompted  us  to  explore  
the   functional   relationship   between   Hh   machinery   and   resistance   to   conventional   treatment   in  
ERMS.  We  used  SJRHB011_XC  and  RD   (relapse  cell   line)  as   in  vitro   culture  system   to  model  
relapse  disease.  We  then   inhibited  Hh  signaling  by  a  pharmacological  approach  using  GANT61  
and  GDC-­0449  inhibitors  targeting  GLI1/2  and  SMO,  respectively.  We  verified  the  on-­target  effect  
of   these   compounds   by   immunoblot   for   GLI1,   which   is   the   main   target   to   be   affected   if   Hh  
pathway  is  modulated.  Both  GDC-­0449  and  GANT61  treatment   led  to  a  downregulation  of  GLI1  
protein  of  ~50%  compared  to  vehicle  control  (Figure  2  A).  Next,  we  performed  cell  viability  assays  
on  cells  treated  with  either  increasing  amounts  of  Hh  inhibitors  (GANT-­61  and  GDC-­0449)  or  co-­
treated   with   de-­bulking   agents   at   EC-­50   concentrations.   We   selected   three   different   cytotoxic  
drugs   namely   doxorubicin,   a   topoisomerase   II   inhibitor,   actinomycin   D,   a   DNA   intercalator  
affecting  mRNA  synthesis  and  vincristine,  a  microtubule  destabilizer,  which  are  all  wildly  used  in  
up-­front  treatments  of  ERMS  patients.  According  to  our  previous  findings,  Hh  signaling  inhibition  
does  not  affect  cell  survival  in  both  SJRHB011_XC  and  RD  cells  at  concentrations  up  to  5  uM  of  
GANT61  and  20  uM  of  GDC-­0449  (Figure  2  B  and  S1  A,  B  and  C).   In  contrast,  we  observed  a  
dose   dependent   increased   sensitivity   to   actinomycin   D   in   presence   of   the   Hh   antagonists  
compared  to  the  single  arm  treatments.  Similarly,  GANT61  could  sensitize  relapse  ERMS  cells  to  
vincristine   whereas   GDC-­0449   was   less   effective.   Finally,   only   the   highest   concentration   of  
GANT61   (5uM)  was  sufficient   to  significantly   increase   the  sensitivity   towards  doxorubicin   in  RD  
cells  and  only  a   trend  was  observed   in  SJRHB011_XC  although   it  was  not  statistical  significant  
(Figure   2   B,   S1   A).   Taken   together   these   results   suggest   that   both   SMO-­   and   GLI-­mediated  
pharmacological   inhibition   increase   the   cytotoxicity   of   standard   chemotherapeutics   in   recurrent  
ERMS  cells.  
  
Genetic  modulation   of   Hh   signaling   does   not   alter   chemo-­sensitivity   in   ERMS   recurrent  
cells  
To   further   study   the   Hh-­mediated   chemo-­sensitization,   we   took   advantage   of   the   Crispr/Cas9-­
genome  editing  tool  to  generate  ERMS  recurrent  cells  with  low  and  high  Hh  signaling  activity  by  
knocking   out   GLI1   (GLI1-­/-­)   and   SUFU   (SUFU-­/-­),   respectively.   Western   blot   analysis   showed  
efficient   protein   depletion   in   both   SJRHB011_XC   (Figure   3   A)   and   RD   (Figure   S2   A)   upon  
transduction  with   lenti-­Crispr  vectors  containing  sgRNAs  directed  against  the  respective  targets.  
Importantly,  GLI1  inactivation  was  accompanied  by  a  down-­regulation  of  GLI1  itself  and  HHIP  at  
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mRNA   levels   in   both   SJRHB011_XC   (Figure   1   B)   and   RD   (Figure   S2   B)   cells   confirming   a  
positive  and  negative  feedback  loop,  respectively.  However,  we  cannot  rule  out  the  possibility  that  
indel  mutations  could  affect   the  stability  of  GLI1  mRNA.  On   the  other  hand,  qRT-­PCR  analysis  
demonstrated  a  clear  up-­regulation  of  the  Hh  targets  in  SJRHB011_XC  SUFU-­/-­  cells  (Figure  3B)  
followed   by   increased   GLI1   protein   expression   (Figure   3A,   lower   panel).   Similar   results   were  
obtained   for   RD   cells   (Figure   S2   A   and   B).   Next,   we   verified   that   genetic   manipulation   of   Hh  
signaling  did  not  alter   cell   viability   in  ERMS  cells   resembling   the  phenotype  observed   following  
treatment  with  Hh-­antagonists  as  single  agents   (Figure  3C  and  S2  C).  Hence,   to  assess   if   this  
holds   true   also   for   the   combination   with   conventional   chemotherapeutics   we   monitored   cell  
viability   upon   treatment   of   Hh   “low”   and   “high”   cells   with   Actinomycin   D   and   vincristine,   which  
showed  the  best  combinatorial  effect  with  Hh  inhibitors  (Figure  2  B,  S1  A,  B  and  C).  Surprisingly,  
either  SUFU  or  GLI1  knock-­out  did  not  affect  the  response  of  ERMS  cells  towards  these  cytotoxic  
drugs  with  only  a  modest  increased  sensitivity  towards  vincristine  in  RD  cells  (Figure  3  A  and  S2  
D).   Therefore,   our   results   indicate   that   specific   modulation   of   GLI1   by   genetic   means   is   not  
sufficient   to   regulate   the   response   to   standard   de-­bulking   agents   in   ERMS   cells   highlighting   a  




Over-­activation  of  Hh  pathway  is  a  common  event  occurring  in  cancer  and  has  been  associated  
with   the   onset   of   several   cancer   entities   including   ERMS   [19,   20].   This   latter   appears   to   be  
hierarchically  organized  where  Hh-­regulated  CSCs  boost  tumorigenesis  by  promoting  ‘stemness’  
features   [17,   18]   .   Because   CSCs   are   often   spared   by   conventional   cytotoxic   agents,   in   the  
present   study   we   investigated   the   role   of   Hh   signaling   in   the   context   of   chemoresistance,   a  
devastating   phenomenon   in   clinical   oncology.   Here,   we   show   a   dramatic   upregulation   of   Hh  
target  genes  (GLI1,  HHIP  and  PTCH1)  in  ERMS  PDXs  compared  to  matched  diagnostic  samples  
from   three   independent   patients.   This   correlates   with   early   findings   showing   that   aberrant   Hh  
signaling  activity  predicts  poor  overall  survival  in  ERMS  population  [14,  21].  Interestingly,  among  
the  GLI  family  members,  GLI1  was  the  only  transcription  factor  to  be  consistently  over-­expressed  
in   relapsed  samples,  whereas  only  minor  changes  were  observed   for  GLI2  and  GLI3   (Figure  1  
and   data   not   shown).      Although   the   role   of   these   latter   is   not   well   understood   in   RMS   and  
warrants  deeper  investigations,  we  have  previously  shown  that  GLI1  is  a  critical  driver  of  tumor-­
initiating   populations   (TIPs)   and   might   represent   a   potential   biomarker   for   patient   stratification  
[17].      
To   functionally   characterize   the   Hh-­mediated   effect   on   chemoresistance,   we   used   primary  
cultures  from  patient  #1,  and  demonstrated  that  in  vitro  the  expression  pattern  of  Hh  targets  was  
retained  as   in   the  original  PDX      (Figure  1C).  The   increased  activity   in   relapsed  cells  correlated  
with  upregulation  of  Hh   ligands  (DHH  and  SHH)   indicating  an  ongoing  autocrine  signaling.  This  
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corroborates   our   previous   findings   where   up-­regulation   of   Hh   target   genes   in   CSC-­enriched  
conditions   (rhabdospheres)   was   associated   with   increased   ligand   expression   [17].   Similarly,   a  
recent   report   has   shown   that   genetic   down-­regulation   of   Hh   ligands   in   RMS   cells   decreased  
tumor   growth   at   similar   extent   as   inactivation   of   GLI1   [22].   Consistent   with   this,   genetic  
aberrations  of  Hh  components  occur  in  only  a  minority  of  RMS  cases  [4,  20,  23,  24].    
If  chemoresistance  relies  on  de-­regulation  of  Hh  signaling,  then  its  inhibition  would  sensitize  cells  
to  debulking  agents.  Our  data  revealed  that  the  viability  of  RMS  recurrent  cells  was  significantly  
decreased   by   combining   anti-­Hh   compounds  with   a  wide   range   of   chemotherapeutics   such   as  
doxorubicin,  actinomnycin  D  and  vincristine.  Generally,  the  chemo-­sensitization  effect  was  more  
pronounced   with   the   GLI   antagonist   GANT-­61,   which   prompted   us   to   explore   the   GLI1  
dependency   by   genetic   means.   Surprisingly,   GLI1   knock-­out   did   not   recapitulate   chemical  
inhibition   in   two   in   vitro   recurrent   models.   Yet,   complete   protein   depletion   of   SUFU,   a   direct  
endogenous  inhibitor  of  the  GLI  transcription  factors,  did  not  alter  chemo-­response  as  well.  Thus,  
it   is  unluckily  that  GLI2  and/or  GLI3  would  compensate  for  GLI1  down-­regulation,  at  least  in  this  
context.   Instead,   we   speculate   that   either   GDC-­0449   or   GANT-­61,   might   affect   additional  
signaling  cascades  besides  Hh  inhibition.  For  instance,  inhibition  of  both  Hh  and  AKT/mTOR  has  
been  proposed  as  mechanism  underling   the  GANT-­61-­mediated   regression  of  RMS  xenografts  
and   as   means   to   enhance   the   effect   of   vincristine   [25].   Consequently,   it   is   not   surprising   the  
synergistic  effect  observed  in  RMS  cells  upon  double  blockade  of  Hh  signaling  and  the  PI3K  axis  
[26].      Furthermore,   a   systematic   gene   expression   profile   in   RMS   cells   treated   with  GDC-­0449  
revealed  a  strong  induction  of  the  UPR  response  as  potential  off-­target  effects  [22].  Given  the  on-­
target   mixed   responses   elicited   by   the   Hh   inhibitors   in   RMS   cells,   a   more   systematic  
characterization  of   the  mode  of  action  of  such  compounds  will  clarify   the  observed  discrepancy  
between  chemical  and  genetic  inhibition  of  Hh  signaling  in  RMS.  
In  conclusion,  our  data  highlight  a  clear  association  between  Hh  signaling  activation  and  relapse  
disease,   confirming   the   prognostic   relevance   of   this   developmental   pathway   in  RMS.  Although  
further  studies  are  needed  to  clarify  the  functional  role  of  Hh-­mediated  chemoresistance,  our  work  
provides  the  rationale  for  using  Hh  antagonists  in  combination  with  first-­line  therapies  in  RMS.    
  
Materials  and  Methods  
  
Patient-­derived  samples,  cell  culture  and  treatments    
PDX   samples  were   processed   as   previously   described   (manuscript   1).   RD   (ATCC,  Manassas,  
VA,   USA),   HEK293T   (ATCC,   LGC   Promochem,   Molsheim,   France)   SJRHB011_X   and  
SJRHB011_Y   cells   were   cultured   in   Dulbecco’s   modified   Eagle’s   medium   supplemented   with  
10%  fetal  bovine  serum,  1%  L-­glutamine  and  1%  penicillin-­streptomycin.  All  cells  were  cultured  in  
5%  CO2  at  37°C.  
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For   drug   treatments,   8000   cells/well  were   seeded   in   96-­well   plates   in   quadruplicate.   24h   after,  
medium  was  replaced  and  drug  was  added  either  manually  or  by  using  HPD300  digital  dispenser  
at  concentrations  indicated  in  each  figure.  72h  later,  cell  viability  was  assessed  by  WST-­1  assay,  
according  to  the  manufacturer’s  instructions.  All  drugs  were  dissolved  in  DMSO,  which  was  used  
as  vehicle  control.  
GANT-­61  (Tocris  Biosciences),  GDC-­0449  (Selleck  Chemicals),  doxorubicin  (Sandoz),  vincristine  
(Selleck   Chemicals)   and   actinomycin   D   (Sigma-­Aldrich)   were   used   at   the   indicated  
concentrations.   For   dose   response   curves   of   chemotherapeutics   as   single   agent   or   in  
combinations,  serial  dilutions  were  performed.  
  
Western  Blot,  lentiviral  production  and  generation  of  knock-­out  cells  
As  recently  described  in  manuscript  2.  Information  regarding  the  antibodies  and  sgRNAs  used  in  
the  study  can  be  found  in  suppl.  Table  1  and  suppl.  Table  2,  respectively.  
  
Quantitative  Real-­time  PCR  
Total   RNA   was   extracted   using   RNeasy   Mini   Kit   (Quiagen)   following   manufacturer’s  
recommendations.   Genomic   DNA   contamination   was   removed   using   RNase-­free   Dnase  
(Quiagen).   RNA   concentration   and   purity   was   evaluated   using   NanoDrop   ND-­1000.cDNA  
synthesis  was  carried  out  using  High  Capacity  cDNA  Reverse  Transcription  kit  (Life  technologies)  
according  to  manufacturer’s  instructions.  Quantitative  Real-­Time  PCR  (qRT-­PCR)  was  performed  
using   commercially   available   mastermix   and   TaqManâ   Gene   Expression   Assays   (Life  
technologies;;  assay  IDs  are  listed  in  the  Suppl.  Table  3)  at  standard  conditions  on  an  ABI  7900  
HT  Real-­Time  PCR  machine  and  the  data  was  analyzed  with  SD  software  (Applied  Biosystems,  
Life   Technologies).   Absolute   and   relative   expression   levels   were   calculated   using   the   ΔΔCt  
method  and  normalized  to  HMBS  or  GAPDH.  
  
Statistical  analysis  
Data   analysis   was   performed   using   GraphPad   Prism   (version   6).   Significance   was   calculated  
using  Student’s   t-­test   (unpaired,   two   tailed).  Differences  were  considered  statistically  different   if  














1.   Belyea,  B.,  et  al.,  Embryonic  signaling  pathways  and   rhabdomyosarcoma:  contributions  
to  cancer  development  and  opportunities  for  therapeutic  targeting.  Sarcoma,  2012.  2012:  
p.  406239.  
2.   Dagher,  R.  and  L.  Helman,  Rhabdomyosarcoma:  an  overview.  Oncologist,  1999.  4(1):  p.  
34-­44.  
3.   Hawkins,  D.S.,  A.A.  Gupta,  and  E.  Rudzinski,  What’s  New  in  the  Biology  and  Treatment  
of  Pediatric  Rhabdomyosarcoma?  Current  opinion  in  pediatrics,  2014.  26(1):  p.  50.  
4.   Chen,   X.,   et   al.,   Targeting   oxidative   stress   in   embryonal   rhabdomyosarcoma.   Cancer  
Cell,  2013.  24(6):  p.  710-­24.  
5.   De   Giovanni,   C.,   et   al.,  Molecular   and   cellular   biology   of   rhabdomyosarcoma.   Future  
Oncol,  2009.  5(9):  p.  1449-­75.  
6.   Oberlin,   O.,   et   al.,   Prognostic   factors   in   metastatic   rhabdomyosarcomas:   results   of   a  
pooled   analysis   from   United   States   and   European   cooperative   groups.   J   Clin   Oncol,  
2008.  26(14):  p.  2384-­9.  
7.   Landier,   W.   and   S.   Bhatia,   Cancer   survivorship:   a   pediatric   perspective.   Oncologist,  
2008.  13(11):  p.  1181-­92.  
8.   Wachtel,   M.   and   B.W.   Schafer,   Targets   for   cancer   therapy   in   childhood   sarcomas.  
Cancer  Treat  Rev,  2010.  36(4):  p.  318-­27.  
9.   Takebe,  N.,  et  al.,  Targeting  cancer  stem  cells  by   inhibiting  Wnt,  Notch,  and  Hedgehog  
pathways.  Nat  Rev  Clin  Oncol,  2011.  8(2):  p.  97-­106.  
10.   Manzella,  G.   and  B.W.  Schafer,   Interfering  with  Hedgehog  Pathway:  New  Avenues   for  
Targeted  Therapy  in  Rhabdomyosarcoma.  Curr  Drug  Targets,  2016.  17(11):  p.  1228-­34.  
11.   Gorlin,  R.J.  and  R.W.  Goltz,  Multiple  nevoid  basal-­cell  epithelioma,  jaw  cysts  and  bifid  rib.  
A  syndrome.  N  Engl  J  Med,  1960.  262:  p.  908-­12.  
12.   Gorlin,  R.J.,  Nevoid  basal  cell  carcinoma  (Gorlin)  syndrome:  unanswered   issues.  J  Lab  
Clin  Med,  1999.  134(6):  p.  551-­2.  
13.   Paulson,  V.,  et  al.,  High-­resolution  array  CGH  identifies  common  mechanisms  that  drive  
embryonal   rhabdomyosarcoma   pathogenesis.   Genes   Chromosomes   Cancer,   2011.  
50(6):  p.  397-­408.  
14.   Zibat,   A.,   et   al.,   Activation   of   the   hedgehog   pathway   confers   a   poor   prognosis   in  
embryonal   and   fusion   gene-­negative   alveolar   rhabdomyosarcoma.   Oncogene,   2010.  
29(48):  p.  6323-­30.  
15.   Rubin,   B.P.,   Bioinformatic   mining   of   gene   expression   datasets   identifies   ETV1   as   a  
critical   regulator   of   oncogenesis   in   gastrointestinal   stromal   tumors.   Cancer   Cell,   2010.  
18(5):  p.  407-­8.  
16.   Walter,  D.,  et  al.,  CD133  positive  embryonal  rhabdomyosarcoma  stem-­like  cell  population  
is  enriched  in  rhabdospheres.  PLoS  One,  2011.  6(5):  p.  e19506.  
17.   Satheesha,  S.,   et   al.,  Targeting   hedgehog   signaling   reduces   self-­renewal   in   embryonal  
rhabdomyosarcoma.  Oncogene,  2016.  35(16):  p.  2020-­30.  
18.   Walter,  D.,  et  al.,  CD133  positive  embryonal  rhabdomyosarcoma  stem-­like  cell  population  
is  enriched  in  rhabdospheres.  PLoS  One,  2011.  6(5):  p.  e19506.  
19.   Hahn,  H.,  et  al.,  Rhabdomyosarcomas  and  radiation  hypersensitivity  in  a  mouse  model  of  
Gorlin  syndrome.  Nat  Med,  1998.  4(5):  p.  619-­22.  
20.   Tostar,  U.,  et  al.,  Deregulation  of  the  hedgehog  signalling  pathway:  a  possible  role  for  the  
PTCH  and  SUFU  genes  in  human  rhabdomyoma  and  rhabdomyosarcoma  development.  
J  Pathol,  2006.  208(1):  p.  17-­25.  
21.   Pressey,   J.G.,   et   al.,   Hedgehog   pathway   activity   in   pediatric   embryonal  
rhabdomyosarcoma  and  undifferentiated  sarcoma:  a  report  from  the  Children's  Oncology  
Group.  Pediatr  Blood  Cancer,  2011.  57(6):  p.  930-­8.  
22.   Almazan-­Moga,   A.,   et   al.,   Ligand-­dependent   Hedgehog   pathway   activation   in  
Rhabdomyosarcoma:  the  oncogenic  role  of  the  ligands.  Br  J  Cancer,  2017.  
23.   Bridge,   J.A.,   et   al.,   Novel   genomic   imbalances   in   embryonal   rhabdomyosarcoma  
revealed  by  comparative  genomic  hybridization  and  fluorescence  in  situ  hybridization:  an  
Manuscript 3 
	  113	  
intergroup  rhabdomyosarcoma  study.  Genes,  Chromosomes  and  Cancer,  2000.  27(4):  p.  
337-­344.  
24.   Calzada-­Wack,   J.,   et   al.,   Analysis   of   the   PTCH   coding   region   in   human  
rhabdomyosarcoma.  Hum  Mutat,  2002.  20(3):  p.  233-­4.  
25.   Srivastava,   R.K.,   et   al.,   GLI   inhibitor   GANT-­61   diminishes   embryonal   and   alveolar  
rhabdomyosarcoma  growth  by   inhibiting  Shh/AKT-­mTOR  axis.  Oncotarget,  2014.  5(23):  
p.  12151-­65.  
26.   Graab,  U.,  H.  Hahn,  and  S.  Fulda,  Identification  of  a  novel  synthetic  lethality  of  combined  
inhibition   of   hedgehog   and   PI3K   signaling   in   rhabdomyosarcoma.   Oncotarget,   2015.  











































Figure  1.  Expression  of  Hh  target  genes  in  diagnostic  and  relapse  samples.    
(A)   GLI1,   HHIP   and   PTCH1   mRNA   levels   (2-­DCT)   assessed   by   quantitative   PCR   (qPCR)   in  
diagnostic   (black  bar)  and   relapsed   (blue  bar)  PDX  pairs.  Patient  #1   (diagnostic:  N=1,   relapse:  
N=2),   patient   #2   (diagnostic:   N=2,   relapse:   N=3),   patient   #3   (diagnostic:   N=3,   relapse:   N=3)  
(mean±sd).  (B)  Western  Blot  analysis  showing  GLI1  protein  levels  in  diagnostic  and  relapse  PDX  
samples.  TUBULIN  was  used  as  loading  control.  Relative  protein  quantification  is  shown  for  each  
blot.   (C,   upper   panel)   Expression   levels   (2-­DCT)   of   GLI1,   HHIP   and   PTCH1   in   diagnostic   and  
relapse  primary  cultures  derived  from  patient  #1  assessed  by  qPCR  (mean±sd;;  N=3).   (C,   lower  
panel)   GLI1   protein   levels   assessed   by   western   blot   analysis   in   the   same   samples.   Relative  
protein  quantification   is  also  shown.  TUBULIN  was  used  as   loading  control.   (D)  Assessment  of  
Hh  ligands  (IHH,  DHH  and  SHH)  expression  by  qPCR  in  primary  cultures  (diagnostic  and  relapse  
cells)  derived  from  patient  #1  (mean±sd;;  N=3).  
  
Figure   2.   Chemical   inhibition   of   Hh   signaling   increases   the   activity   of   standard   chemo-­
therapeutics.    
(A)  Protein  levels  analysis  of  GLI1  upon  treatment  with  GANT61  (left  panel)  and  GDC-­0449  (right  
panel)   assessed   by   western   blot.   TUBULIN   was   used   as   loading   control.   Relative   protein  
quantification   is   also   shown.   (B)   Cell   viability   analysis   upon   co-­treatment   of   Hh   antagonists  
(GANT61  and  GDC-­0449)  with  doxorubicin  (left  panel),  actinomycin  (right  panel)  and  vincristine  
(VCR)  (lower  panel)  in  SJRHB011_XC  cells.  Data  are  expressed  as  percentage  (%)  of  living  cells  
relative  to  vehicle  control  (mean±sd;;  N=3-­4).  
  
Figure   3.   Inhibition   of   Hh   signaling   components   by   genetic   means   does   not   influence  
chemo-­sensitivity.  
(A)  Assessment  of  GLI1  or  SUFU  knock-­out  efficiency  in  SJRHB011_XC  cells  transduced  with  a  
lentiCrispr  vector  containing  sgRNAs   targeting  either  GLI1   (sgB_GLI1  and  sgC_GLI1)  or  SUFU  
(sgC_SUFU  and  sgA_SUFU).  A  scramble  sgRNA  sequence  (SC)  was  used  as  negative  control.  
(B)  Hh  target  genes  (GLI1,  HHIP  and  PTCH1)  mRNA  levels  (2-­DCT)  assessed  by  quantitative  PCR  
(qPCR)  in  GLI1  or  SUFU  knock-­out  cells  (mean±sd;;  N=3).  (C)  Cell  viability  assessed  by  WST-­1  in  
SC,  GLI1  and  SUFU  knock-­out  cells.  Each  data  point   is  expressed  as  percentage  of   living  cells  
relative   to  vehicle  control   (mean±sd;;  N=3).   (D)  Dose  response  curve  of  GLI1  and  SUFU  knock-­
out   cells   following   treatment  with   increasing   concentrations  of   either   actinomycin   (left   panel)   or  







Supplemental  Figure  1  (relative  to  Figure  2).    
(A,   B   and   C)   Cell   viability   analysis   upon   co-­treatment   of   Hh   antagonists   (GANT61   and   GDC-­
0449)  with  doxorubicin   (A),   actinomycin   (B)   and   vincristine   (VCR)   (C)   in  RD  cell   line.  Data  are  
expressed  as  percentage  (%)  of  living  cells  relative  to  vehicle  control  (mean±sd;;  N=3).  
  
Supplemental  Figure  2  (relative  to  Figure  3)  
(A)  Assessment  of  GLI1  or  SUFU  knock-­out  efficiency  in  RD  cell  line  transduced  with  a  lentiCrispr  
vector  containing  sgRNAs  targeting  either  GLI1  (sgA_GLI1,  sgB_GLI1  and  sgC_GLI1)  or  SUFU  
(sgA_SUFU  and  sgC_SUFU).  A  scramble  sgRNA  sequence  (SC)  was  used  as  negative  control.  
(B)  Hh  target  genes  (GLI1,  HHIP  and  PTCH1)  mRNA  levels  (2-­DCT)  assessed  by  quantitative  PCR  
(qPCR)   in  GLI1   or   SUFU   knock-­out   cells   (RD)   (mean±sd;;  N=3).   (C)  Cell   viability   assessed   by  
WST-­1  in  SC,  GLI1  and  SUFU  knock-­out  cells  (RD).  Each  data  point  is  expressed  as  percentage  
of   living  cells   relative   to  vehicle  control   (mean±sd;;  N=3).   (D)  Dose   response  curve  of  GLI1  and  
SUFU   knock-­out   cells   (RD)   following   treatment   with   increasing   concentrations   of   either  
actinomycin  (left  panel)  or  vincristine  (right  panel)  (mean±sd;;  N=4).  
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PRIMARY ANTIBODIES
Detected Protein Applications Molecular Weight (kDa) Species Clonality Dilution Catalog Number (#) Company
GLI1 WB 133 Rabbit Polyclonal 1:1000 2534 Cell signaling
SUFU WB 54 Rabbit Monoclonal 1:1000 2522 Cell signaling
-TUBULIN WB 50 Mouse Monoclonal 1:5000 T-9026 Sigma Aldrich
-ACTIN WB 45 Rabbit Monoclonal 1:1000 4970 Cell signaling
SECONDARY ANTIBODIES
Anti-Mouse IgG1 WB 1:2500 7076S Cell signaling






GENE sgRNA sequence (de-PAM-end) Backbone vector used
SCRAMBLE GCACTACCAGAGCTAACTCA pLentiCRISPR-V2 (Addgene, #52961) 
sgA_GLI1 ATCCCACATCCTCAGTCCCG pLentiCRISPR-V2 (Addgene, #52961) 
sgB_GLI1 ACATGCTGGTTGGCAAGTGC pLentiCRISPR-V2 (Addgene, #52961) 
sgC_GLI1 TGTATGAAACTGACTGCCGT pLentiCRISPR-V2 (Addgene, #52961) 
sgA_SUFU CTAACATAGTCCAAGGGGTC pLentiCRISPR-V2 (Addgene, #52961) 
sgC_SUFU AGCCCGTGCAGACACCCTTT pLentiCRISPR-V2 (Addgene, #52961) 
Suppl. Table 2
List of TaqMan®-probe based gene expression assays used in the study.
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Current   treatment   regimens   for   rhabdomyosarcoma   (RMS),   the   most   common   pediatric   soft  
tissue  cancer,  rely  on  conventional  chemotherapy,  and  although  they  show  clinical  benefit,  there  
is   a   significant   risk   of   adverse   side   effects   and   secondary   tumors   later   in   life.   Therefore,  
identifying   and   targeting   sub-­populations   with   higher   tumorigenic   potential   and   self-­renewing  
capacity   would   offer   improved   patient   management   strategies.   Hedgehog   signaling   has   been  
linked  to  the  development  of  embryonal  RMS  (ERMS)  through  mouse  genetics  and  rare  human  
syndromes.   However,   activating   mutations   in   this   pathway   in   sporadic   RMS   are   rare   and  
therefore  the  contribution  of  hedgehog  signaling  to  oncogenesis  remains  unclear.  Here,  we  show  
by  genetic  loss-­  and  gain-­of-­function  experiments  and  the  use  of  clinically  relevant  small  molecule  
modulators  that  hedgehog  signaling  is  important  for  controlling  self-­renewal  of  a  subpopulation  of  
RMS   cells  in   vitro  and   tumor   initiation  in   vivo.   In   addition,   hedgehog   activity   altered  
chemoresistance,   motility   and   differentiation   status.   The   core   stem   cell   gene   NANOG   was  
determined   to   be   important   for   ERMS   self-­renewal,   possibly   acting   downstream   of   hedgehog  
signaling.   Crucially,   evaluating   the   presence   of   a   subpopulation   of   tumor-­propagating   cells   in  
patient  biopsies   identified  by  GLI1  and  NANOG  expression  had  prognostic  significance.  Hence,  
this   work   identifies   novel   functional   aspects   of   hedgehog   signaling   in   ERMS,   redefines   the  
rationale  for  its  targeting  as  means  to  control  ERMS  self-­renewal  and  underscores  the  importance  















Rhabdomyosarcoma   (RMS)   comprises   of   a   heterogeneous   set   of   neoplasms   that   possess  
features   of   halted   skeletal  muscle   differentiation   and   is   the  most   common   pediatric   soft   tissue  
cancer.   The   two   major   histological   subtypes,   embryonal   (ERMS)   and   alveolar,   differ   in   their  
molecular   cytogenetic   profiles,   clinical   presentations   and   prognosis.   ERMS   accounts   for   about  
70%  of  RMS  cases  and  possesses  a   relatively  more  complex  genomic   landscape  with   frequent  
alterations   within   the   RAS   pathway.1,  2,  3  Currently,   pre-­treatment   histology   and   initial   clinical  
presentation  guide  risk  stratification  to  determine  therapy  intensity.  Although  a  majority  of  ERMS  
patients  have  good  prognosis,  clinical  benefit  from  current  treatments  has  reached  a  plateau  and  
prognosis  is  dismal  for  high-­risk  metastatic  ERMS  patients.2  Therefore,  there  is  an  urgent  need  to  
implement   rationally   selected   targeted   treatment   options   to   reduce   rate   of   relapse,   therapy  
burden  and  improve  clinical  outcome.  
Hedgehog  pathway,  a  master  developmental  signaling  system,  is  commonly  activated  in  sporadic  
ERMS.4,  5,  6,  7  Canonical   hedgehog   pathway   is   a   ligand-­activated   signaling   system   with   three  
ligand  variants—Sonic   (SHH),   Indian   (IHH)  and  Desert   hedgehog   (DHH).  The  secreted   ligands  
bind   to   the   extracellular   domain   of   the   Patched   (PTCH)   receptor   leading   to   the   release   of   the  
receptor   Smoothened   (SMO).   SMO   then   translocates   to   the   primary   cilium   to   activate   the  
downstream  signaling  cascade   that   involves  relieving   inhibition  of  Suppressor  of  Fused  (SUFU)  
on  activity  of  the  GLI  transcription  factors.  The  ligands  available  for  activation  can  be  titrated  by  
the   transmembrane   Hedgehog-­interacting   protein   (HHIP).   There   are   three   GLI   transcription  
factors,   of   which   GLI1   is   the  most   potent   transactivator.   Low-­level   gains   in   the   GLI1   genomic  
region   have   been   noted   in  ERMS  patients.5The   expression   of  GLI   target   genes,  which   include  
components  of   the  hedgehog  pathway  such  as  GLI1,  PTCH1  and  HHIP,   can  be  used   to  study  
pathway  activation  status.8,  9  
Recent   data   suggest   that   ERMS   is   a   hierarchically   organized   tumor.10,  11,  12  At   present,   little   is  
known  about   the   pathways   used   to  maintain   self-­renewal   and   tumorigenic   properties   of  ERMS  
tumor-­propagating  cells  (TPCs).  In  the  present  study,  using  small  molecules  and  various  genetic  
approaches,  we   show   that   hedgehog   signaling  modulates  ERMS  TPC   features   of   self-­renewal  
and   tumor   initiation.  We   describe   additional   novel   roles   played   by   this   pathway   in   determining  
ERMS   chemoresistance,   invasion   and   differentiation,   and   identify   NANOG   as   a   functionally  
important  self-­renewal  gene  that  could  be  downstream  of  the  pathway,  previously  unknown  in  any  
soft  tissue  sarcoma.  Importantly,  we  show  that  functional  intra-­tumoral  heterogeneity  identified  by  









Hedgehog  signaling  is  necessary  for  ERMS  self-­renewal  and  efficient  tumorigenesis  
We  analyzed  the  expression  of  hedgehog  pathway  components  in  ERMS  sphere  cultures  that  are  
enriched   in   de-­differentiated,   self-­renewing   and   highly   tumorigenic   cells.11  Quantitative   PCR  
(qPCR)   analysis   revealed   that   the   expression   of   hedgehog   target   genes   was   upregulated   in  
ERMS  spheres  (Figure  1a  and  Supplementary  Figures  1a  and  c)  and  xenografts  from  ERMS  cell  
lines  and  patient-­derived  tumors  (Figure  1b  and  Supplementary  Figures  1d  and  f)  compared  with  
adherent  cultures.  The  addition  of  hedgehog  agonist  SAG1.3  during  primary  sphere  formation  led  
to   enhanced   secondary   sphere   formation   (RD:  +50%  and   RH36:  +170%;;  Figure   1c)   indicating  
that  activating   the  hedgehog  pathway  could   increase  self-­renewal   in  ERMS  cells.  Similarly,   the  
use   of   two   independent   siRNAs   against   SUFU   led   to   significantly   increased   sphere-­initiating  
ability   (Figure   1d  and  Supplementary   Figures   1g   and   i).   To   exclude   any   extraneous   effects   of  
sphere  media  components  on  hedgehog  pathway  activation,  ERMS  adherent  cells  were  treated  
with  SAG1.3  prior  to  plating  in  sphere  media.  Again,  treatment  led  to  a  dose-­dependent  increase  
in   sphere   initiation   without   affecting   cell   cycle   profile   or   viability   (Figure   1e  and  Supplementary  
Figures  1j  and  l). 
We  performed  single  cell  cloning  of  RD  cell   line  that  showed  heterogeneous  expression  of  GLI1  
to   isolate   subpopulations   with   varying   levels   of   hedgehog   pathway   activity.   All   the   29   clones  
analyzed   also   showed   heterogeneous   GLI1   expression   (data   not   shown),   indicating   that   the  
pathway   is   dynamically   controlled.   We   performed   sphere-­initiation   studies   using   two   clones  
(Clones   E8   and   H3)   that   had   fewer   GLI1high  cells   than   bulk   RD   cells   and   Clone   F2   that   was  
enriched   in   GLI1high  cells   (Supplementary   Figures   2a   and   b).   Clone   E8   and   Clone   H3   had  
significantly   lower   spherogenicity   (by  50%  and  40%,   respectively)   and  Clone  F2  had   increased  
sphere-­initiating  capacity  (+30%;;  Supplementary  Figure  2c)  highlighting  that  a  population-­intrinsic  
level  of  hedgehog  signaling  could  determine  self-­renewal  capacity.  
To  study   the  role  of  hedgehog  pathway  activation   in  more  detail,  we  generated  stable  cell   lines  
that  overexpressed  full-­length  GLI1  (pCMV-­GLI1).  At  the  endogenous  level,  we  could  detect  the  
more   stable   shorter   isoform   of  GLI1   (~130  kDa;;  Figure   1f)   reportedly   derived   from   the   160kDa  
full-­length   protein.13  pCMV-­GLI1   cells   showed   an   increased   expression   of   downstream   targets,  
PTCH1  and  HHIP,  compared  with   the  control   (Figure  1f  and  Supplementary  Figures  2d  and  e).  
We  also   found  the  expression  of  PGDFRA,  a  known  hedgehog  target  gene  that  was  previously  
implicated  in  ERMS  biology,14,  15  to  be  increased  (Supplementary  Figures  2d  and  e).  pCMV-­GLI1  
cells  possessed  enhanced  primary  sphere-­forming  and  colony-­forming  abilities   (Figures  1g  and  
h  and  Supplementary   Figure   2f).   When   plated   for   secondary   sphere   formation,   the   relative  
increase   in   sphere-­initiation   capacity   became   more   apparent   (RD:  +87%  and   RH36:  +230%)  
indicating   improved   self-­renewal.   Importantly,   pCMV-­GLI1   cells   displayed   significantly   faster  
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tumor   growth   rate   when   injected   orthotopically   in   NOD/SCID   mice   (Figures   1i   and   j).   The  
xenografts  retained  GLI1  overexpression  (Supplementary  Figure  2g)  and  were  confirmed  to  be  of  
ERMS   histotype   (Supplementary   Figure   3).   Taken   together,   the   active   hedgehog   pathway   in  
ERMS  cells  leads  to  higher  self-­renewal  and  increased  tumor-­initiating  capacity.  
Next,   we   inhibited   the   hedgehog   pathway   both   pharmacologically   and   genetically.   ERMS   cells  
treated  with  SMO  inhibitor  GDC-­0449  or  GLI   inhibitor  GANT61  during  primary  sphere   formation  
showed   decreased   sphere   numbers   (Figure   2a  and  Supplementary   Figure   4a).   GDC-­0449  
treatment   led   to   an   88%  decrease   in   secondary   sphere   formation   for  RD   cells   and  RH36   cells  
showed  no  spheres  formation.  GANT61  treatment  was  more  potent  because  no  viable  cells  were  
available   for   secondary   sphere   formation   from   either   cell   line.   Using   two   independent   siRNAs  
against   GLI1   in   adherent   cells   significantly   decreased   sphere   initiation   (Figure  
2b  and  Supplementary  Figures  4b  and  c).  Next,  cells  were  treated  with   inhibitors  (also   including  
the   SMO   inhibitor   LDE-­225)   under   adherent   conditions   and   then   plated   for   sphere   formation.  
Dose-­dependent   decrease   in   sphere   initiation   was   observed   with   all   drugs   (Figure  
2c  and  Supplementary  Figure  4d).  Treatments  did  not  alter  cell  cycle  profile  or  viability  status  of  
the  cells  (Supplementary  Figures  4e  and  h).  Pre-­treatment  of  RD  cells  with  GANT61  in  vitroled  to  
slower   tumor   initiation  in   vivo  owing   to   reduced   hedgehog   pathway   activity   at   the   time   of  
engraftment  (Figures  2d  and  e  and  Supplementary  Figures  4i–k).  
To   study   the   long-­term   effects   of   inhibition,   we   generated   stable   cell   lines   that   overexpressed  
SUFU  (pCMV-­SUFU)  to  inhibit  GLI  activity  directly  or  expressed  shRNA  against  SMO  (shSMO)  to  
inhibit   the  canonical   ligand-­based  hedgehog  signaling.  Both   inhibitory  systems  led  to  decreased  
target  gene  expression  (Figures  2f  and  g  and  Supplementary  Figures  5a  and  e).  Adherent  colony-­
forming   ability,   sphere   initiation   and   renewal   were   markedly   decreased   by   either   hedgehog-­
inhibition   strategies   (Figures   2h   and   i  and  Supplementary   Figures   5f   and   g).   Although   no  
significant  changes  occurred  in  proliferation  or  cell  cycle  profiles  (Supplementary  Figures  5h  and  
n  and   data   not   shown),   significant   decrease   in   tumor   growth   kinetics   was   observed  in  
vivo  (Figures  2j–m).   Impressively,  RD  cells  showed  no  palpable   tumor  growth   in   the  majority  of  
hedgehog-­inhibited   xenografts   at   the   time  when   the   controls   reached  maximum   allowed   tumor  
volumes.  While   tumor   initiation   rate  was  100%  for   control   cells,  only   three  out  of   five  mice  and  
three   out   of   seven   mice   injected   with   pCMV-­SUFU   and   shSMO   cells,   respectively,   eventually  
developed   tumors.   Taken   together,   the   inhibition   of   hedgehog   pathway   reduces  in   vitro  self-­
renewal  and  in  vivo  tumor  initiation.  
Pathway   activation   seemed   to   be   largely   ligand-­based   because   inhibition   of   either   receptor-­
mediated  or  GLI-­based  hedgehog  signaling  led  to  similar  and  comparable  effects  on  self-­renewal  
and   tumorigenesis.  Accordingly,  we   found   increased  expression  of  hedgehog   ligands  DHH  and  
IHH  in  RH36  spheres  and  xenografts  (Supplementary  Figures  6a  and  c),  and  of  DHH  in  RD  cells  
(Supplementary   Figures   6b   and   d)   compared   with   adherent   cultures.   Also,   patient-­derived  
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xenograft  (PDX)  samples  showed  higher  expression  of  both  (RH70)  or  IHH  ligand  (RH73)  in  vivo  
(Supplementary   Figures   6e   and   f).   DHH   and   IHH   were   also   found   to   be   the   most   commonly  
expressed   hedgehog   ligands   in  ERMS  patient   tumors,  with   on   average   a   higher   expression   of  
DHH  (Supplementary  Figures  6g  and  h).  Surprisingly,  SHH  was  expressed  only   in  a  minority  of  
tumor  biospies  and  not  at  all  in  adherent  cell  lines,  sphere  cultures,  xenografts  or  murine  skeletal  
muscle.  Additionally,  using  species-­specific  qPCR  probes,  we  could  determine  that  ligand-­based  
signaling  was  occurring  in  an  autocrine  manner  with  a  minor  inverse-­paracrine  contribution  from  
the   stroma   within   xenografts   (Supplementary   Figures   6k   and   n).   Therefore,   ligand-­based  
hedgehog  signaling   is   active   in  ERMS  and  seems   to   increase  under   conditions  of   self-­renewal  
and  in  vivo  tumorigenesis  and,  importantly,  is  necessary  for  TPC  functionality.  
  
Hedgehog   signaling   alters   chemoresistance,   differentiation   status   and   cell   motility   of  
ERMS  cells  
TPCs   might   also   be   responsible   for   tumor   recurrence   by   being   more   resistant   to  
chemotherapeutic  treatments.16  To  test  this  notion,  we  treated  our  stable  cells  with  serial  dilutions  
of   irinotecan   or   doxorubicin   that   are   currently   used   in   clinical   management.   We   observed   on  
average  higher  IC50  values  for  pCMV-­GLI1  cells  compared  with  a  control  indicating  that  cells  with  
increased  hedgehog  activity  are  more  resistant  (Table  1).  Conversely,  cells  with  inhibited  pathway  
were   more   sensitive   to   conventional   drugs.   Interestingly,   treatment   of   wild-­type   RD   cells   with  
increasing  doses  of   irinotecan  also  enhanced  sphere-­initiating  capacity,  which  could  be  rescued  
by  combined  treatment  with  hedgehog  inhibitor  LDE-­225  (Supplementary  Figures  7a  and  b).  This  
implies   that   high-­dose   chemotherapy   treatment   currently   used   in   clinical   management   could  
enrich  for  hedgehog-­active  TPCs.  
Next,   we   evaluated   the   effect   of   hedgehog   signaling   on   ERMS   differentiation.   Expression   of  
PAX7   is   highest   in   muscle   stem   cells,   while   committed   muscle   progenitor   cells   express  
MYOGENIN.   Therefore,   expression   of   these   proteins   provides   a   convenient   readout   to   assess  
the  differentiation  status.  Indeed,  the  expression  of  these  markers  was  mutually  exclusive  also  in  
ERMS   cells   indicating   that   the   differentiation   programs   present   during   normal  myogenesis   are  
also  active   in   the  pathological  state  (Figure  3a  and  Supplementary  Figure  7c).  pCMV-­GLI1  cells  
possessed   increased   PAX7+  cells   and   concomitantly   fewer   MYOGENIN+  cells   (Figures   3a–
c  and  Supplementary   Figure   7c),   whereas   inhibition   of   the   pathway   induced   differentiation   as  
evidenced   by   a   reduction   in   the   percentage   of   PAX7+  and   gain   in   MYOGENIN+  cells   (Figures  
3a  and  Supplementary   Figures   7d   and   e).   Treatment   with   small   molecule   modulators   induced  
similar   alterations   in   the   differentiation   status   (Supplementary   Figures   7f   and   i).   Furthermore,  
significant   increase  in  the  expression  of  terminal  muscle  differentiation  markers  CKM  and  MYL1  
was   noted   upon   long-­term   treatment   with   GANT61   (Supplementary   Figure   7j).   These   data  
suggest   that  activation  of  hedgehog  signaling  confers  a  more  stem-­like  state,  whereas  pathway  
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inhibition   induces  differentiation.  We  could  not   find  significant  co-­localization  of  PAX7  and  GLI1  
expression   (data   not   shown)   indicating   that   PAX7  may   not   be   a   direct   target   of  GLI1.   Rather,  
hedgehog   pathway   activation   might   induce   de-­differentiation   by   reducing   the   transcriptional  
activity  of  pro-­differentiation  muscle  regulatory  factors.17  
A  previous  study  evaluating  in  vivo  tumor  heterogeneity   in  a  zebrafish  model  of  ERMS  reported  
that   the   Myogenin-­expressing   (differentiated)   compartment   had   higher  
invasiveness.12  Concordantly,   we   observed   that   the   hedgehog-­inhibited   cells   possessed  
increased  ECM   invasion   capacity   (Figures   3f   and   g  and  Supplementary   Figure   8a).   This   effect  
was  cell   autonomous  because  coating   the  membrane   filter  with  gelatin  did  not  alter   the   results  
(Supplementary   Figure   8a).   Surprisingly,   in   the   absence   of   a   basement  membrane  matrix,   the  
differentiated  cells  had  much  lower  migratory  ability  (Figures  3h  and  i  and  Supplementary  Figure  
8b),   indicating  that  matrix  adhesion  probably  has  an  important  role  in  determining  cell  motility   in  
ERMS.  
  
NANOG  is  functionally  important  for  ERMS  self-­renewal  
To   identify  genes   that  could  be   regulated  by   the  hedgehog  pathway   in  ERMS  cells,  we  used  a  
stem   cell-­focused   qPCR-­based   screening   approach   interrogating   162   genes   associated   with  
developmental   pathways   and   the   stem   cell   phenotype.   We   found   147   genes   to   be   reliably  
expressed   (Ct   value<35),   of   which   142   were   common   to   both   cell   lines.   Non-­supervised  
hierarchical   clustering   identified   genes   either   positively   or   negatively   modulated   by   hedgehog  
signaling   (Figure   3j).   In   general,   we   found   more   genes   to   be   negatively   regulated   by   the  
hedgehog  signaling  and  among  them  were  several  components  of  TGF-­β,  Wnt  and  Notch  (in  RD  
cells;;  data  not  shown)  signaling  pathways.  Interestingly,  expression  of  the  stem  cell  transcription  
factor   NANOG   was   positively   regulated   by   the   hedgehog   pathway   in   both   ERMS   cell   lines  
studied.   NANOG   is   a   homeodomain-­containing   transcription   factor   essential   for   establishing  
pluripotency18  with  a  known  function  in  TPC  maintenance  in  many  adult  cancers.19  It  has  already  
been  characterized  as  a  GLI  target  gene  in  neural  stem  cells,  medulloblastoma  and  glioblastoma  
neurospheres.20,  21  Therefore,  we  chose  to  further  study  its  role  in  ERMS.  
First,  we  confirmed  alterations  in  NANOG  expression  noted  in  the  screen  on  additional  samples  
(Supplementary   Figures   9a   and   d).   Next,   ERMS   cells   were   co-­immunostained   for   GLI1   and  
NANOG.  The  expression  of  both  proteins  was  found  to  be  heterogeneous  and  strictly  co-­localized  
in   both   cell   lines   and   primary   cells   from   three   PDX   samples   (Figure   4a  and  Supplementary  
Figures  9e  and  f).  Upon  GLI1  overexpression  or  SAG1.3  treatment,   the  percentage  of  NANOG-­
expressing  cells  increased  significantly  (Figures  4b  and  c  and  Supplementary  Figures  10a  and  c).  
NANOG   expression   was   higher   in   sphere   cultures   and   xenografts   than   adherent   cultures  
(Supplementary  Figures  10d  and  g).  These  data  indicate  that  NANOG  expression  correlates  with  
hedgehog  pathway  activity,  both   in  ERMS  cells  and  patient  samples,   implying  that   it  could  be  a  
target  gene  of  the  pathway  in  ERMS  similar  to  observations  in  other  cancers.  
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We  also  reduced  NANOG  expression  in  RD  cells  using  transient  and  stable  genetic  means  and  
both  approaches  led  to  decreased  sphere  formation  (Figures  4d  and  e).  Transient  overexpression  
of  NANOG  significantly  improved  spherogenicity  (Figures  4f  and  g).  Importantly,  ectopic  NANOG  
expression  in  hedgehog-­inhibited  cells  rescued  the  lowered  self-­renewal  ability  back  to  the  level  
of  controls,   indicating   that  NANOG  could  act  epistatic   to  hedgehog  pathway  (Figures  4f  and  g).  
We  also  noted  that  alteration  in  NANOG  expression  led  to  a  concordant  change  in  the  expression  
of  GLI1   (Supplementary  Figures  11a  and  c),  which  could  be  either  due   to   the  effect  on  overall  
proportion  of  ERMS  stem  cell-­like  population  marked  by  GLI1  expression  or  the  direct  modulation  
of   GLI1   expression   as   previously   reported   in   brain   cancers.21  Interestingly   the   expression   of  
PDGFRA   was   also   decreased   upon   NANOG   knockdown   (Supplementary   Figure   11a).   To  
evaluate   the   role   of   NANOG   on   self-­renewal   and   tumor   growth   independently,   we   generated  
stable   rescue   lines   where   NANOG   expression   was   decreased   in   GLI1   overexpressing   cells  
(GLI1+shNANOG)  and  corresponding  empty  vector  (pCMV+pLKO.1)  or  GLI1  overexpression  only  
controls   (GLI1+pLKO.1)   (Supplementary  Figures  11d  and  e).  When  both  RD  and  RH36   rescue  
systems  were  allowed  to  form  spheres,  secondary  sphere  formation  was  increased  significantly  in  
the   GLI1+pLKO.1   cells   for   both   cell   lines   (RD:  +108%  and   RH36:  +59%)   and   impressively,  
NANOG  knockdown  rescued  it  back  to  almost  control  levels  (Figures  4h  and  i).  Additionally,  the  in  
vivo  tumor  growth  rate  of  GLI1+shNANOG  cells  was  significantly  lower  than  control  cells  (Figure  
4j  and  Supplementary   Figures   11f   and   g).   Taken   together,   NANOG   emerges   as   a   functionally  
important   gene   for   TPC   properties   in   ERMS   that   could   act   downstream   of   the   hedgehog  
signaling.  
  
GLI1  and  NANOG  expression  has  prognostic  value  for  ERMS  patients  
Finally,  we  evaluated  whether   the  expression  of  GLI1  and  NANOG  is  clinically   relevant.  To   this  
end,   we   performed   a   double-­blind   analysis   of   GLI1   and   NANOG   expression   in   a   previously  
described   set   of   tissue   microarrays   (TMA)   with   multiple   tumor   cores   from   116   ERMS   patient  
samples   using   immunohistochemistry.22Reliable   protein   expression   status   was   obtained   for   91  
patients,  most  of  whom  were  negative  for  both  proteins.  However,  patients  positive  for  one  were  
in  80%  of  the  cases  also  positive  for  the  other.  We  observed  that  only  tumor  cells  expressed  GLI1  
and  NANOG  and,  importantly,  the  expression  was  heterogeneous  as  seen  in  cell  cultures  (Figure  
5a  and  Supplementary  Figure  11h).  Correlation  with  clinical  data  revealed  that  the  expression  of  
GLI1  alone  could  predict  significantly  worse  overall  survival  and  a  similar  trend  was  observed  for  
NANOG  status  (Figures  5b  and  c).  These  patients  also  tended  to  have  worse  event-­free  survival  
although   the   data   did   not   reach   statistical   significance   (Supplementary   Figures   11i   and   j).  
Importantly,  it  was  only  when  the  patients  were  distinguished  based  on  the  presence  of  GLI1+  and  
NANOG+  cellular   sub-­populations   within   their   tumors   that   we   observed   statistically   significant  
worse  event-­free  and  overall  survival  (Figures  5d  and  e).  The  distribution  of  patient-­  and  tumor-­
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related   parameters   was   similar   among   patient   subgroups.   Chi-­square   tests   revealed   no  
significant   differences   between   the   groups   (data   not   shown).  Owing   to   low   patient   numbers,   it  
was   not   possible   to   assess   whether   GLI1   and/or   NANOG   expression   could   be   used   as  
independent   prognostic   markers.   Nevertheless,   our   analysis   reveals   that   intra-­tumoral  
heterogeneity  represented  by  the  expression  of  both  GLI1  and  NANOG  can  help  identify  a  subset  
of  ERMS  patients  with  worse  outcome  and  therefore  is  clinically  relevant.  
  
Discussion  
Although  previous  studies  have  identified  hedgehog  signaling  as  a  clinically  relevant  pathway  in  
ERMS,4,  5  its  functional  role  in  ERMS  pathology  and  particularly  its  contribution  to  the  hierarchical  
organization  seen   in  ERMS  has  not  been   investigated.  Here,  we  show   that  hedgehog  pathway  
activity  is  an  important  determinant  of  ERMS  ‘stemness’  features  such  as  self-­renewal  and  tumor  
initiation,   as   previously   shown   for   other   malignancies.23  Therefore,   clinical   strategies   for   using  
hedgehog   inhibitors   in   ERMS   would   need   to   accommodate   the   conceptual   implications   of   the  
cancer  stem  cell  model.24,  25  For   instance,  tumor  regression  may  not  be  an  appropriate  endpoint  
to   estimate   treatment   efficacy,   because   the   effect   of   hedgehog   pathway  modulation   on   ERMS  
pathology  was  not  due  to  changes  in  cell  cycle,  cell  viability  or  proliferation.  
Pathway  activation   seems   to  be  occurring  primarily   by  autocrine   secretion  of   IHH   and/or  DHH.  
This  is  in  line  with  an  earlier  study  ruling  out  SHH  autocrine  signaling  in  ERMS  patients.6  Pathway  
inhibition  was  effective  at   the   level  of  SMO  as  well  as  of  GLI,  which  could  avoid  emergence  of  
cross  talks  converging  on  the  GLI-­code  and  resistance  mechanisms  in  the  clinics.9  Furthermore,  
we   found   that   modulating   the   pathway   can   alter   sensitivity   to   generic   drugs.   Therefore,  
combination   therapy  with   hedgehog   inhibitors  might   allow   the   usage   of   lowered   drug   doses   to  
reduce  treatment-­related  morbidity.  
Interestingly,   our   work   suggests   novel   negative   feedback   mechanisms   between   hedgehog  
signaling  and  key  muscle  differentiation  pathways,  Wnt,  Notch  and  TGFβ.26,  27,  28  Previous  reports  
show   that   inhibition   of   Notch   and   TGFβ   and   activation   of   Wnt   could   lead   to   ERMS  
differentiation.7,  29,  30  Interestingly,   activation   of   the   Wnt   pathway   induced   differentiation   and  
reduced  tumor  initiation  in  a  RAS-­driven  zebrafish  ERMS  model.  The  authors  also  identified  the  
hedgehog   inhibitor   cyclopamine   as   one   of   the   top   drug   candidates   from   a   large-­scale   small  
molecular   screen   that   could   differentiate   ERMS   cells   and   reduce   tumor   growth  in   vivo.31  This  
study   supports   our   findings   and   further   highlights   crosstalk   between   ‘stemness’   pathways   that  
could  define  ERMS  TPC  behavior.  However,  the  more  differentiated  compartments  are  also  likely  
to  have  important  roles  in  tumor  progression  (this  study  and  Ignatius  et  al.12).  
Previously,   PTCH1   mRNA   expression   in   ERMS   patients   was   shown   to   predict   poor  
outcome.4  Although   PTCH1  mRNA   expression   correlates   significantly   with   that   of   GLI1  mRNA  
(data  not  shown  and  Zibat  et  al.4),  PTCH1  provides  negative  feedback  cues  into  the  pathway  that  
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could   obscure   the   final   outcome   on   cellular   self-­renewal.   Hence,   PTCH1   protein   expression  
status   may   not   be   a   reliable   predictor   of   prognosis.   We   reported   that   ERMS   patients   with  
CD133high  expression   have   poor   overall   survival,11  but   the   functional   role   of   CD133   protein   is  
currently  unclear.  Also,  the  impact  of  other  potential  ERMS  TPCs  markers  (FGFR3  (ref.  32)  and  
MYF5   (ref.  12)  on  prognosis   is  unknown.  We   identify  NANOG  as  a   functionally   important  gene  
whose   expression   along  with  GLI1   could   serve   as   novel   prognostic   indicators.   Importantly,   we  
detected  clear  GLI1-­NANOG  co-­localization  in  ERMS  PDX  cells.  However,  we  were  unable  to  do  
so   on   the   TMA   tumor   cores   owing   to   the   lack   of   serial   sections.   Interestingly,   we   observed  
heterogeneous  expression  of  GLI1  and  NANOG  also  within  alveolar  RMS  patient  tumor  cores  but  
without   prognostic   significance   (data   not   shown).   Therefore,   the   GLI1-­NANOG   TPC   marking  
could  be  important  specifically  for  ERMS  patient  stratification  and  further  highlights  the  biological  
disparity  between  the  two  RMS  variants.  
Expression   of   transcription   factors   important   for   development   of   neural   crest-­derived  
mesenchymal   and   neural   tissues,   namely   PAX6,   PITX2   and   LMX1B,33,  34,  35were   positively  
regulated   by   the   hedgehog   pathway,   whereas   myogenic   differentiation   factors   were  
downregulated.   Therefore,   GLI1-­NANOGhigh  ERMS   cells   could   possess   a   pre-­myogenic  
multipotent   phenotype   reminiscent   of   neural   crest   or   non-­myogenic   origin   for   ERMS.   This   is  
concordant  with   recent  observations   in  hedgehog-­activated  mouse  models,  wherein  ERMS   ‘cell  
of  origin’  was  determined   to  be   from  either  pre-­somitic  or  non-­muscle  mesenchyme.36,  37  ERMS  
cells  expressing  other  potential  TPC  markers  have  been  described  to  be  restricted  to  the  skeletal  
muscle   lineage.10,  32,  38  It   is   therefore   possible   that   different   ERMS   TPC   subpopulations   with  
varying   differentiation   potentials   are   concomitantly   present   within   tumors.   The   hierarchical  
relationship   between   these   potential   compartments   and   their   relative   importance   for   ERMS  
tumorigenicity  is  yet  to  be  determined  and  warrants  further  research.  
It  is  likely  that  the  hedgehog-­active  TPC  phenotype  is  a  widespread  feature  because  activation  of  
RAS   signaling   is   common   in  ERMS1,  3  and   is   known   to   have   a   positive   influence  on   hedgehog  
signaling.39  Interestingly,  also,   the   loss  of  p53  can   increase  GLI-­NANOG  signaling   in  stem  cells  
and   TPCs   of   neural   origin.20,  21  The   cell   lines   used   in   this   study   represent   these   genetic  
backgrounds  (RD:  NRASQ61H;;  p53R248Vand  RH36:  HRASQ61K).  Hence,  hedgehog-­driven  targeting  
could  be  of  broad  interest  in  sporadic  ERMS.  Our  study  highlights  that  phenotypic  and  functional  
tumor   heterogeneity   could   have   significance   for   clinical   management   of   ERMS   patients   and  








Materials  and  Methods  
Patient-­derived  samples  
Early  passages  of  ERMS  PDX  samples  RH70  (SJRHB011_Y),  RH72  (SJRHB013_X)  and  RH73  
(SJRHB011_X)  were  obtained  from  St.  Jude  Children’s  Research  Hospital  (USA)  and  previously  
described   in  detail   in.1  All  patient   tissue  specimens  used  only   for  RNA  extraction  were  obtained  
from   the   Swiss   Pediatric  Oncology  Group   (SPOG)   Tumor   Bank   except   ZH_ERMS,   which  was  
obtained  from  the  Department  of  Pathology,  University  Hospital  Zurich.  The  use  of  SPOG  Tumor  
Bank  tissue  samples  was  approved  by  the  Ethical  Review  Board  of  Zurich  (Ref.  No.  StV-­18/02).  
Written  informed  consent  was  obtained  from  each  patient  by  the  hospital  that  provided  the  tissue  
samples.  The  TMA  used  in  this  study  included  multiple  tumor  cores  from  149  RMS  patients  (116  
ERMS  and  33  alveolar  RMS)  enrolled  in  the  German  soft-­tissue  sarcoma  group  (CWS)  studies  -­
81,  -­86,  -­91  and  -­96  as  previously  described.22  
  
Orthotopic  xenograft  generation  
RD  (3  ×  105cells/mouse)  or  RH36  (2.5  ×  105cells/mouse)  were  injected  into  the  femoral  muscles  
of   one   leg   of   4–6-­week-­old   NOD.CB17-­Prkdcscid  mice   (NOD/SCID;;   Jackson   Laboratory,   Bar  
Harbor,  ME,  USA).  Animals  were  chosen  from  either  sex  and  were  assigned  randomly  to  different  
groups.   Once   tumor   was   palpable,   size   was   determined   every   4   days   by   measuring   two  
diameters  (d1  and  d2)  in  right  angles  of  both  legs  with  a  Vernier  caliper  until   tumors  reached  the  
maximum  allowed  volume  of  1000  cm3  or  followed  for  120  days.  Tumor  volumes  were  calculated  
using  the  following  formula:  V=[4/3  x  π  x  1/2(d1+d2)]injected  leg−[4/3  x  π  x  1/2(d1+d2)]control  leg.  
For   PDX   generation,   dissociated   cells   were   resuspended   in   matrigel   (Corning,   Amsterdam,  
Netherlands)  at  1  ×  104  cells/μl  and  100  μl  was  injected  as  described  above.  
Freshly  isolated  xenografts  were  stored  in  RNAlater  (Ambion,  Huntingdon,  Cambridgeshire,  UK)  
for  RNA  extraction,  snap-­frozen  in  liquid  N2  for  protein  extraction  or  fixed  in  4%  paraformaldehyde  
for   imunohistochemistry.   The   experiments   were   conducted   in   a   non-­blind   manner   and  
approved  by  the  veterinary  office  of  Canton  Zurich.  
  
Tumor  dissociation  
PDX  samples  were  minced  with  scalpels  and  digested  using  Liberase  DH  (0.62  WU/ml;;  Roche,  
Rotkreuz,  Switzerland)   in  buffer  containing  1  ×  HBSS,  10  mM  HEPES,  200  U/ml  DNase  (Roche)  
and   1  mM  MgCl2,   at   37  °C   for   70  min.   The   cells   were   pelleted,   resuspended   in   Dulbecco's  
modified  Eagle's  media  +10%  fetal   bovine  serum  and  passed   through  a   cell   strainer   to   remove  




Cell  culture  and  treatments  
Human  ERMS  cell  lines  RD  (ATCC,  Manassas,  VA,  USA),  RH36,  RH18  (both  kindly  provided  by  
Peter  Houghton,  St.  Jude’s  Children’s  Hospital,  USA)  and  TTC442  (kindly  provided  by  Timothy  J.  
Triche,   Children’s   Hospital   Los   Angeles,   USA)   were   cultured   in   Dulbecco's   modified   Eagle's  
media   supplemented   with   10%  fetal   bovine   serum,   2  mM  L-­glutamine   and   100  U/ml   penicillin-­
streptomycin.   Sphere   cultures   were   maintained   as   previously   described.11  The   cell   lines   were  
authenticated   by   short   tandem   repeat   analysis   and   regularly   checked   for   mycoplasma  
contamination.   For   sphere   formation,   equal   numbers   of   cells   were   plated   at   clonal   density   in  
Ultra-­Low   attachment   plates   (Corning).   Primary   spheres   were   dissociated   using   Accutase  
(Sigma-­Aldrich,   Buchs,   Switzerland)   and   stained   with   Trypan   Blue   solution   (Sigma-­Aldrich)   for  
counting.  Equal  numbers  of  viable  sphere  cells  were  plated  for  secondary  sphere  formation.  For  
single   cell   cloning,   RD   cells   were   plated   in   96-­well   plates   in   stringent   single   cell   dilution  
(0.5  cell/well)   in   normal   adherent   culture   media.   After   16   h,   the   wells   with   single   cells   were  
marked   and   followed   for   viable   colony   formation.  Upon   reaching   confluency,   the   cultures  were  
propagated  in  larger  plate  formats.  Drugs  used  included  SMO  inhibitors  GDC-­0449  and  LDE-­225  
(Selleck,  Munich,  Germany),  GLI  inhibitor  GANT61  (Tocris,  Bristol,  UK)  and  GLI  activator  SAG1.3  
(Calbiochem,  San  Diego,  CA,  USA).  For  IC50  measurements  of  irinotecan  (SN-­38;;  Sigma-­Aldrich)  
and   doxorubicin   (Sandoz,  Rotkreuz,   Switzerland),   cells   were   plated   in   quadruplicate   in   96-­well  
plates   and   treated   with   five-­step   serial   dilutions   for   72  h   in   10%  fetal   bovine   serum   media.  




Adherent  cells  were  transfected  with  Silencer  select  siRNAs  (Ambion,  Life  technologies)  against  
GLI1  (#1:  s5814;;  #2:  s5816),  SUFU  (#1:  s28520;;  #2:  s28521),  NANOG  (#1:  s36649;;  #2:  s36650)  
or   scrambled   control   (Silencer  Negative  Control#  2)   using   Lipofectamine  RNAiMAX   (Invitrogen,  
Zug,   Switzerland)   at   a   final   concentration   of   10  nM.   Sphere   growth   was   initiated   24  h   post  
transfection.  
  
Cell  viability,  proliferation  and  clonogenic  assays  
To  assess  cell  viability  and  proliferation,  cells  were  plated  in  quadruplicate  per  condition  in  96-­well  
plates.   After   treatment,   viability   was   measured   using   WST-­1   (Roche).   Cell   proliferation   was  
measured   24   h   post   plating   using   Cell   Proliferation   ELISA,   BrdU   (chemiluminescent)   assay  
(Roche).  Clonogenic  assay  was  performed  as  described  by  Franken  et   al.40  In   brief,   cells  were  
seeded  in  dilution  of  1  cell/μl  in  six-­well  plates  in  normal  culture  media.  Media  was  changed  every  
3   days   until   colonies   (>50   cells)   were   visible.   Cells   were   fixed   and   stained   using   with   Crystal  
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Violet   staining   solution   (0.5%  Crystal   Violet   and   6%  gluteraldehye   in   water).   Colonies   were  
quantified  using  ImageJ  software  (version  1.47).  
  
Quantitative  PCR  
Normal   human   skeletal   muscle   pooled   RNA   lysate,   referred   to   as   AdSkM_P,   from   five   adults  
(R1234171_P)   and   individual   RNA   lysates   from   three   fetal   donors   (R1244171;;   Lot  #  A503105,  
B505186,   A508111)   were   purchased   from   (Amsbio,   Lugano,   Switzerland).   Total   RNA   was  
extracted   using  RNeasy  Mini  Kit   (Qiagen,  Basel,  Switzerland)  with  RNase-­free  DNase.  Normal  
murine   muscle   RNA   was   extracted   from   femoral   muscle   of   NOD/SCID   mice.   Complementary  
DNA   synthesis   was   carried   out   using   High-­Capacity   cDNA   Reverse   Transcription   kit   (Life  
Technologies,   Zug,   Switzerland).   QPCR   was   performed   using   Taqman   mastermix   and   Gene  
Expression  Assays  (Life  Technologies;;  assay  IDs  are  listed  in  Supplementary  Table  1).  Absolute  
and  relative  expression  levels  were  calculated  using  the  ΔΔCt  method  and  normalized  to  HMBS  
(unless   otherwise   specified)   or   GAPDH.   For   screening,   RT2  Profiler   PCR   Arrays   (Stem   Cell  
Signaling   (PAHS-­047ZE)   and  Stem  Cell   Transcription  Factors   (PAHS-­501ZE))  were   purchased  
from  Qiagen.  Data  analysis  was  performed  using  the  RT2  Profiler  PCR  Array  Analysis  web-­based  
software  (version  3.5).  Non-­supervised  hierarchical  clustering  was  performed  using  by  dChip.  
  
Western  blotting  and  immunofluorescence  
Total  protein  was  extracted  using  RIPA  buffer  (50  mM  Tris-­Cl,  pH  6.8,  100  mM  NaCl,  1%  Triton  X-­
100,  0.1%  SDS)  supplemented  with  Complete  Mini  Protease  Inhibitor  Cocktail  (Roche).  Proteins  
were   separated   using   NuPAGE   gradient   SDS–PAGE   pre-­cast   gels   (Life   Technologies)   and  
detected   by   chemiluminescence   using   Amersham   ECL   Detection   reagent   (GE   Healthcare,  
Glattbrugg,   Switzerland)   or   SuperSignal   West   Femto   Maximum   Sensitivity   Substrate   (Thermo  
Scientific,   St   Leon-­Rot,   Germany).   For   immunofluorescence,   cells   were   fixed   with  
4%  paraformaldehyde  and  incubated  over  night  at  4  °C  with  primary  antibodies.  All  the  antibodies  
and  further  details  are  listed  in  Supplementary  Table  2.  
  
TMA  scoring  and  data  analysis  
TMA  was  evaluated  by  a  senior  pathologist  (PB).  A  minimum  of  two  desmin-­positive  intact  cores  
was   required   for   the   patient   to   be   included   in   the   analysis.   At   least   three   stained   cells   were  
required   to   label   a   patient   as   positive.   Tumors   from   91   ERMS   and   23   alveolar   RMS   patients  
provided  reliable  GLI1  and  NANOG  expression  status.  Clinical  data  were  analyzed  independently  
by  CWS  study  member  (SF)  who  was  blind  to  the  hypothesis.  Statistical  analysis  was  performed  
using  SPSS  software  (version  21,  (IBM,  Armonk,  NY,  USA))  based  on  all  data  available  up  to  the  





Data   were   analyzed   using   GraphPad   Prism   (version   4.03).   Significance   was   calculated   using  
Student’s  t-­test  (unpaired,  two-­tailed),  and  if  the  variance  was  found  to  be  significantly  different  by  
F-­test,   then   Welch’s   correction   was   used.   Normal   distribution   of   data   was   assessed   using  
D’Agostino   and   Pearson   normality   test.   Mann–Whitney   test   was   used   to   assess   significance  
when  data  were  non-­parametric.  Tumor  growth  curves  were  compared  using  two-­way  analysis  of  
variance  with  Bonferroni  post  hoc  tests.  Only  animals  that  showed  tumor  growth  were  included  in  
the   final   analysis.  P<0.05  was   considered   significant.   The   total   sample   size   (‘n’)   and   biological  
replicates  (‘N’)  per  condition  per  experiment  are  indicated  in  the  figure  legends.  Each  experiment  
was   replicated   at   least   twice.   Data   are   represented   as   mean   with   s.d.   as   error   bars   unless  
otherwise  mentioned.  No  power  analysis  was  used  to  pre-­determine  sample  size.  
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Activation   of   hedgehog   signaling   increases   self-­renewal   and   tumorigenicity   of   ERMS   cells.   (a)  
Left   panel:   Expression   levels   of   hedgehog   signaling   components   in   RD   spheres   (n=6;;   N=2)  
compared  with  adherent  monolayer  cultures  (n=9;;  N=3)  by  quantitative  PCR  (Log10  scale).  Right  
panel:  Western  Blot  anaysis  showing  expression  of  indicated  proteins  in  RD  adherent  and  sphere  
cells.  (b)  GLI1  RNA  expression  levels  (relative  to  HMBS)  in  patient-­derived  samples  when  grown  
as  xenografts   (‘in  vivo’;;  n=6,  N=2)  or  dissociated  and  cultured  as  adherent  cells   (‘in  vitro’;;  n=6,  
N=2)  determined  by  qPCR.   (c)  Sphere-­initiation   capacity  of  ERMS  cells   treated  with  hedgehog  
agonist   SAG1.3   (500   nM)   every   48   h   (three   rounds)   during   primary   sphere   formation   and  
thereafter  plated  for  secondary  sphere  formation  in  normal  sphere  media  (n  =9;;  N=3).  (d)  Sphere  
formation  after  siRNA-­mediated  knockdown  of  SUFU  (10  nM)  in  RD  adherent  cells  compared  with  
scrambled  control  siRNA  (N=2).  (e)  Sphere  formation  following  48  h  treatment  of  ERMS  adherent  
cultures  with  SAG1.3  (n=5;;  N  =5).  (f)  Western  blot  analysis  of  indicated  proteins  in  ERMS  stable  
cell   lines.  Primary  (1°)  and  secondary  (2°)  sphere  formation  measured   in  ERMS  stable   lines  (g:  
RD;;   N=3   and   h:   RH36;;   N   =3).   (i)   Tumor   growth   rate   of   RD-­based   stable   lines   pCMV-­Empty  
(n=6/6)  and  pCMV-­GLI1  (n=5/5)  injected  orthotopically  in  NOD/SCID  mice.  (j)  Tumor  growth  rate  
of  RH36-­based  stable  lines  pCMV-­Empty  (n=2/6)  and  pCMV-­GLI1  (n=4/6)  injected  orthotopically  
in   NOD/SCID  mice.   Error   bars   in   i   and   j   represent   s.e.m.   Each   data   point   in   the   scatter   plots  
represents  a   technical   replicate  with   the   line  drawn  at   the  mean.   In  bar  graphs,  data   represent  
mean  ±s.d.  *Po0.05;;  **Po0.01;;  ***Po0.001;;  ****Po0.0001.  FL,  full-­length.  
  
Figure  2  
Inhibition   of   hedgehog   signaling   decreases   self-­renewal   and   tumorigenicity   of   ERMS   cells.   (a)  
Sphere-­initiation   capacity   of   RD   cells   treated   with   small-­molecule   inhibitors   GDC-­0449   or  
GANT61   every   48   h   (three   rounds)   during   primary   sphere   formation   and   further   plated   for  
secondary   sphere   formation   in   normal   sphere   media   (n=9;;   N=   3).   §   No   viable   cells   were  
recovered   for  secondary  sphere   formation.   (b)  Sphere   formation  measured   following  siRNA  (10  
nM)  mediated  GLI1  knockdown   in  RD  adherent  cells   (n=6;;  N=2).   (c)  Sphere-­formation  ability  of  
RD  adherent  cells  after  48  h  treatment  with  hedgehog  inhibitors  (n=12,  N  =6  for  GDC-­0449  and  
GANT61;;  n=6,  N=2   for  LDE-­225).  Tumor  growth   rate   (d)  and   tumor  weight   (e)  of  RD  cells  pre-­
treated   in   vitro   with   GANT61   (3μM)   (n=5   per   condition).   Western   blot   analysis   of   indicated  
proteins   in   stable   ERMS   lines   overexpressing   tagged   SUFU   (f;;   Myc-­DDK)   and   knockdown   of  
SMO  (g).  Primary  (1°)  and  secondary  (2°)  sphere  formation  measured  in  ERMS  stable  lines  (h:  N  
=2   per   cell   line;;   i:   N=2-­4   per   cell   line   except   2°   sphere   formation).   Tumor   growth   kinetics   of  
hedgehog  inhibited  pCMV-­SUFU  (j:  RD;;  n=3/5  and  k:  RH36;;  n=3/6)  and  control  pCMV-­Empty  (j:  
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RD,   n=5/5   and   k:  RH36,   n=2/6)   cells   in  NOD/  SCID  mice.   Tumor   growth   kinetics   of   hedgehog  
inhibited   shSMO   (l:  RD,   n=3/7   and  m:  RH36,   n=6/7)   and   control   pLKO.1   (l:  RD,   n=7/7   and  m:  
RH36,   n=7/7)   cells   in  NOD/SCID  mice.  Error   bars   in   d,   e,   j–m   represent   s.e.m.   In   bar   graphs,  
data  represent  mean±s.d.  *Po0.05;;  **Po0.01;;  ***Po0.001.  
  
Figure  3  
Hedgehog  signaling  alters  the  differentiation  status  and  motility  of  ERMS  cells.  (a)  Representative  
images  of  RD  cells  stained  for  PAX7  and  MYOGENIN  expression.  All  images  were  taken  at  ×  400  
magnification.  Scale  bar   represents  20  μm.   (b  and  d)  Quantification  of  percentage  of  PAX7-­  or  
MYOGENIN-­positive  RD  cells  normalized  to  DAPI-­stained  nuclei  counted  per  viewing  field,  using  
ImageJ  (n=4).  (c  and  e)  Quantification  of  PAX7-­  or  MYOGENIN-­positive  RH36  cells  (n=5).  (f  and  
g)   Total   number   of  RD   cells   that   could   invade   through  matrigel-­coated   porous  membrane   filter  
towards  a  growth  serum  gradient  over  48  h  (n  =3;;  N=3).  (h  and  i)  Relative  migration  of  RD  cells  
across  porous  membrane  filter  towards  a  growth  serum  gradient  over  48  h  (n=15;;  N=3).  (j)  Non-­
supervised  hierarchical  clustering  of  genes  positively  and  negatively  regulated  by  the  hedgehog  
pathway   common   to   both  RD   and  RH36   cell   lines.   Each   column   represents   the   average  RNA  
expression   fold   change   for   the   labelled   genes   within   the   hedgehog-­modulated   stable   cell   line  
made   relative   to   its   respective  empty  vector  control   (n=2;;  N=2).   *Po0.05,   **Po0.01,   ***Po0.001.  
Data  represent  mean±s.d.  
  
Figure  4  
Nanog  is  a  functionally  important  target  gene  of  hedgehog  pathway  in  ERMS.  (a)  Representative  
images  of  RD  cells  co-­stained  for  GLI1  and  NANOG  expression.  All  images  were  taken  at  ×  400  
magnification.  Scale  bar  represents  20  μm.  Quantification,  using  ImageJ,  of  NANOG-­expressing  
cellular  compartments  normalized  to  DAPI-­stained  nuclei  per  viewing  field   in  ERMS  stable   lines  
(b;;  N=2)  and  RD  cells  treated  with  SAG1.3  (500  nM)  for  48  h  (c;;  N=2).  (d)  Sphere  formation  in  RD  
cells   with   stable   knockdown   of   NANOG   (shNANOG;;   N=3).   (e)   Sphere   formation   measured  
following   siRNA   (10   nM)   mediated   NANOG   knockdown   in   RD   adherent   cells   (N=2).   (f   and   g)  
Primary   sphere   formation   upon   transient   overexpression   of   NANOG   in  RD   cells   (n=12;;   N   =2).  
Data  represent  mean±s.d.  Secondary  sphere  formation  in  RD  (h)  and  RH36  (i)  rescue  systems  (N  
=3).   (j)   Tumor   growth   rate   of   RH36   cells   in   NOD/SCID   mice   (n=6/6   per   cell   line).   Error   bars  










Supplemental  Figure  1.    
Analysis  of  ERMS  spheres,  xenografts  and  effect  of  transient  activation  of  hedgehog  pathway.  
mRNA  expression  of  multiple   hedgehog   signaling   components   in  RH36   (a;;   n=9;;  N=3  per   cell  
type),  TTC442  (b;;  n=6;;  N=2  per  cell  type)  and  fusion-­negative  RH18  (c;;  n=6;;  N=2  per  cell  type)  
spheres  compared  to  adherent  monolayer  cultures  by  qPCR.  (d)  GLI1  mRNA  expression  levels  
(relative   to   HMBS)   in   indicated   cell   lines   when   grown   as   xenografts   (“in   vivo”;;   n=6,   N=2)   or  
cultured  as  adherent  cells  (“in  vitro”;;  n=9,  N=3)  determined  by  qPCR.  PTCH1  (e)  and  HHIP  (f)  
mRNA  expression  levels  relative  to  HMBS  in  indicated  ERMS  sample  determined  by  qPCR  (for  
PDX:  n=6,  N=2  per  condition;;  for  cell  lines:  n=6,  N=2  for  “in  vivo”  and  n=9;;  N=3  for  “in  vitro”).  (g)  
Western   blotting   for   indicated   proteins   upon   siRNA   mediated   knockdown   of   SUFU   in   RD  
adherent   cells.   (h)   Sphere   formation   measured   following   siRNA   (10nM)   mediated   SUFU  
knockdown  in  RH36  adherent  cells  (N=2).  (i)  SUFU  protein  expression  in  RH36  adherent  cells  
after   siRNA-­mediated   knockdown.   Flow   cytometry-­based   cell   cycle   profile   estimation   from  
Propidium  Iodide  staining  of  RD  (j)  and  RH36  (k)  cells  treated  with  SAG1.3  for  48  hours  (n=2;;  
N=2  per  cell   line  per  condition).   (l)  Viability  of  ERMS  cells,  evaluated  by  WST  assay,  after  48  
hours  treatment  with  SAG1.3  (n=12;;  N=4).  *P<0.05,  **P<0.01,  ***P<0.001,  ****P<0.0001.  Data  
represent  mean  ±  S.D.  PDX  –  Patient-­derived  xenografts  
  
Supplemental  Figure  2.    
Single   cell   cloning   and   effect   of   GLI1   over-­expression   on   ERMS   cells.   (a)   Representative  
images  of  bulk  RD  cells  and  three  clonal  cultures  established  from  single  cells   immunostained  
for  GLI1  expression.  All  images  were  taken  at  200x  magnification.  Scale  bar  represents  50µm.  
(b)   Western   Blotting   to   assess   overall   GLI1   protein   expression   level   in   single   cell   clones  
compared   to  bulk  RD  cells.   (c)  Sphere   forming  ability  of  single  cell  clones   relative   to  bulk  cell  
line  (N=2).  The  expression  of  target  genes  upon  stable  over-­expression  of  GLI1  (pCMV-­GLI1)  in  
RD   (d;;   n=10,  N=5)  and  RH36   (e;;   n=12,  N=4)  compared   to  control   cells   (pCMV-­Empty;;   set  at  
baseline).  Log10  scale.  (f)  Right  panel:  Colony  forming  ability  of  RD  cells  stably  over-­expressing  
GLI1  relative  to  empty  vector  transfected  cells  (N=4).  Left  panel:  Representative  images  of  the  
colonies  stained  with  Crystal  Violet   in  one  well  of  a  standard  6-­well  plate.  (g)  Western  blotting  
for   indicated   proteins   using   lysates   of   xenografts   from   stable   cell   lines.   *P<0.05,   **P<0.01,  
***P<0.001,  ****P<0.0001.  Data  represent  mean  ±  S.D.  ns  -­  not  significant  
  
Supplemental  Figure  3.    
Immunohistochemical   analysis   of   ERMS   xenografts.   Representative   images   of  
immunohistochemistry   performed   on   formalin-­fixed   paraffin-­embedded   (FFPE)   sections   of  
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ERMS   xenografts   grown   in   NOD/SCID  mice.   The   images   for   H&E   (Hematoxylin   and   Eosin),  
Myogenin  and  Desmin   images  were   taken  at  200x  magnification.  Scale  bar   represents  50µm.  
The   images   for  GLI1   staining  were   taken   at   400x  magnification.   Scale   bar   represents   20µm.  
The  presence  of  a   few  rhabdomyoblasts  was  noted  within   the  xenografts.  The  xenografts  had  
low   differentiation   with   no   visible   strap   cells.   GLI1   staining   was   found   to   be   heterogeneous  
within  xenografts  and  the  over-­expression  was  more  readily  detected  in  case  of  RD.  The  RH36  
pCMV-­GLI1  xenograft  contained  more  number  of  strongly  positive  GLI1  cells  and  in  general  the  
tumor  appeared  to  be  composed  of  more  primitive  looking  cells.  
  
Supplemental  Figure  4.    
Effect  of  hedgehog  inhibition  by  synthetic  small  molecules  on  ERMS  cells.  (a)  Sphere  initiation  
for   RH36   cells   treated   with   small-­molecule   inhibitors   GDC-­0449   or   GANT61   every   48h   (3  
rounds)  during  primary  sphere   formation  and   further  plated   for  secondary  sphere   formation   in  
normal  media  (n=6,  N=2).  #  No  spheres  formed.  §  No  viable  cells  were  recovered  for  secondary  
sphere   formation.   (b)  GLI1  protein  expression   is  decreased  upon  siRNA-­mediated  knockdown  
in   RD   adherent   cells.   (c)   Left   panel:   Sphere   formation   measured   following   siRNA   (10nM)  
mediated  GLI1  knockdown   in  RH36  adherent  cells   (N=2).  Right  panel:  GLI1  protein   reduction  
upon   siRNA-­mediated   knockdown   in   RH36   adherent   cells.   (d)   Sphere   initiation   of   RH36  
adherent   cells   pre-­treated   with   hedgehog   inhibitors   (48   hours)   (n=9,   N=3   for   GDC-­0449   and  
GANT61;;   n=6,   N=2   for   LDE-­225).   Cell   cycle   profiles   generated   by   flow   cytometry-­based  
measurement  of  Propidium  Iodide  staining  of  RD  (e)  and  RH36  (f)  cells  treated  with  hedgehog  
inhibitors  for  48  hours  (n=2,  N=2  per  cell  line  per  condition).  Viability  evaluated  by  WST  assay,  
of  RD  (g)  and  RH36  (h)  cells  after  48  hours   treatment  with  hedgehog   inhibitor   (n=12,  N=4  for  
GDC-­0449  and  GANT61;;  n=6,  N=2  for  LDE-­225).  (i)  Western  blotting  for  GLI1  in  RD  adherent  
cells   treated   with   3µM   GANT61   (48h).   (j)   Representative   whole   mounts   of   xenograft   tumors  
formed  by   injecting  RD  cells  either  pre-­treated  with  vehicle  or  GANT61   (3µM)   for  48  hours   in  
vitro.   (k)   Representative   images   of   immunohistochemistry   performed   on   FFPE   sections   of  
xenograft  tumors  formed  by  injecting  RD  cells  either  pre-­treated  with  vehicle  or  GANT61  (3µM).  
The  xenografts   from  GANT61  pre-­treatment  have   fewer  GLI1  strongly  positive  cells  and   lower  
desmin   positivity.   The   images   for   H&E,   Myogenin,   Desmin   and   MIB1   were   taken   at   200x  
magnification.   Scale   bar   represents   50µm.   The   images   for  GLI1   staining  were   taken   at   400x  
magnification.   Scale   bar   represents   20µm.   *P<0.05,   **P<0.01,   ***P<0.001.   Data   represent  
mean  ±  S.D.  
  
Supplemental  Figure  5.    
Effect   of   stable   genetic   hedgehog   inhibition   on   ERMS   cells.   mRNA   expression   of   hedgehog  
target  genes  in  RD  (a;;  n=6,  N=2)  and  RH36  (b;;  n=3,  N=1)  cells  over-­expressing  SUFU  (pCMV-­
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SUFU)  relative  to  empty  vector  control   (pCMV-­Empty),  assessed  by  qPCR.  mRNA  expression  
of   hedgehog   target   genes   in   RD   (c;;   n=9,   N=3)   and   RH36   (d;;   n=9,   N=3)   cells   with   stable  
knockdown  of  SMO  (shSMO)  relative  to  emtpy  vector  control  (pLKO.1),  assessed  by  qPCR.  (e)  
Western  blotting  for  indicated  proteins  in  control  and  stable  SMO  knockdown  ERMS  cell  lines  (f)  
Right   panel:   Colony   forming   ability   of   pCMV-­SUFU   RD   cells   relative   to   pCMV-­Empty   cells  
(N=2).  Left  panel:  Representative  images  of  the  Crystal  Violet  stained  colonies  in  one  well  of  a  
standard   6-­well   plate.   (g)   Right   panel:   Colony   forming   ability   of   shSMO   RD   cells   relative   to  
pLKO.1   cells   (N=2).   Left   panel:   Representative   images   of   the  Crystal   Violet   stained   colonies  
formed   in   one  well   of   a   standard   6-­well   plate.   (h   and   i)   Cell   proliferation  measured   by   BrdU  
incorporation   in  RD  cells   (n=6,  N=2).   (j)  Histogram  plots   of   cell   cycle   profiles   generated   from  
Propidium  Iodide  (PI)  staining  of  RD  stable   lines  by   flow  cytometry.   (k  and   l)  Quantification  of  
cell  cycle  stage  distributions  observed   in  RD  cell   lines  with  different  hedgehog  pathway  status  
(n=2,  N=2  per   cell   line).   (m   and  n)  Quantification  of   cell   cycle  stage  distributions  observed   in  
RH36   cell   lines   with   different   hedgehog   pathway   status   (n=2,   N=2   per   condition).   *P<0.05,  
***P<0.001.  Data  represent  mean  ±  S.D.  ns  –  not  significant.  
  
Supplemental  Figure  6.    
Cell   autonomous   ligand-­based   hedgehog   pathway   activation   in   ERMS.   Relative   mRNA  
expression  level  of  hedgehog  ligands  in  ERMS  sphere  cells  (a:  RH36;;  n=9,  N=3  and  b:  RD;;  n=6,  
N=2)   compared   to   adherent   cells   (a:   RH36;;   n=9,   N=3   and   b:   RD;;   n=9,   N=3).   Absolute   RNA  
expression   level  of  hedgehog   ligands   in  ERMS  xenografts  (c:  RH36;;  d:  RD;;  n=12,  N=4  per  cell  
line)   and   their   respective   in   vitro   cultured   cells   (n=9,   N=3   per   cell   line)   normalized   to  
housekeeping   gene  HMBS.   (e   and   f)   Absolute   RNA   expression   level   of   hedgehog   ligands   in  
ERMS  PDX  samples  when  grown  as  tumors  (“in  vivo”)  and  when  taken  into  culture  as  adherent  
cells   (“in   vitro”)   normalized   to   HMBS   (n=6;;   N=2   per   condition   per   PDX   sample).      (g,  h   and   i)  
QPCR   for   indicated   hedgehog   ligands   performed   on   nine   ERMS   patient   tumor   samples.   Data  
normalized  to  geometric  mean  of  HMBS  and  GAPDH.  (j)  Scatter  plot  depicting  data  from  panels  
g,  h   and   i   (excluding   patient   TB271).   Each   data   point   represents   a   single   patient   and   the   line  
represents   median   expression   level   in   the   cohort.   Species-­specific   ligand   RNA   expression  
estimated   in   ERMS   cell   line-­derived   xenografts   (k:   RD;;   n=12,   N=4   per   condition   and   l:   RH36;;  
n=48,   N=16   for   human-­specific   probes;;   n=30,   N=10   for  mouse-­specific   probes).   Expression   of  
Dhh   is  higher  within  ERMS  tumors  (m:  RD;;  n=12,  N=4  and  n:  RH36;;  n=30,  N=10)  compared  to  
normal  murine  skeletal  muscle  (n=6;;  N=2).  Expression  levels  are  normalized  to  Gapdh.  *P<0.05.  
P-­value   for  k   and   l   from  Mann-­Whitney   test.   Data   represent  mean   ±   S.D.   FeSkM_P   -­   Pool   of  
Fetal  Skeletal  Muscle  RNA  (3  donors);;  AdSkM_P  -­  Pool  of  Adult  Skeletal  Muscle  RNA  (5  donors);;  
h  -­  human;;  m  –  mouse;;  N.E.  –  Not  Expressed,  ns  –  not  significant.  
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Supplemental  Figure  7.    
Effect   of   hedgehog   pathway   modulation   on   ERMS   chemoresistance   and   differentiation.   (a)  
Sphere   initiation   ability   of   RD   cells   treated   for   48   hours   with   SN-­38   (active   metabolite   of  
Irinotecan).  Post-­treatment  equal  number  of  viable  cells  were  counted  and  plated  at  clonal  density  
(n=9,  N=3).   (b)  Sphere   initiation  ability  of  RD  cells   treated   for  48  hours  with  SN-­38  alone  or   in  
combination  with  SMO  inhibitor  LDE-­225  (n=8,  N=2).  (c  and  e)  Representative   images  of  RH36  
cells   stained   for   PAX7   and   MYOGENIN   expression.   (d)   Representative   images   of   RD   cells  
stained   for   PAX7   and   MYOGENIN   expression.   All   images   were   taken   at   400x   magnification.  
Scale   bar   represents   20µm.   Intra-­cellular   flow   cytomtery   for   PAX7   or   MYOGENIN   positivity  
performed   on   RH36   cells   treated   for   48   hours   with   indicated   concentrations   of   hedgehog  
inhibitors   GDC-­0449   (f),   GANT61   (g)   or   agonist   SAG1.3   (h)   (n=2,   N=2   per   condition).   (i)  
Percentage   of   PAX7-­   or   MYOGENIN-­positive   RD   cells   treated   for   48hrs   with   3μM   GANT61,  
normalized   to  DAPI  stained  nuclei  counted  per  viewing   field  using   ImageJ  and  made  relative   to  
vehicle  treated  cells  (n=7).  (j)  The  mRNA  expression  of  indicated  genes  in  RD  cells  after  6  days  
of   treatment   with   GANT61,   normalized   to   HMBS   and   made   relative   to   expression   in   vehicle  
treated  cells.  The  drug  was  replaced  after  72  hours  (n=3).    *P<0.05,  **P<0.01,  ***P<0.001.  Data  
represent  mean  ±  S.D.  
  
Supplemental  Figure  8.    
Effect  of  hedgehog  pathway  modulation  on  ERMS  cell  motility.  Representative  images  of  RD  cells  
stained  with  Crystal  Violet  post-­invasion  (a)  and  post-­migration  (b)  in  trans-­well  assay.  All  images  
were  taken  at  200x  magnification.  Scale  bar  represent  50µm.  
  
Supplemental  Figure  9.    
Confirmation  of  qPCR  screen  hit.  NANOG  RNA  expression  analysis  using  Taqman-­based  qPCR  
in  pCMV-­GLI1  (a:  n=12,  N=4),  shSMO  (b:  n=9,  N=3)  and  pCMV-­SUFU  (c:  n=6,  N=2)  ERMS  cells  
relative   to   their   respective  control  cell   lines.   (d)  Western  blotting   for  NANOG  protein  expression  
(arrow)   in   control   and   SUFU-­overexpressing   ERMS   cells.   (e)   Representative   images   of   RH36  
stable   cells   co-­immunostained   for  GLI1   and  NANOG   expression.   (f)   Representative   images   of  
primary  cells  from  ERMS  PDX  samples  co-­immunostained  for  GLI1  and  NANOG  expression.  All  
images   (e  and   f)  were   taken  at  400x  magnification.  Scale  bar   represents  20µm.   *P<0.05.  Data  





Supplemental  Figure  10.    
Modulation   of   NANOG   expression   by   hedgehog   pathway   activation.   (a)   NANOG   expressing  
RH36  cells  counted  after  48hrs  treatment  with  SAG1.3  (n=3).  Representative  images  for  RD  (b)  
and  RH36  (c)  cells  treated  with  SAG1.3  and  stained  for  NANOG.  All  images  were  taken  at  400x  
magnification.  Scale  bar  represents  20µm.  (d)  NANOG  RNA  expression,  normalized  to  HMBS,  in  
RD   xenografts   (n=6,   N=2)   and   adherent   cultures   (n=9,   N=3).   (e)   NANOG   expression   in  RH36  
xenografts   and   adherent   cells.   Left   panel:   NANOG   RNA   expression   normalized   to   HMBS   in  
xenografts   (n=6,   N=2)   and   adherent   cells   (n=9,   N=3).   Right   panel:   Western   blot   showing  
expression  of   indicated  proteins.   (f)  NANOG  RNA  expression   in  ERMS  sphere   cells   relative   to  
adherent  cultures  (n=6,  N=2).  (g)  NANOG  protein  expression  level  (arrow)  in  ERMS  adherent  and  
sphere  cells.  *P<0.05,  **P<0.01.  Data  represent  mean  ±  S.D.  
  
Supplemental  Figure  11.    
Characterization   of   phenotype   rescue   cell   lines   and   additional   clinical   data   analysis.   (a)   Left  
panel:  RNA  expression  analysis  of   indicated  genes   in  RD  cells  with  stable  NANOG  knockdown  
(shNANOG)   relative   to   control   (pLKO.1)   (n=6,   N=2).   Right   panel:   Western   Blot   analysis   of  
indicated   proteins.   (b)   Left   panel:   RNA   analysis   of   indicated   genes   upon   siRNA-­mediated  
NANOG  knockdown  (10nM;;  48  hours)  in  RD  adherent  cells  (n=6;;  N=2).  Right  panel:  Western  Blot  
analysis   of   indicated   proteins   upon   siRNA-­mediated  NANOG  knockdown   in  RD  adherent   cells.  
**P<0.01,   ***P<0.001   from  Student’s   t-­test.   (c)  Western   Blot   analysis   of   RD   cells   for   indicated  
proteins  upon   transient  overexpression  of  NANOG.  Expression  analysis   to  verify   the  stable  cell  
lines  generated   from  RD  (d)  and  RH36  (e)  cells  with  knockdown  of  NANOG  in   the  presence  of  
GLI1   over-­expression   (n=6;;   N=2).   Data   represent   mean   ±   S.D.   (f)   Representative   images   of  
immunohistochemistry   performed   on   FFPE   sections   of   RH36   stable   line   xenografts   grown   in  
NOD/SCID  mice.  The  images  were  taken  at  200x  magnification.  Scale  bar  represents  50µm.  (g)  
Western   blot   analysis   of   indicated   proteins   in   RH36   xenografts.   (h)   Representative   images   of  
immunohistochemistry   staining   for   GLI1   and   NANOG   within   an   ERMS   patient   tumor   core.   All  
images  were   taken   at   400x  magnification.   Scale   bar   represents   20µm.   Kaplan-­Meier   curve   for  
event-­free  survival  of  91  ERMS  patients  determined  to  be  either  negative  (black  line)  or  positive  
(grey  line)  for  expression  of  GLI1  (i)  or  NANOG  (j)  alone.  The  P-­values  were  generated  using  log-­









































































































Transfection,  transduction  and  generation  of  stable  cell  lines  
The  plasmids  pCMV6-­Entry   (C-­terminal  Myc  and  DDK  Tagged)   referred   to  as  pCMV-­Empty,  
GLI1-­transcript   variant   1-­   Myc-­DDK   (referred   to   as   pCMV-­GLI1),   SUFU-­Myc-­DDK   tagged  
(referred   to   as   pCMV-­SUFU)   were   purchased   from   Origene.   The   plasmids   pEGIP   (26777;;  
referred   to   as   pE1F),   and   pSin-­EF-­Nanog-­Pur   (16578;;   over-­expressing   NANOG)   were  
purchased   from   Addgene.   All   plasmid   transfections   were   carried   out   using   Lipofectamine®  
2000   (Invitrogen)   following   manufacturer’s   instructions.   Transduction   of   MISSION®   TRC1.5  
shRNA   lentiviral   particles   (Sigma-­Aldrich)   -­   control   (pLKO.1;;   SHC001V),   TRCN0000014364  
(shSMO)  and  TRCN0000004885  (shNANOG)  -­  was  carried  out  at  MOI  1.5  in  1µg/ml  Polybrene  
(Sigma-­Aldrich)  supplemented  media.  For  stable  cell  line  generation,  plasmid  transfected  cells  
were  continuously  cultured   in  media  supplemented  500  µg/ml  G-­418  antibiotic   for  3-­4  weeks  
and   thereafter   maintained   in   100   µg/ml   antibiotic   media;;   viral   transduced   cells   were  
continuously  cultured   in  media  supplemented  with  1µg/ml  Puromycin   (Invivogen)   for  10  days  
and  thereafter  maintained  in  0.3  µg/ml  antibiotic  media.  Stable  pCMV-­Empty  and  pCMV-­GLI1  
cells  were  transduced  with  pLKO.1  and  shNANOG  viral  particles  and  selected  with  Puromycin  
as  described  above  to  generate  stable  phenotype  rescue  system.  The  effect  of  the  expression  
of  the  transgene  was  regularly  checked  using  qPCR  and  western  blotting  through  the  course  of  
the  experiments.  Occasionally  the  stable  lines  were  challenged  with  higher  doses  of  antibiotics  
to  ensure  that  the  cell  lines  being  propagated  carried  the  transgene  constructs.  
  
Trans-­well  migration  and  invasion  assays  
Migration  assays  were  carried  out  using  BD  Falcon™  cell  culture  inserts  (BD  Biosciences;;  8µm  
pore   size)   in   24-­well   format.   For   invasion   assays,   BioCoat™   matrigel-­coated   inserts   (BD  
Biosciences)  or   inserts  coated  manually  with  gelatin  were  used.  Cells  were  maintained  in  1%  
FBS  media   for   4hrs  prior   to  plating  and  allowed   to  migrate  over  24hrs  or   invade  over  48hrs  
towards  10%  FBS  medium.  The  membrane  was   fixed  with  4%  paraformaldehyde   (PFA;;  Carl  
Roth),  cells  stained  with  0.05%  Crystal  Violet  and  visualized  using  Olympus  CX41  microscope.  
Images  were   captured   from  5   viewing   fields   across   the  membrane   using   INFINITY   software  
(version  6,  Lumenera).  Cells  were  counted  manually  using  ImageJ  software  (version  1.47).    
  
Cell  cycle  analysis  
Cells   were   fixed   with   ice-­cold   70%   ethanol   and   re-­suspended   in   propidium   iodide   solution  
(1xPBS,   1%   Triton   X-­100,   100mg/ml   RNaseA,   1mg/ml   Propidium   Iodide   solution)   just   before  
analysis.  For   intra-­cellular   staining,   cells  were   fixed  with  cold  4%  PFA  and  permeabilized  with  
0.2%   Triton   X-­100.   Antibodies   used   are   indicated   in   Supplementary   Table   2.   Flow   cytometry  
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was   performed   on   a   BD   FACS   Canto   II   instrument   (BD   Biosciences)   using   BD   FACSDiva  
software.  Data  was  analyzed  with  FlowJo  software  (version  7.6.1,  TreeStar  Inc.).  
  
Immunohistochemistry  
Cells   were   visualized   using   Leica   6000   DM   epifluorescence   microscope   and   images   were  
captured   using  OpenLab   software   (version   3,   Improvision).  Cells   stained   only  with   conjugated-­
secondary   antibodies   were   used   as   controls.   Cell   count   estimation   and   image   analysis   was  
performed   using   ImageJ.   Immunohistochemistry   was   performed   on   3   µm   thick   sections   from  
blocks   of   formalin-­fixed,   paraffin-­embedded   tissue   at   the   Institute   of   Surgical   Pathology  
(University   Hospital   Zurich).   The   procedure   for   detecting   GLI1   and   NANOG   expression   was  
optimized  by  Sophistolab  AG  (Eglisau,  Switzerland)  using  an  array  containing  a  series  of  normal  
tissue  and  cancer  tissues  as  controls.  In  brief,  immunohistochemistry  was  performed  according  to  
manufacturer’s  guidelines  on  Leica  BondMax  instruments  using  Refine  HRP-­Kits  (Leica  DS9800)  
and  buffer-­solutions  from  Leica  Microsystems  Newcastle,  Ltd.  Slides  were  visualized  using  Zeiss  
Axioskop   microscope.   Images   were   captured   and   analyzed   using   CellB   software   (version   3.4;;  




































































Expression Assay ID 
HMBS Human Hs00609297_m1 
GAPDH Human Hs02758991_g1 
GLI1 Human Hs01110766_m1 
GLI2 Human Hs01119974_m1 
GLI3 Human Hs00609233_m1 
PTCH1 Human Hs00181117_m1 
HHIP Human Hs01011008_m1 
SMO Human Hs01090242_m1 
SUFU Human Hs00171981_m1 
SHH Human Hs00179843_m1 
IHH Human Hs00745531_s1 
DHH Human Hs00368306_m1 
NANOG Human Hs02387400_g1 
PDGFRA Human Hs00998018_m1 
CKM Human Hs00176490_m1 
MYL1 Human Hs00984899_m1 
Shh Mouse Mm00436528_m1 
Dhh Mouse Mm01310203_m1 
Ihh Mouse Mm00439613_m1 






1   Abbreviations:  WB   –  Western   Blotting,   IF   –   Immunofluorescence,   IC-­FC   –   Intra-­cellular   Flow  
Cytometry,  IHC  –  Immunohistochemistry,  HRP  –  Horseradish  peroxidise  
  
2   HRP-­conjugated   secondary   antibodies   for   IHC   were   purchased   pre-­diluted   in   the   reagents  
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7.  Discussion  &  Outlook  
  
RMS   accounts   for   the   majority   of   soft-­tissue   sarcomas   in   children   and   multimodal   treatment  
schedules   including  standard  chemotherapy,  surgery  and   radiotherapy   remains   the  mainstay  of  
therapy   since   almost   half   century.   Although   this   treatment   approach   revolutionized   the   care   of  
childhood  cancers   leading  to   impressive  cure  rates  especially   for  paediatric  acute   lymphoblastic  
leukemia  (5-­years  event-­free  survival  approaching  80%),  no  further  progress  has  been  made  over  
the  last  20-­30  years  [236].  Importantly,  only  now  we  start  recognizing  the  alarming  cases  of  late  
morbidity   following  aggressive  chemotherapy  and   radiotherapy  cycles   that  are   routinely  applied  
since  children  tolerate  much  better  than  adults  dose  intensive  cytotoxics  [237].  Despite  the  great  
examples  of  novel  targeted  therapies  approved  for  adult  cancers  in  recent  years,  no  molecularly-­
oriented   drugs   have   entered   the   clinic   for   the   management   of   RMS   patients   so   far.   This  
underlines  critical   issues  associated  with  pediatric  drug  development,  which  does  not  meet   the  
interest   of   the   large   financial   markets.   Indeed,   childhood   cancers   represent   only   1-­2%   of   the  
global  cancer  burden,  thus  only  a  small  fraction  of  patients  might  be  enrolled  in  clinical  trials.  Yet,  
the  relative  success  rate  of  standard  treatments  would  confine  the  study  population  to  relapse  or  
metastatic   groups   only,   who   might   not   be   a   good   “read-­out   window”   to   assess   drug   activity.  
Importantly,   the   general   drug   development   pipeline   of   industry   currently   considers   exclusively  
compounds   that   have   already   entered   phase   II   studies   for   adult   cancers   [237].  However,   such  
system   might   be   misleading   since   the   cancer   spectrum   in   adulthood   is   largely   dominated   by  
carcinomas   harboring   a   genetic   landscape   far   more   complex   than   pediatric   tumors   [7].   Thus,  
relevant  targets  for  these  latter  will  be  completely  underrepresented  in  adult  malignancies.    
To  tackle  this  situation,  in  our  studies  we  set  out  to  develop  a  predictive  and  functional  pre-­clinical  
platform   to   inform   on   personalized   treatment   strategies   for   RMS   patients.   To   this   aim,   we  
employed  PDX  models  and  systematic  characterized  culture  conditions  suitable  for  derivation  and  
maintenance  of  RMS  primary  cultures  (RPCs)  (manuscript  1).  Furthermore,  we  provide  a  proof-­
of-­concept  drug-­testing  program   to   identify  patient-­specific   vulnerabilities  or  novel   combinatorial  
options  for  patients  refractory  to  the  standard-­of-­care  therapies  (manuscript  1  and  2).  These  latter  
are   associated   with   increased   Hh   output   (manuscript   3),   indicating   that   it   might   represent   a  
potential   bio-­marker   to   capture   patients   with   poor   outcome   or   to  monitor   over   time   the   risk   of  
relapse  of  patients  undergoing  first-­line  treatments.  A  summary  of  the  key  findings  of  the  present  
thesis  is  depicted  in  (Figure  17).  
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Figure  17.  Overview  of   the  main  findings  of   the  present   thesis.  The   first  aim  of   this  project  
was   to  establish  PDX  models   from  RMS  patients  and  characterize   in  vitro   culture  conditions   to  
efficiently   derive   and  maintain  RMS  primary   cultures   (RPCs)   (manuscript   1).   These   latter  were  
then  employed  for  proof-­of-­concept  high-­throughput  compound  screens  to  identify  patient-­specific  
vulnerabilities  (manuscript  1).  Moreover,  we  describe  a  clear  dependency  of   recurrent  RPCs  on  
BCL-­XL  and  MCL-­1  axis  and  their  inhibition  can  be  exploited  by  co-­treatment  with  BH3-­mimetics  
and   standard   chemotherapy.   Finally,   increased   expression   of   Hh   target   genes   correlated   with  
relapsed  disease  in  our  cohort  of  PDX  samples  underscoring  the  clinical  relevance  of  Hh  pathway  
activity  in  RMS  patients  (manuscript  3).    
            
7.1.  Establishment  of  novel  pre-­clinical  models  of  RMS  
In  our  attempts  to  establish  RMS  patient-­derived  cells  as  reliable  pre-­clinical  model  of  RMS,  we  
developed   a   culture   screen   protocol   to   test   a   wide   range   of  medium   compositions   and  matrix  
requirements.  Using  a   large  panel  of   samples,  we  demonstrated,   to  our  knowledge   for   the   first  
time  in  RMS,  a  general  negative  effect  of  serum-­containing  media  on  the  growth  of  RPCs.  These  
findings  might   explain   the   very   low   success   rate   of   cell   line  derivation  achieved   in   the  past   for  
several   solid   and   liquid   cancer   entities   [238,   239].   Similar   to   others,   we   observed   a   serum-­
induced  growth  arrest  accompanied  by  dramatic  morphological  changes  that  in  some  cases  were  
associated   with   skeletal   muscle   differentiation   [240,   241].   Although   we   do   not   know   which  
component   or   mixture   of   factors   present   in   the   serum   are   responsible   for   this   phenotype,   we  
hypothesize  that  it  might  not  adequately  reflect  the  fluid  that  cells  are  exposed  to  in  their  natural  
environment.  Interestingly,  few  RPCs  could  be  propagated  in  presence  of  serum  but  this  occurred  
either  after  a  long  adaptation  period  in  culture  (1-­2  months)  or  for  cells  harboring  TP-­53  mutation  
(single   case).   In   vivo   tumorigenic   assays   revealed   that   1   out   of   2   serum-­derived   cells   had  
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genetic  aberrations.  Similar  in  vitro  artifacts  are  frequently  detected  in  traditional  cancer  cell  lines,  
which  often   loose   tumorigenicity  or  metastatic  potential   [240,  242].   In  contrast,   cells   cultured   in  
serum-­free  media,  rapidly  proliferated   in  vitro  or  in  vivo  and  closely  preserve  most  of  the  genetic  
aberrations   and   histological   features   of   the   original   PDX.   Furthermore,   the   use   of   serum  
replacements   (B-­27)   can   provide   a  more   standardized   system   of   cell   culture,   thus   limiting   the  
batch-­to-­batch  variability  of  biological  extracts.    
Our  systematic   investigation  of  parameters  for  efficient   in  vitro  cultivation  of  RPCs  revealed  that  
matrix  support  (matrigel  or  gelatin)  is  highly  recommended  and  in  some  cases  even  necessary  for  
cell  viability.  Probably,  this  might  better  model  the  pro-­survival  interactions  between  cancer  cells  
and  the  extracellular  matrix  (ECM)  occurring  in  vivo.  Interestingly,  the  presence  of  growth  factors  
(GFs)  not  always  was  beneficial  for  the  growth  of  RPCs,  highlighting  the  fact  that  generalization  
of   culture  conditions  cannot  always  be  applied.   In   line  with   this,  we  discovered   in  one  case  an  
unexpected   growth   inhibition   of   RPCs   upon   bFGF   supply.   Although  we   did   not   investigate   the  
underlying  molecular  mechanism,  previously  studies  demonstrated  that  bFGF-­induced  cell  death  
is  dependent  on  a  sustained  activation  of  p38MAPK  in  a  panel  of  Ewing’s  sarcoma  cell  lines  [243,  
244].    
Altogether,  we  uncovered  culture  condition  requirements  for  derivation  and  maintenance  of  RPCs  
in  vitro,  which   in   the   future  might  be   translated  directly  on  patient  biopsies   to  minimize   time   for  
identification  of  clinically  effective  therapeutics.    
  
7.2.  Identification  of  novel  pharmacological  dependencies  in  RMS  
Our   study   provides   compelling   evidence   for   using   high-­throughput   drug   screens   in   RPCs   to  
capture   patient-­to-­patient   response   variations   that   might   guide   personalized   therapies.   Indeed  
heterogeneous  responses  were  observed   for  different  agents   in  clinical  development  or  already  
approved   for   other   cancer   types.   For   example,   despite   a   general   strong   activity   of   different  
proteasome  and  PLK1   inhibitors  across  different  patients,  a  single   resistant  case  was   identified  
with   our   platform.   Such   distinct   pattern   correlated   with   the   presence   of   PAX7-­FOXO1  
translocation,  which  occurs   in  only  a  minority  of  ARMS  patients.  Although  we  cannot  draw  any  
conclusion  on  the  potential  involvement  of  PAX7-­FOXO1  in  this  phenotype,  our  findings  indicate  
that   preliminary   functional   testing   would   be   highly   informative   not   only   to   identify   effective  
compounds  but  also  to  avoid  undesired  side  effects  of  unexpected  inactive  drugs.  For  example,  
bortezomib  has  become  a  standard-­of  care  for  relapse  multiple  myeloma  (MM)  and  holds  promise  
for  several  solid  cancers,  however  dose-­limiting  toxicities  and  emergence  of  resistance  remains  a  
major  concern   [245,  246].  Among   individual  sensitivities,   the  BH3  mimetic  ABT-­263  exhibited  a  
strong  effect   in   three  patients  with   IC-­50  within   the   range  of   therapeutic  doses   (low  nanomolar  
concentrations),   further   supporting   the   feasibility   of   our   drug   platform   to   nominate   therapeutic  
candidates.    
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Impressively,   clustering  analysis   of   drug   responses  unveiled   that   cells   harboring  PAX3-­FOXO1  
fusion  protein  displayed  a  very  similar  pharmacological  response  pattern.  Albeit,  a  larger  panel  of  
samples  is  required  to  correlate  drug-­response  with  PAX  fusion  status  in  RMS,  we  speculate  that  
in   addition   to   the   distinct   histological   and   genetic   make-­up   of   PFP   and   PFN,   also   specific  
pharmacological  sensitivities  might  discriminate  these  two  subtypes.  This   is  not  surprising  since  
PFP   and   PFN   are   believed   to   eventually   originate   from   different   cell(s)   of   origin   and   to   follow  
divergent  models  of   tumorigenesis.  According  to  this,  mouse  models  experiments  demonstrated  
that  PFN  mainly  develop  from  adult  muscle  stem  cells,  which  is  consistent  with  the  fact  that  PFN  
display   a   gene   expression   signature   resembling   satellite   cell   activation   [174,   247].   In   contrast,  
maturing  myoblasts  or  terminally  differentiated  MyF-­6-­expressing  cells  have  been  reported  as  the  
origin  of  PFP  tumors  [170,  248].  Hence,  the  cellular  context  where  the  oncogenic  event(s)  occur  
might  affect  the  molecular  signature  characterizing  these  two  subgroups.  In  this  regard,  the  RAS  
pathway  is  found  frequently  mutated  exclusively  in  PFN  [164],  which  mostly  rely  on  the  MEK/ERK  
axis.  Similarly,  we  also  observed  a  clear  sensitivity  to  trametinib  (MEK  inhibitor)  in  RAS-­mutated  
PFN   cells.   Controversy,   an   exquisite   sensitivity   to   AKT   inhibitors   (3   out   of   4)   and   everolimus  
(mTOR  antagonist)  was  detected  in  PFP  cells  (mainly  PAX3-­FOXO1  fusion  positive),  suggesting  
a  dependency  on  the  mTOR/AKT  axis.  Although  this  might  simply  reflect  the  intact  RAS  status  in  
these   cells,   two   AKT   consensus   phosphorylation   sites   have   been   identified   in   the   FOXO1  
domain,   thus   corroborating   a   potential   link   between   AKT   and   PAX3-­FOXO1   [249].   This  
hypothesis   is   further  supported  by   the   fact   that  AKT  can  modulate   the   transcriptional  activity  of  
PAX3-­FOXO1  to  inhibit  muscle  differentiation  in  mouse  ARMS  cells.  [250].  Finally,  dose-­response  
validations   confirmed   that   the   ATM/ATR   inhibitor   (AZ-­20)   was   among   the   top   drug   candidates  
with  a  strong  activity  in  PFP  cells,  which  warrants  further  investigations.  
  
7.3.  Characterization  of  novel  combination  options  for  chemoresistant  RMS  
Although  nowadays,  resistance  to  conventional  therapy  remains  a  challenging  clinical  problem  to  
overcome,  novel  therapeutic  options  have  not  been  introduced  into  standard  treatment  regimens  
so  far,  which  might  be  due  at  least  in  part  to  the  lack  of  appropriate  pre-­clinical  models.  To  fill  this  
gap,   we   have   generated   a   set   of   PDXs   and  matched   RPCs   derived   from   diagnostic/recurrent  
pairs   of   the   same   patient   representing   initial   chemosensitive   and   subsequent   chemoresistant  
disease.  After  validating  the  chemorefractory  phenotype  of  relapse  RPCs,  we  used  these  latter  as  
system   to   identify   sensitizers   to   standard   chemotherapy.  Hence,  we   describe   the  BH3-­mimetic  
ABT-­263   as   a   key   pharmacological   approach   to   bypass   the   apoptotic   blockade   of   standard  
chemotherapy   in   high-­risk   group   RMS   samples.   Mechanistically,   the   ABT-­263/chemotherapy  
exploits  the  dual  inhibition  of  BCL-­XL  and  MCL-­1  axis  to  restore  programmed  cell  death  in  ERMS  
recurrent  cells.  
  
Discussion & Outlook 
	   	   	   	   	   	   	   	   	  171	  
Resistance  to  apoptotic  stimuli  constitutes  one  of  the  hallmarks  in  cancer  and  provides  an  escape  
route  to  counteract  the  cytotoxic  effect  of  conventional  therapy  [9,  10,  251].  Most  chemotherapy  
drugs  induce  the  intrinsic  pathway  of  apoptosis,  which  is  largely  controlled  by  the  BCL-­2  proteins  
family.   Consequently,   imbalance   between   pro-­   and   anti-­   apoptotic   BCL-­2   proteins   has   been  
shown   to  contribute   to  chemorefractory  disease,  although   it   remains  poorly  understood   in  RMS  
[251].  Among  the  BCL-­2  pro-­survival  members,  BCL-­2,  BCL-­XL  and  MCL-­1  are  the  most  studied  
in  cancer   [252].  The  oncogenic   role  of  BCL-­2  was   initially  described   in   follicular   lymphomas  as  
consequence   of   a   t(14;;18)   translocation   [253,   254].   Thereafter,   over-­expression   of   BCL-­2   has  
been   found   in   several   solid   and   hematological   cancers   and   has   been   shown   to   prevent  
chemotherapy-­induced   cell-­death   [255,   256].   Nevertheless,   in   our   study   pharmacological   and  
genetic   inhibition   of   BCL-­2   appeared   to   be   dispensable   to   sensitize   RMS   cells   to   both  
topoisomerase  inhibitors  (doxorubicin)  and  microtubule  destabilizers  (vincristine).  Accordingly,  by  
screening   datasets   of   gene   expression   profiles,   we   did   not   find   evidence   of   BCL-­2   over-­
expression   in   RMS.   In   contrast,   we   found   that   mainly   inhibition   of   BCL-­XL   mounts   a  
chemosensitive   response   in   recurrent   ERMS.   Although   BCL-­XL   has   been   demonstrated   to   be  
transcriptional   regulated   by   PAX3-­FOXO1   and   to   mediate,   at   least   in   part,   its   anti-­apoptotic  
response,  no  studies  have  addressed  the  functional  role  of  BCL-­XL  in  PFN  tumors  so  far   [257].  
Our   work   corroborates   previous   findings   showing   the   critical   role   of   BCL-­XL   in   the   context   of  
chemoresistance   for   other   cancer   entities   [125,   258-­260].   Albeit,   BCL-­XL   targeting   compounds  
represent  an  attractive  strategy   to   incorporate   in  standard   treatment  protocols  of  RMS  patients,  
severe  sides  effects  have  to  be  taken  into  account.  In  fact,  because  BCL-­XL  plays  a  pivotal  role  
for  survival   in  platelets,   thrombocytopenia  has  been  observed   in  pre-­clinical  mouse  models  and  
patients  treated  with  ABT-­263  [261,  262].  Therefore,  re-­design  of  new  treatment  schedules  in  pre-­
clinical  settings  is  warranted  to  reverse  these  dose-­limiting  toxicities.  
From  a  mechanistic  standpoint  we  demonstrate  that  ABT-­263/standard  chemotherapy  rely  on  the  
BCL-­XL/MCL-­1  axis,  which  is  partially  controlled  by  the  pro-­apoptotic  BH3-­only  NOXA.  Although  
MCL-­1  depletion  has  been  shown  to  sensitize  cells  to  ABT-­263,  specific  MCL-­1  inhibitors  are  still  
in   pre-­clinical   development   [263,   264].   Here,   we   demonstrate   that   current   debulking   agents  
applied  for   the  management  of  RMS  patients  can  exploit  MCL-­1   inhibition.   It   is   likely  that   this   is  
not  a  direct  effect  but  rather  secondary  to  cell  cycle  regulation  by  chemotherapy.  In  fact,  different  
studies   have   shown   that   MCL-­1   protein   stability   undergoes   a   cell   cycle-­dependent   regulation  
through   post-­translational   modifications   including   phosphorylation   and   ubiquitination   [265-­267].  
Additionally,  also  NOXA  has  been  suggested  to  promote  proteasomal  degradation  of  MCL-­1  and  
might  provide  the   link  between  the  chemo-­mediated  up-­regulation  of  NOXA  and  downregulation  
of  MCL-­1  that  we  observe  in  our  system  [268].  Therefore,  more  experiments  are  needed  in  order  
to  clarify  the  mode  by  which  chemotherapy  regulate  MCL-­1  in  RMS.  
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7.4.  Challenges  of  targeting  Hh  pathway  in  RMS1  
Our  data  revealed  that  relapsed  RMS  tumors  exhibit  a  strong  up-­regulation  of  Hh-­targets  (GLI1,  
HHIP  and  PTCH1)  suggesting  increased  steady-­state  activity  of  the  pathway.  Such  correlation  is  
in  agreement  with  previous  studies  showing  that  activation  of  Hh  signaling  is  clinically  relevant  in  
PFN   tumors   [223,   269].   Therefore,   assessment   of   Hh   signaling   status   might   help   to   identify  
specific  subgroups  of  RMS  with  poor  outcome  and/or  risk  to  relapse.    
Given   the   importance  of  Hh  signaling   in  modulating  self-­renewal  and   tumorigenicity  of  CSCs   in  
ERMS,  we  reasoned  that  Hhhigh  chemo-­resistant  clones  (CSCs)  might  be  selected  upon  first-­line  
treatments.  Alternatively,   iper-­activation  of   the  pathway   following  chemotherapy  may  promote  a  
transition  of   chemo-­sensitive   cancer   cells   toward  a   resistant   phenotype.  These  hypotheses  are  
strengthened   by   the   fact   that   we   conducted   a   pairwise   comparison   of   Hh   target   genes   in  
individual  PDX  samples  derived  from  tumors  before  chemotherapy  and  following  chemo-­relapse.  
Accordingly,   our   findings   indicate   that   multi-­strategy   approaches   including   anti-­Hh   and   bulk-­
reducing   drugs   may   be   more   effective   in   tumor   eradication,   particularly   for   high-­risk   group  
patients.    
Several  inhibitors  targeting  different  components  of  Hh  molecular  machinery  are  available  to  date  
(Figure   18).   This   includes   ligand   inhibitors   (i.e,   robotnikinin,   5E1   and   MEDI-­5304   neutralizing  
antibodies),   Hh   acyltransferase   antagonists   (i.e.,   RU-­SKI   43),   compounds   against   SMO   (i.e.,  
cyclopamine,   Cur-­61414,   SANT1-­4,   LDE   225,   GDC-­0449,   HPI   2-­3,   IPI   926,   BMS-­833923,  
ALLO1-­2,   Itraconazole),  ciliogenesis   inhibitors   (CA1,  CA2  and  HPI-­4)  and  GLI  antagonists   (i.e.,  
GANT58,   GANT61,   HPI-­1,   forskolin   and   Arsenic   Trioxide   (ATO),   glabrescione   B)   [270-­272].  
Currently,  clinical  trial  strategies  involving  Hh  pathway  inhibitors  include  SMO  antagonists,  based  
on   the   success   in   preclinical   models   for   different   cancer   types.   In   particular,   GDC-­0449   (or  
vismodegib)   has   been   recently   approved   by   US   Food   and   Drug   Administration   (FDA)   for   the  
treatment   of   locally   advanced   and/or   metastatic   BCC   [273-­275].   Yet,   LDE-­225   alone   and  
Vismodegib  (Curis/Roche)  in  combination  with  a  Notch  inhibitor    (R04929097)  have  entered  into  
clinical  trials  for  recurrent  RMS  and  adult  advanced  RMS,  respectively  [276,  277].  This  highlights  
the   importance  of   studying  developmental   pathways   in  pediatric   tumors,  which  might  offer  new  
options  for  future  targeted  therapies.  However,  deeper  investigations  on  the  mechanism  of  action  
of  these  compounds  are  needed  since  we  could  not  recapitulate  the  pharmacological  inhibition  of  
Hh   signaling   by   genetic   means.   For   instance,   GANT-­61,   an   inhibitor   of   GLI   activity   has   been  
reported  to  reduce  RMS  tumor  growth  in  the  chick  chorioallantoic  membrane  (CAM)  assay  and  in  
xenograft   mouse   models,   but   only   at   high   concentrations   [278-­280].   Similarly,   forskolin   and  
betullic  acid,  two  naturally  occurring  anti-­Hh  compounds  have  been  shown  to  reduce  proliferation  
or  induce  apoptosis  in  RMS  although  the  effect  was  not  specifically  related  to  suppression  of  Hh  
pathway  [281,  282].  Also,  cyclopamine,  a  natural  occurring  compound  targeting  SMO,  has  been  
shown  to  be  effective  in  reducing  proliferation  of  RMS  primary  cells  isolated  from  Ptch+/-­  mice  or  
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human   RMS   cell   lines   in   vitro   [279,   283,   284].   Nevertheless,   this   effect   is   likely   to   be   Hh-­
independent   since   our   attempts   to   genetically  modulate  Hh   signaling   at   different   levels   did   not  
affect  RMS  cell  growth  (manuscript  3  and  [269]).  Thus  we  speculate  that  chemical  inhibition  of  Hh  
signaling  might  also  interfere  with  other  signaling  pathways.  Such  phenomenon  has  been  shown  
to   take   place   in   RMS,   where   GANT-­61   treatment   could   reduce   tumor   growth   in   mice   by  
concomitant  inhibition  of  Hh  and  AKT/mTOR  signaling  [285].  Hence,  to  clarify  the  specificity  of  the  
anti-­Hh   compounds   and   the   dynamic   changes   of   Hh   pathway   following   chemotherapy   we  
attempted  to  generate  an  endogenous  GLI-­reporter  system  by  knocking-­in  a  GFP  into   the  GLI1  
locus  via  the  Crispr-­Cas9  genome-­editing  tool  (data  not  shown).  Although  we  did  not  succeed,  we  
emphasize   the   need   of   establishing   new   methods   that   enable   to   track   the   response   of   Hh-­
activating   cells.   Furthermore,   such   system  would   help   to   unravel   the   role   of   non-­canonical   Hh  
mediators   in   RMS,   which   have   been   shown   as   mechanism   of   resistance   to   SMO   antagonists  
[286].  Therefore,  it  would  open  new  avenues  to  interfere  with  down-­stream  Hh  components  since  
direct  and  specific  targeting  of  transcription  factors  such  as  GLI1  remains  a  difficult  task.  
Finally,   the   therapeutic   window   of   anti   Hh   compounds   remains   incompletely   addressed   in  
childhood  cancers.  This   is  an   important  caveat  given  the   indispensable   function  of  Hh  signaling  
during   development.   Therefore,   it   is   not   unexpected   to   find   that   short-­term   blocking   of   Hh  
pathway   in  young  mice  resulted   in  severe  and   irreversible  side  effects,  specifically   in   the  bones  
[287].  Also,  knockout   for  Ptch1  and  Sufu  as  well  as  Gli1/Gli2  double  mutants   (lacking   the  DNA  
binding   domain   of   Gli1   and   Gli2)   are   not   compatible   with   life   in   mice   due   to   defects   during  
neurogenesis  and  heart  or  lung  abnormalities  [217,  230,  288].  In  contrast,  mice  homozygous  for  a  
Gli1  mutant   allele   have   a   normal   phenotype   suggesting   that  Hh   inhibitors   targeting   specifically  
Gli1  might  be  well  tolerated  in  children  [288].    
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Figure  18.  Targeting  Hh  Signaling.  Schematic  representation  depicting  Hh  pathway  and  current  
inhibitors  targeting  both  canonical  and  non-­canonical  Hh  signaling  activation  in  cancer  
    
7.5.  Conclusions  
Over   the   last   decades   it   has   become   increasingly   clear   that   cancer   is   characterized   by   inter-­
individual  heterogeneity,  which   is  one  of   the  main  reasons  for   treatment  failure.  To  address  this  
problem,   more   patient-­specific   therapeutic   approaches   are   necessary.   One   possibility   takes  
advantage   of   comprehensive   genomic   profiling   to   detect   cancer-­specific,   actionable   driver  
oncogenes.  Unfortunately,   such  genome-­based  drug  selection   is  not   feasible   for   tumors,  which  
are  driven  by  mutated  but  “undruggable”  targets  and  have  an  otherwise  low  mutational  burden,  a  
characteristic  of  many  pediatric   sarcoma  cancers  such  as   rhabdomyosarcoma   (RMS),   in  which  
fusion   transcription   factors   are   the  main   drivers   of   tumorigenesis.   In   this   study   we   describe   a  
complementary  approach  circumventing   these  problems  by  using  patient-­derived   in  vitro  and   in  
vivo  model   systems   that   enables   direct   drug-­profiling   of   patient   tumor   cells.  We  also   show   the  
feasibility  of  such  platform  to  identify  effective  drug  pairs  in  patients  where  responses  to  standard-­
of-­care   therapies  have  been  exhausted.  Hence,  we  provide  means   to  prioritize  actionable  drug  
targets  and  thus  counteract  the  slow  rate  of  drug  development  for  children  (Figure  19).  
In   conclusion,   we   believe   that   these   findings   will   help   to   fill   the   existing   gap   between  
basic/translational   science   and   clinical   practice.  Moreover,   having   established   a   large   panel   of  
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RPCs  representative  of  a  greater  inter-­  and  intra-­  patient  heterogeneity,  new  biological  questions  







                                                                                             
  
Figure  19.  Precision  medicine  strategy  for  RMS  patients.  Drawing  of   the  current  model   (left  
panel)  and  an  alternative  personalized  strategy   (right)   for   the  management  of  RMS  patients.   In  
this   latter,  PDXs  and  RPCs  will  be  generated   in  parallel  during   the  course  of   the  clinical   trial   to  
identify   drug   sensitivities   in   individual   patients.   Hence,   at   the   time   of   assessment   of   the   initial  
outcome,  physicians  will  have   information  about   the  best   treatment   to  apply   for  each  patient  or  
group  of  patients.  This  will  limit  the  emergence  of  adverse  effects  or  occurrence  of  ‘no  response’.  
Finally,   the   establishment   of   bio-­banks   with   annotated   information   about   genomic   and   gene  
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